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Purpose:  Survival from childhood, teenage, and young adult cancer has increased substantially, 
with approximately 80% now surviving at least five-years.  However, curative treatments are 
often associated with adverse late effects.   This thesis investigated the risk of late adverse health 
and social outcomes following five-year survival of cancer diagnosed before age 40 years using 
the British Childhood Cancer Survivor Study (BCCSS) and Teenage and Young Adult Cancer 
Survivor Study (TYACSS). 
 
Material and Methods:  The BCCSS is a population-based cohort of 34,489 five-year survivors of 
childhood (<15 years) cancer diagnosed from 1940-2006 in Great Britain.  The TYACSS is a 
population-based cohort of 200,945 five-year survivors of teenage and young adult (15-39 years) 
cancer diagnosed from 1971-2006 in England and Wales.   
 
Results:  Some survivors were found to have increased risks of premature mortality, subsequent 
primary neoplasms, hospitalizations, poor quality-of-life, and psychosocial limitations.  However, 
for premature mortality, the number of excess deaths is decreasing among those more recently 
diagnosed for several causes-of-death.   
 
Conclusions:  Survivors of cancer diagnosed before age 40 are at an increased risk of a range of 
adverse late effects compared to that expected.  The findings reported in this thesis will be useful 
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Survivorship from childhood, teenage, and young adult cancers has increased since the 1970s 
due to improved treatment therapies, centralization of treatment, inclusion in clinical trials, 
and improved supportive care.  Currently, approximately 80% of individuals diagnosed with 
malignancy under the age of 40 years will become five-year survivors.  Although the five-
year survival rate is encouraging, these individuals continue to face increased risks of long-
term adverse health and social outcomes compared to that expected from the general 
population.  Previous literature has shown increased risks of premature mortality, subsequent 
cancers, chronic health conditions, poor quality-of-life, and a range of adverse psychosocial 
outcomes.  Due to the fact that the number of survivors of childhood, teenage, and young 
adult cancers is expected to continue to increase with time, it has become ever more important 
to investigate the risks and causes of these adverse outcomes in order to determine the public 
health and healthcare implications. 
 
In this thesis I will utilize the British Childhood Cancer Survivor Study and Teenage and 
Young Adult Cancer Survivor Study, which combined include approximately 235,000 five-
year survivors of cancer diagnosed before the age of 40 years, in order to assess a wide range 
of adverse outcomes.  Due to the large study population size, long available follow-up time, 
and population-based design of these cohorts, the results from the studies included in this 
thesis provide a reliable and unbiased basis to develop and update evidence-based clinical 
follow-up guidelines.  Additionally, this research will provide new data for risk stratification 
and planning intervention studies.  In doing so, the ultimate goals of this thesis are to 
contribute to the current understanding of late effects and provide evidence to assist in the 
prevention and/or control of excess risks of adverse health outcomes among childhood, 







































The aim of this chapter is to provide a foundation for the research presented in this thesis by 
summarizing and critically evaluating the existing literature on childhood, teenage and young 
adult cancers.  A particular emphasis will be placed on evaluating the adverse late effects of 
cancer and its treatment on health, quality-of-life, and a range of psychosocial outcomes.  This 
chapter will also describe the study populations under investigation and present the main aims 
of the thesis.  Thus, this chapter should serve as the conceptual and methodological 
underpinning for the five subsequent chapters, which each present an individual study, a 
corresponding in-depth review of evidence, and the relevant methods for the specific research 
question under investigation.   
 
2.1. Childhood Cancer 
2.1.1. Incidence and Survival 
Cancer in childhood, which for this thesis is restricted to individuals aged 0 to 14 years, is 
relatively rare and accounts for approximately 0.5% of all cancers in Great Britain1.  
Approximately 1,400 children in Great Britain are diagnosed with cancer each year1.  Boys 
are more likely to develop cancer compared to girls, with a ratio of approximately 6:5; 
however, this varies by diagnostic group1.  In general, the childhood cancer diagnostic groups 
are classified into the following categories using the International Classification of Childhood 
Cancers2: leukemias, lymphomas, central nervous system (CNS) tumors, neuroblastoma, 
retinoblastoma, renal tumors, hepatic tumors, malignant bone tumors, soft tissue sarcomas, 
germ cell tumors, and other/unspecified cancers.  The most frequent diagnostic groups are 
leukemias, CNS tumors, and lymphomas, which account for over two-thirds of all childhood 
cancers (Figure 2.1). 
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Figure 2.1:  Main types of childhood cancer in Great Britain (2001-2010)1     
 
Although in Great Britain cancer is the most common cause-of-death among children, 
accounting for approximately 20% of deaths, survival has improved dramatically over the past 
several decades (Figure 2.2)3.  When comparing those diagnosed from 1971-1975 to those 
diagnosed in 2006-2010, the one-year survival rate increased by 28%, ultimately reaching 
91% in the latter group.  Similarly, five-year survival after childhood cancer has increased 
substantially over time; in 1971-1975 only 40% of children diagnosed with cancer survived at 
least five years, whereas the five-year survival rate for those diagnosed from 2006-2010 was 
82%.  This pattern of substantial improvements also characterizes ten-year survival, which 




Figure 2.2:  One-, five-, and ten-year actuarial survival of childhood cancer in Great Britain 
(1971-2010)4 
 
As a consequence of this improved survival in more recent decades, it has been estimated that 
there are approximately 33,000 people in the United Kingdom who are alive, previously 
diagnosed with a childhood cancer, and have survived for at least five years5.  Each year this 
survivor population is expected to grow by an additional 1,300 survivors, making it important 
to not only monitor short-term survival, but also long-term outcomes.  
 
2.1.1. Long-term Follow-Up Guidelines 
Various groups have developed recommendations for follow-up of childhood cancer 
survivors, including the United Kingdom Children’s Cancer Study Group6, Scottish 
Intercollegiate Guidelines Network7, United States Children’s Oncology Group8, and Dutch 
 7 
Childhood Oncology Group9.  Where possible, the guidelines are developed by using 
evidence from literature to identify high-risk survivors for a range of outcomes.  
Unfortunately, evidence may be very weak relating to some outcomes.  In general, the 
guidelines recommend that survivors of childhood cancer should be on active follow-up 
throughout their lifetime.  The recommended model of care is through a long-term follow-up 
program, although follow-up through a general practitioner or a hybrid of the two is also 
used10.  In the early years following diagnosis of the primary cancer, survivors are monitored 
for recurrences6,10; however, as the time since diagnosis increases, the balance changes where 
survivors are increasingly monitored in order to provide risk-based care for potential late 
effects of cancer and its treatment6,10.  The extent of long-term morbidity risk depends on the 
type and site of the first primary neoplasm, age at treatment, and treatment received7.  By 
creating guidelines that stratify recommendations of follow-up based upon these factors, 
clinicians can anticipate the likely late adverse effects that should be considered, evaluated, 
and treated for their survivor patients6.  Furthermore, guidelines also provide educational 
resources and information on patient counseling6–9.  Although individual initiatives to develop 
recommendations for long-term follow-up by countries or regions has led to informative 
reports, current work is being undertaken through the International Guideline Harmonization 
Group to establish a universal strategy for childhood cancer survivors11.  Through this 
collaborative effort, duplication of efforts will be reduced and the use of expertise would be 
optimized, ultimately identifying gaps in knowledge in current guidelines11.  In doing so, this 
collaborative guideline effort will hopefully reach its ultimate goal of optimizing quality of 




2.1.2. Adverse Late Effects 
Despite the considerable improvement in survival over time, childhood cancer survivors 
remain at an increased risk of adverse late effects due to the cancer and its treatment10,12.  
Medical treatments and interventions, such as radiotherapy, chemotherapy, and surgery, 
utilized to cure or control the cancer and improve survival can have a spectrum of detrimental 
long-term effects including an increased risk for premature mortality13–23, second primary 
neoplasms (SPNs)21,23–34, cardiac impairments20,21,23,31–37, endocrine 
deficiencies20,21,23,32,34,35,37–41, pulmonary dysfunction20,23,32,35,42, immune system 
suppression21,23,35, gastrointestinal problems23,32,33, genitourinary disorders23,32, neurocognitive 
deficits20,21,23,32,34,35,43–45, sensory loss32, musculoskeletal abnormalities20,23,32,33,35, and 
infertility20,23,31,33,35,46–49.  These impairments together with other factors may then cause 
further limitations with regards to education attainment50–53, employability50,54,55, quality-of-
life56–67, and other psychosocial outcomes33,55,59,68–78.  Thus, as the prevalence of childhood 
cancer survivors continues to increase, it is ever more important to quantify risks of adverse 
outcomes and identify potential risk factors in order to provide an evidence base for long-term 
clinical follow-up and establish opportunities for interventions – both of which aim at 
reducing the total burden of late effects in existing survivors and those treated for cancer in 
the future. 
 
2.1.2.1. Premature Mortality 
Mortality rates among childhood cancer survivors continue to be elevated far beyond five-
year survival when compared to the general population13–19,79.  Three of the largest studies 
from Great Britain13, the United States14, and the Nordic countries19 have reported 10.7-, 8.4-, 
and 8.3-fold increased risks of mortality compared to that expected from the general 
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population, respectively.  The leading cause-of-death in the short-term has been previously 
shown to be due to recurrence or progression of the childhood cancer13–16,19,80.  However, as 
time from original diagnosis increases, the risk of mortality due to SPNs, circulatory diseases, 
and respiratory causes increases13–15,19,27,81; in a study from Great Britain, 77% of  the excess 
number of deaths observed among those surviving beyond 45 years from diagnosis were due 
to SPNs and circulatory deaths13.  Although several reports have assessed whether mortality 
among five-year survivors of childhood cancer differs by treatment era17–19,82, further 
assessment is necessary in order to determine the net effect of more modern treatments in both 
the medium- and long-term.  Inevitably, there remains uncertainty as to longer-tem risks in 
individuals treated more recently in the 1990s and 2000s due to limited follow-up currently. 
 
2.1.2.2. Subsequent Primary Neoplasms 
Early reports of cancer-related or treatment-induced SPNs among childhood cancer survivors 
was published in the 1970s83.  Since then, the risk of SPNs has been investigated in many 
cohorts of childhood cancer survivors24–26,28,29,84.  Within these previous studies, the 
cumulative risk of a subsequent cancer has been estimated to be between 3-5% at 20-25 years 
from diagnosis25,84,85.  However, in a study from Great Britain, the cumulative risk of SPNs in 
childhood cancer survivors increased to 14% by age 60 years, whilst only 8% was expected24.  
Bone and glioma SPNs accounted for the majority of excess SPNs in survivors aged under 30 
years (>50%), whilst breast, respiratory genitourinary, and digestive SPNs increased rapidly 
with attained age, accounting for 52% of excess SPNs in those aged 40 years or more24.  Only 
one large study to date has assessed risk of SPNs by treatment era84; in the findings from this 
Nordic study, the cumulative risk of SPNs at 50 years age was 8.6% in those diagnosed from 
1943-1959 (pre-chemotherapy era), 12.2% in those diagnosed from 1960-1974 (first 
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generation chemotherapy era), and 13.3% in those diagnosed from 1975-2005 (combination 
chemotherapy era)84.  The fact that this study found that the cumulative risk for SPNs in fact 
increased for those treated more recently suggests that this is a crucial question to investigate 
further.  Furthermore, few studies have assessed the risk of SPNs in childhood cancer 
survivors beyond age 50, and thus reassessment of these risks is necessary with increased 
follow-up.  
 
2.1.2.3. Chronic Health Conditions 
A study of over 10,000 childhood cancer survivors from the United States found that the risk 
of self-reported chronic health conditions was high86.  After a mean follow-up of 26.6 years, 
62% of survivors reported at least one chronic health condition of a grade 1-4 by the Common 
Terminology Criteria for Adverse Events (CTCAE) scoring87, with 27% reporting a condition 
categorized as severe (grade 3), life-threatening (grade 4), or disabling (grade 4)86.  A large 
proportion of these survivors also reported having two (38%) or three or more (24%) chronic 
conditions of a grade 1-486.  These percentages equated to a three-fold increased risk of 
having at least one chronic condition of a grade 1-4 and a five-fold increased risk of having 
two or more chronic conditions of a grade 1-4 compared to a sibling comparison group86.  
These findings have been complemented by the results of two other studies that assessed 
ascertained chronic health conditions among childhood cancer survivors in a hospital clinic 
setting in the Netherlands88 and United States89.  The first of these studies, which assessed 
1,362 Dutch survivors, found that 75% of survivors had at least chronic condition of any 
CTCAE grade, 59% had two or more chronic conditions of any CTCAE grade, and 25% had 
five or more chronic conditions of any CTCAE grade after a median follow-up period of 17.0 
years88.  Among survivors with chronic conditions, 37% had at least one condition graded a 3 
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or 488.  Similarly, the study from the United States found that, among the 1,713 participants, 
98% had one or more chronic health conditions graded 1-4 according to the CTCAE, with 
68% of survivors having a severe, life-threatening, or disabling condition89.  Over time, the 
incidence of chronic conditions has been reported to increase with no suggestion of a 
plateau86,89,90; however, this increasing risk of chronic conditions over time would also be 
expected in the general population and thus it is important to compare these findings with a 
control group wherever possible to quantify the level of excess risk.  Amongst the condition 
categories assessed, survivors were at particular risk of chronic health conditions due to 
cardiac86,88,89, respiratory88,89, endocrine86,88,89, and neurologic causes88,89.     
 
2.1.2.3.1. Cardiac Conditions 
Survivors of childhood cancer are at an increased risk of coronary artery disease, 
cardiomyopathy/congestive heart failure, pericardial disease, arrhythmias and valvular 
abnormalities when compared to a sibling control group86,91,92.  Adverse effects of radiation 
and chemotherapy on cardiac function have been widely documented10,12.  Radiation to the 
chest, mantle, or spine is associated with valvular dysfunction, pericarditis, and coronary 
artery disease93–95.  Survivors of Hodgkin lymphoma treated with mediastinal radiation have 
the highest reported risk of radiation-associated cardiovascular disease and cardiac death 
among childhood cancer survivors96,97.  Similarly, anthracycline chemotherapy has been 
associated with dose-dependent cardiotoxicity resulting in cardiomyopathy/heart failure98 and 
arrhythmias99.  In a study by Steinherz and colleagues, 11% of survivors had congestive heart 
failure following anthracycline doses of less than 400 mg/m2 100; this percentage increased to 
100% among individuals treated with anthracyclines at doses of more than 800 mg/m2 100.   
Furthermore, in a Dutch study of approximately 600 survivors, the risk of anthracycline-
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induced heart failure was found to increase over time, ultimately reaching approximately 5% 
at 15 years after treatment101, which corresponds with two other previous reports102,103.  These 
findings are similar to an American study which reported a cumulative incidence of 4% at 30 
years after diagnosis92.  Notably, in both the Dutch and America studies, the cumulative 
incidence did not plateau, but rather appeared to accelerate with age92,101.  Although adverse 
cardiac health conditions have been documented up to 30 years after diagnosis, little is known 
about the risk in the longer term as survivors reach the decades of life when the risk of cardiac 
disease begins its inexorable increase in the general population.  Cardiac health conditions 
remain one of the leading causes of morbidity and mortality in childhood cancer survivors and 
thus it is important to continue to monitor survivors and use the evidence to update clinical 
follow-up guidelines in order to determine the best strategies for early detection or prevention 
of such diseases.       
 
2.1.2.3.2. Respiratory Conditions 
The lung is sensitive to both radiation and chemotherapy104.  Early treatment-induced lung 
disease (occurring two to six months after exposure) among childhood cancer survivors has 
been characterized as an acute phase of radiation pneumonitis and/or chemotherapy-induced 
interstitial lung injury, whilst the late effects of treatment generally present as pulmonary 
fibrosis10,12,42,105.  Exposure to chest irradiation42,106,107, bleomycin42,105, mitromycin-C105, 
nitrosoureas42,105, busulfan42,105, and cyclophosphamide42,105,108 have been previously linked to 
pulmonary toxicity.  In a large American study assessing respiratory complications after 
childhood cancer, survivors reported an increased risk of lung fibrosis, emphysema, 
pneumonia, chronic cough, bronchitis, and several other respiratory conditions compared to a 
sibling cohort42.  Chest irradiation was found to be significantly associated with ten of the 
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fifteen respiratory conditions under investigation in the study, although nitrosoureas, 
bleomycin, busulfin, and cyclophosphamide were each associated with at least one 
condition42.  As time since diagnosis increased, the incidence of respiratory complications 
also continued to increase90, with survivors exposed to chest irradiation and respiratory toxic 
chemotherapy being the greatest at risk, followed by survivors exposed to chest irradiation 
only42.  When assessed by diagnostic group, impaired respiratory function due to 
antineoplastic treatment has been previously reported in survivors of childhood leukemia109–
111, rhabdomyosarcoma112, Wilms106,107, CNS tumors113, and Hodgkin lymphoma114–116.  
Although research has assessed respiratory complications up to 25 years past diagnosis, 
further research is needed on later adverse respiratory outcomes, especially as it is known that 
chemotherapy and radiation exposure can cause complications many years after treatment42.   
 
2.1.2.3.3. Endocrine Conditions 
Among the spectrum of chronic health complications due to cancer treatment, endocrine 
abnormalities are the most common, inflicting a negative impact on quality-of-life, sexual 
function, growth, and body image12.  In particular, neuroendocrine abnormalities may arise 
from damage to the hypothalamic-pituitary axis, which is vulnerable to certain tumors, 
radiation, chemotherapy, and surgical trauma10. Hypothalamic-pituitary axis injury has been 
widely studied, with increased risks of growth hormone deficiency117–123, 
hypothyroidism124,125, hyperthyroidism124, gonadal dysfunction118,125–131, and other endocrine 
disorder being reported widely among survivors of childhood cancer.  In two studies from the 
United States and Australia, the proportion diagnosed with an endocrine (including 
reproductive) disorder was 62%89,132.  When only severe, life-threatening, or disabling 
endocrine events were assessed, a Dutch study of over 1,300 childhood cancer survivors 
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reported a prevalence of 9% and 5% for fertility and endocrine disorders, respectively88.  This 
high prevalence of dysfunction equated to approximately a five-fold increased risk of a 
severe, life-threatening, or disabling endocrine chronic condition when compared to a sibling 
cohort90.  Survivors treated with radiotherapy to the head and neck reported an eight-fold 
increased risk of endocrine chronic conditions compared to those not exposed to 
radiotherapy133.  An increased risk of endocrine chronic conditions was also observed for 
individuals treated with total body irradiation and radioactive iodine133.  Similarly, when 
survivors exposed to alkylating agents and/or radiation to the hypothalamic-pituitary axis, 
thyroid, or reproductive organs were assessed in more detail, 61%, 14%, 66%, and 12% of 
survivors had disorders affecting the hypothalamic-pituitary axis, thyroid, male gonadal 
function, and female gonadal function, respectively89.  Survivors of CNS tumors have been 
found previously to most likely to experience endocrinopathies37,118,133, with 43% reporting 
one or more endocrine chronic conditions37;individuals previously diagnosed with leukemia 
and Hodgkin lymphoma have also been reported to have increased risks of endocrine 
conditions, though125.  Due to the fact that endocrine late effects are common, generally 
treatment-related, and progress to other chronic conditions, it is essential to further evaluate 
these outcomes to reduce the risk of morbidity and premature mortality whilst also improving 
quality-of-life134.        
 
2.1.2.3.4. Neurologic Conditions 
Neurologic conditions, such as seizures, motor dysfunction/hemiparesis, and sensory loss, 
accounted for approximately 19% of all adverse chronic conditions observed in a study from 
the Netherlands133; 8% of the severe, life-threatening, and disabling chronic conditions 
observed were due to neurologic causes133.  Similarly, when only severe, life-threatening, 
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disabling, or fatal neurologic events were assessed, an American study found that survivors of 
childhood cancer were approximately 4-times more at risk than the sibling comparison 
cohort90; the increased risk was highest among survivors aged 5-19 years (HR:10.6; 
95%CI:5.8-19.3), when compared to the sibling cohort, although survivors aged 20-34 years 
and 35 or more years still had a statically significant increased risk of approximately two-
fold90.  Radiotherapy was associated with a more than two-fold increase in risk of neurologic 
chronic conditions133, and survivors of CNS tumors135–138 and acute lymphoblastic 
leukemia139–144 were at increased risks of dysfunction due to therapy-related damage.  Whist 
other nervous system abnormalities, such as neurocognitive and neuropsychologic outcomes, 
have been well documented in childhood cancer survivors145, data is limited on neurologic 
complications.  Neurologic morbidity continues to increase across the lifespan and thus there 
is a need for longitudinal, risk-based follow-up90.  Furthermore, due to the strong treatment-
dependent nature of neurologic chronic conditions, additional research may yield important 
findings on how morbidity may change with newer surgical, radiotherapy, and chemotherapy 
approaches. 
 
2.1.2.4. Hospitalizations/Healthcare Usage 
With such a high prevalence of chronic health conditions, increased hospitalizations or 
healthcare usage among childhood cancer survivors would also be expected.  In a study of 
British childhood cancer survivors, the risk of non-hospital-based contact with a doctor was 
found to be only slightly increased among survivors compared to the general population 
sample146.  However, in the same cohort, the risk was substantially higher among survivors 
compared to the general population sample for hospital outpatient, hospital day-patient, and 
inpatient care146.  Results were similar in two Canadian studies that measured the prevalence 
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of contact with a general practitioner during the past year and hospitalizations147,148.  A 
Scottish study that measured the risk of admission to acute hospitals also reported an 
increased risk, particularly among survivors of hepatic tumors, CNS tumors, leukemia, and 
neuroblastoma149.  These findings are generally consistent with a different report which found 
that survivors of bone sarcoma and CNS tumors had the highest excess risks for outpatient 
and inpatient care, whilst survivors of Hodgkin lymphoma, neuroblastoma, and Wilms had 
the highest excess risk for being hospitalized as a day patient146.  As the largest study to assess 
hospitalizations or healthcare usage in childhood cancer survivors was still limited in numbers 
of survivors in their 50s or 60s146, it is important to continue to monitor the use of health care 
services as this population continues to age and experience more morbidities.          
 
2.1.2.5. Health Related Quality-of-Life 
Health related quality-of-life among childhood cancer survivors is affected by physical and 
psychological late effects associated with the original tumor and its treatment, as well as by 
the practical implications of the late effects.  For example, the childhood cancer experience 
may lead to cognitive and psychological impairments, both of which may impact quality-of-
life and impede post-treatment adjustment60.  In a report of American childhood cancer 
survivors, approximately 11% reported fair or poor health, but 44% had an impairment in at 
least one of the health domains assessed60.  When these individuals were compared to a 
sibling cohort and general population norms, survivors were found to report poorer physical 
and social health-related quality-of-life59.  Mental health quality-of-life, however, has been 
reported to be similar if not better than expected from the general population59,150.  Survivors 
of CNS tumors59,60,62,150, lymphoma59,60,151, bone sarcoma59,60,150, and soft tissue sarcomas59,60 
have been reported to have the poorest health related quality-of-life.  Other risk factors for 
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poor health related quality-of-life include being female59,60,152–155, older in age59,153, having a 
low educational attainment59,60,153, and cranial irradiation or surgery60,154,155.  Due to the fact 
that childhood cancer survivors report deficits in health related quality-of-life, it is crucial to 
continue to monitor health status among this at risk population in order to facilitate recovery 
and optimize well-being throughout the lifespan.    
 
2.1.2.6. Psychosocial Outcomes & Behaviors 
Aspects of diagnosis, treatment, and recovery of childhood cancer may disrupt social 
developmental, emotional well-being, and academic progress – all of which may have further 
adverse psychosocial effects throughout the life course55,105,156.  Although most childhood 
cancer diagnoses report relatively similar psychosocial outcomes as those observed in the 
general population or sibling comparison groups10, the majority of survivors remain 
challenged in areas that relate to social adaptation due to the fact that the diagnostic groups 
reporting excess risks (e.g. CNS and leukemia) account for a large proportion of childhood 
cancer survivors52,68,157.  Thus, it is crucial to understand the long-term psychosocial impacts 
of diagnosis and treatment in order to develop targeted interventions to prevent or improve 
adverse psychosocial outcomes and behaviors, particularly those relating to educational 
attainment, employment, marriage, smoking status, and alcohol habits. 
 
2.1.2.6.1. Educational Attainment 
Educational attainment is a key element in determining an individual’s development and 
progression through life52.  Varying degrees of deficits have been reported among childhood 
cancer survivors in relation to educational attainment and diminished cognitive functioning.  
A study of British childhood cancer survivors found that survivors have lower educational 
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attainment than the general population52; however, upon further investigation, these deficits 
were confined to survivors of CNS tumors and leukemia52.  Similar results were found in an 
American cohort51.  Poor educational outcomes were also previously reported to be associated 
with earlier age at treatment158–162, female gender158,160,163–165, and cranial 
irradiation158,159,161,165–168.   These findings illustrate the increased academic risk that 
childhood cancer survivors face and thus the need for interventions to improve educational 
outcomes169.   
 
2.1.2.6.2. Employment 
After completing primary, secondary, or higher education, an important measure of normal 
development is employment55,170.  Childhood cancer may impact employment status as 
survivors are at an increased risk of chronic diseases, mental and physical limitations, 
recurrences, and SPNs; these adverse health outcomes may influence the likelihood of an 
individual being able to work as it is known that, even in the general population, individuals 
with health limitations or disabilities are more likely to be unemployed171.  When the 
likelihood of unemployment was assessed in a meta-analysis, the results showed that adult 
survivors of childhood cancer were twice as likely to be unemployed compared to controls170.  
Similarly, Pang et al. found that approximately 6% of American survivors had never been 
employed whilst only 1% was expected172.  Risk factors for unemployment included a young 
age at diagnosis, cranial irradiation, female gender, and not finishing secondary 
schooling172,173.  Survivors of CNS tumors were also reported to have the highest risk of 
unemployment at approximately five-fold that expected170.  Given the excess risk in 
unemployment, clinical and supportive services are needed in order to better manage recovery 
and accommodate disabilities170.  Furthermore, as the employment needs of survivors may 
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change over time, it is also important that future research also assesses specific employability 
and health reasons that are associated with obtaining and maintaining employment173.   
 
2.1.2.6.3. Marital Status 
The majority of young adults in today’s society aspire to marry174.  Thus, marriage represents 
a social life-event that can be used to measure the adaptation of survivors to life beyond 
cancer55.  Marital rates have been found to be lower in survivors of childhood cancer than 
expected in control populations56,157,175–177.  Individuals exposed to radiotherapy68,175 and 
males50,157,175,177 appear less likely to marry than individuals not exposed to radiotherapy and 
females.  Age at diagnosis157,175, educational attainment50,175, and income175 have also been 
associated with likelihood of marriage.  Furthermore, in reports from Great Britain and the 
United States, survivors of CNS tumors were found to be least likely to marry68,175,178–180.  As 
childhood cancer survivors may face challenges in regards to relationships, it is important that 
regular follow-up also addresses the psychosocial needs of each survivor and that these 
factors are monitored throughout the life course.  Nonetheless, it is reassuring that studies 
assessing divorce have found that survivors are generally comparable with the general 
population175,180–183, although some reports have found an increased risk among specific 
diagnostic subgroups176,180,182.             
 
2.1.2.6.4. Smoking Status 
As smoking is a major risk factor for a range of medical conditions, it is important that 
smoking is discouraged among childhood cancer survivors as they are already at an increased 
risk of adverse health outcomes due to their previous cancer and its treatment.  In a study 
from Great Britain, approximately one-fifth of survivors reported being current smokers and 
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30% had smoked regularly at some point in their lives70.  The smoking prevalence was similar 
in a study from the United States.  When compared to the general population or healthy 
control subjects, a wide range of studies reported that survivors of childhood cancer were 
substantially less likely to smoke73,184–190.  Although these findings are reassuring, studies 
have found that those who do smoke are less likely to quit when compared to siblings or other 
control subjects184,186,187.  Thus, it is important that strategies are developed and integrated 
into long-term follow-up programs in order to prevent the initiation of smoking among 
childhood cancer. 
 
2.1.2.6.5. Alcohol Habits 
Studies assessing alcohol use in childhood cancer survivors have reported that these 
individuals are similar or less likely to be a current drinker when compared to the general 
population or sibling cohort69,72,190–192.  Survivors were also less likely to consume excessive 
or risky amounts of alcohol compared to controls69,72,185,190.  Although generally survivors 
appear to be living healthier lives compared to the general population in relation to alcohol 
use, survivors who have similar heavy drinking habits as the general population may have an 
even higher risk of a variety of late effects as alcohol could increase already heightened risks 
of SPNs and chronic conditions6925,85,193,194.  For example, studies from the United States and 
Great Britain found that survivors of Hodgkin lymphoma, Wilms, and bone sarcoma reported 
similar adverse drinking behaviors as the comparative populations; these diagnostic groups 
are already at an increased risk of adverse outcomes due to their likely exposure to 
abdominal/chest irradiation and/or anthracycline drugs and thus excessive alcohol use may 
make these risks even higher69,71.  Based on these findings, survivors should be advised on the 
health risks associated with alcohol consumption.  It is particularly important that survivors 
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are aware of these risks at a young age as early alcohol consumption has been associated with 
heavier drinking later in life72. 
 
2.2. Teenage and Young Adult Cancer 
2.2.1. Incidence and Survival 
The age range for teenage and young adult cancer is defined in various ways across the world.  
At a national level, the United Kingdom describes teenage and young adult cancers as a 
cancer being diagnosed between the ages of 15 to 24 years195.  Approximately 2,200 
individuals are diagnosed each year with a teenage or young adult cancer in the United 
Kingdom, accounting for less than 1% of cancers at all ages195.  The spectrum of diagnostic 
types of cancer affecting teenage and young adults differ from those in childhood and older 
populations196 and thus are classified differently.  Teenage and young adult cancers are 
generally classified according to the scheme proposed by Birch et al., which utilizes the 
following ten groups197: leukemias, lymphomas, CNS and other intracranial and intrapsinal 
neoplasms (CNS tumors), osseous and chrondromatous neoplasms, Ewing sarcoma and other 
neoplasms of bone (bone tumors), soft tissue sarcomas, germ cell and trophoblastic neoplasms 
(germ cell tumors), melanoma and skin carcinoma, carcinomas excluding skin, miscellaneous 
neoplasms, and unspecified malignant neoplasms (Figure 2.3).  Leukemias, lymphomas, CNS 
tumors, bone and soft tissue sarcomas, testicular cancer, breast cancer, non-gonadal germ cell 
tumors, and melanoma account for approximately 95% of the cancers in this age 




Figure 2.3:  Main types of teenage and young adult cancer for individuals diagnosed with 
cancer between the ages of 15-24 years in England (1979-1997)197 
 
Survival from cancer in teenagers and young adults has improved over time and is currently 
approximately 82%200.  In the United Kingdom, five-year survival increased significantly 
from 75.7% to 82.2% among 15-24 year olds diagnosed with cancer in 1992-1996 and 2002-
2006, respectively.  When assessed further by diagnostic group, five-year survival was 
observed to increase for leukemias, lymphomas, germ cell tumors, and melanoma; five-year 
survival rates remained similar for CNS tumors, bone tumors, soft tissue sarcoma, and 




Figure 2.4:  Five-year relative survival rates by diagnostic group for individuals diagnosed 
with cancer between the ages of 15-24 years (1991-2005)195 
 
2.2.2. Long-term Follow-Up Guidelines 
In contrast to childhood cancer, no standardized clinical guidelines for long-term follow-up 
exist for individuals diagnosed with a teenage or young adult cancer201.  The most likely 
explanation for this absence of standardized clinical follow-up guidelines relates to the lack of 
evidence of risks of adverse health outcomes.  Due to the paucity of published literature on 
teenage and young adult cancer, survivors instead receive care determined primarily by the 
opinion of their treating oncologists201.  Due to the variability in opinions of oncologists, 
some survivors receive extended follow-up whilst others receive care through their oncologist 
for one to two years at which point they are then discharged to their general practitioner201.  
Follow-Up may be further disrupted due to other factors, such as insurance, employment 
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issues, geographical location, and lower levels of concern for future treatment-related 
morbidities201.  As a result of the lack of standardized follow-up, most survivors are unaware 
of their risks of adverse health outcomes and some are not receiving adequate care.  Thus, it is 
crucial to expand the literature on teenage and young adult cancers in order to develop the 
vital evidence needed to deliver risk-based health monitoring, psychosocial support, and 
interventions for current and future survivors of teenage and young adult cancer201. 
 
2.2.3. Adverse Late Effects 
Among the limited current studies age definitions for teenage and young adult cancer vary, 
and thus for the purpose of this thesis teenage and young adult cancer will be defined as an 
individual diagnosed with cancer between the ages of 15 to 39 years.  The lower age limit was 
determined by the definition for childhood cancer, which was described previously to include 
individuals diagnosed with cancer before the age of 15.  The upper age limit was decided 
based upon biological and physiological maturity, which occurs around puberty, and 
achievement of final height, which remains fairly stable during an adult’s 20s and 30s.  Thus, 
the effects of hormonal decline, diminishing immunity, and increasing development of 
chronic diseases of adulthood should be largely insignificant among those aged less than 40 
years.  Individuals under the age of 40 years are also more likely to identify psychologically 
with younger patients than more mature patients.  Furthermore, previous literature has 
suggested that the late effects of cancers diagnosed before age 40 years may substantially 
differ from older populations, and thus it is important to analyze this group separately as 
radiotherapy, chemotherapy, and surgery may have different effects among those diagnosed at 
an older age202,203.  By including all cancers between the ages of 15 to 39 years, our findings 
will provide comprehensive evidence for improving outcomes for teenage and young adult 
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cancer survivors because we partially or entirely encompass the more limited age ranges used 
in previous studies of survivors of teenage and young adult cancer. 
 
Limited studies so far suggest that teenage and young adult cancer survivors are at an 
increased risk for late effects due to their cancer and treatment received, with approximately 
two-thirds of survivors experiencing at least one late effect that is severe or life-
threatening201,204–206; however, the degree of risk depends on the type of cancer, treatment 
received, and age at diagnosis.  Risks may be further influenced by factors such as lifestyle 
behaviors, family history, and health comorbidities196.  Studies have previously shown in sub-
populations of teenage and young adult cancers that these individuals are at an increased risk 
of premature mortality, SPNs, chronic health conditions, and adverse psychosocial 
outcomes201.  However, to date, research assessing adverse late effects for the entire age range 
of teenage and young adult cancers is limited, with the majority of studies assessing patients 
diagnosed up to the ages of 21 or 24 years196.  As a large proportion of teenage and young 
adult survivors are now surviving at least five years, it is crucial to monitor the long-term 
outcomes that may be affected by cancer and its treatment in order to improve outcomes in 
these individuals through appropriate guidelines and clinical interventions. 
 
2.2.3.1. Premature Mortality 
Few studies have investigated premature mortality in teenage and young adult cancer survivor 
populations207–210.  In a study assessing premature mortality among five-year survivors of 
teenage and young adult cancers in Finland, survivors of cancers diagnosed when aged 15 to 
19 years were 6-times more likely to die than expected, whilst those aged 20 to 34 years at 
diagnosis were 5-times more at risk than expected209.  These findings were similar to a study 
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conducted in Canada, which reported a six-fold increased risk of death among survivors of 
cancer diagnosed between the ages of 20 to 24 years208.  In absolute terms, the most frequent 
cause-of-death among teenage and young adult cancer survivors was neoplastic causes 
followed by cardiovascular complications207,211.  Similarly, when the excess risk was 
assessed, the risk of death was highest for neoplastic causes, infectious causes, cardiovascular 
diseases, and respiratory diseases207.  Risk of death was observed to decrease with age at 
diagnosis; survivors diagnosed between the ages of 15 to 19 years experienced 25-fold and 
three-fold the number of deaths from neoplastic and non-neoplastic causes, respectively, 
whilst the corresponding risk for those aged 20 to 34 at diagnosis was 14-fold and two-fold209.  
These findings clearly confirm an already increased risk and need for monitoring of late 
effects among teenage and young adult cancer survivors; they also illustrate the need for 
teenage and young adult focused studies, as assessment of premature mortality and 
generalizability of results are still limited.      
 
2.2.3.2. Subsequent Primary Neoplasms 
Compared to the general population, survivors of teenage and young adult cancers are at a 
significantly higher risk of developing a SPN201,212; however, the majority of these studies 
were restricted by the age range or diagnostic group assessed.  In individuals aged 15 to 21 
years at diagnosis, the risk of SPNs was greatest for breast cancer, non-melanoma skin 
cancers, and other solid organ cancers213,214.  Among individuals treated for Hodgkin 
lymphoma between the ages of 21 to 39 years, the most frequently observed SPNs were 
breast, thyroid, lung, and gastrointestinal cancers215; female survivors of Hodgkin lymphoma 
who were treated with chest irradiation have been shown to have a substantially increased risk 
of breast SPNs, and there is a strong interaction between chest irradiation and age at 
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diagnosis202,203,216,217.  Alkylating chemotherapeutic agents have also been associated with a 
moderately increased risk for lung SPNs in Hodgkin lymphoma survivors originally 
diagnosed before the age of 40 years218.  Teenage and young adult survivors of testicular 
cancer have also been found to be at an increased risk for SPNs, particularly leukemia, 
contralateral testicular cancer, malignant mesothelioma, and cancers of the esophagus, lung, 
stomach, colon, and pancreas219,220.  Studies assessing SPN risk in teenage and young adult 
survivors of breast, cervical, NHL, melanoma, leukemia, CNS tumors, bone sarcoma, and soft 
tissue sarcoma have been limited, with only a few cohorts assessing these risks212,221–225; 
nonetheless excess risks were observed compared to that expected for all diagnostic groups201.  
As risks of SPNs among teenage and young adult survivors remain understudied, it is 
essential that further investigations are undertaken in order for clinicians to provide 
appropriate evidence-based care. 
 
2.2.3.3. Chronic Health Conditions 
Investigations assessing chronic health conditions among teenage and young adult cancer 
survivors are few.  As it is known that childhood cancer survivors are at an increased risk of 
chronic health conditions due to their cancer and its treatment, one can hypothesize that these 
risks likely exist among teenage and young adult cancer survivors as well.  However, the 
majority of studies investigating chronic health conditions assess only one diagnostic group or 
use a very restricted age at diagnosis range.   A study in Scotland found that individuals 
diagnosed with cancer from 15 to 19 and 20 to 24 year were 3.5- and 2.4-times more likely 
than expected to be hospitalized, respectively, suggesting an increased risk of chronic health 
conditions149.  Other studies have also reported increased risks of cardiovascular92,226–233, 
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respiratory234, endocrine194,234–237, and neurologic136,194,238,239 conditions, which will now be 
explored further.   
 
2.2.3.3.1. Cardiac Outcomes 
Significant increases in cardiovascular morbidity have been reported in survivors of teenage 
and young adult cancers92,201,226–230.  In a study assessing cardiovascular disease in over 
40,000 survivors of cancer diagnosed between the ages of 15 to 39 years in Denmark, 
approximately 25% of survivors had been admitted to the hospital for a cardiovascular cause, 
which equated to a 30% increased risk of cardiac hospitalization compared to the general 
population227.  A study from Finland also reported significantly increased risks of 
cardiovascular morbidity in teenage and young adult survivors (aged 20 to 34 years) 
compared to siblings, where risks of cardiomyopathy/cardiac insufficiency, myocardial 
infarction/cardiac ischemia, atherosclerosis/brain vascular thrombosis, and cardiac arrhythmia 
were 3.6-, 1.8-, 1.7-, and 1.4-times higher than that expected, respectively210.  Chest 
irradiation and anthracycline chemotherapy are the strongest risk factors for adverse cardiac 
outcomes among survivors92,228–230.  Survivors of Hodgkin lymphoma210,228–230 and testicular 
cancer231–233 have also been reported to have increased risks of adverse cardiac outcomes 
likely due to effects of radiotherapy and chemotherapy treatment.  As cardiovascular disease 
is the leading cause of non-neoplastic morbidity and mortality in teenage and young adult 
cancers, further investigation is necessary in different study populations in order to provide 





2.2.3.3.2. Respiratory Outcomes 
Recurrent pneumonia, chronic cough, supplemental oxygen use, and shortness of breath are 
all adverse respiratory outcomes that teenage and young adult cancer survivors face196.  In a 
study of cancer survivors diagnosed between the ages of 20 to 24 in Canada, survivors were 
70% more likely to be hospitalized for a respiratory-related cause compared to the control 
population234.  Chest irradiation and chemotherapy drugs, such as bleomycin, busulfan, 
BCNU, and CCNU, have been linked to pulmonary toxicity when used together or 
individually42,201,232,240–242.  Research into respiratory outcomes remains understudied in 
teenage and young adult cancer survivors; as childhood cancer survivors are at a known 
increased risk of adverse respiratory conditions, investigations into this matter for survivors of 
cancer diagnosed when older is necessary in order to identify at risk populations and make 
appropriate evidence-based recommendations for follow-up.     
 
2.2.3.3.3. Endocrine Outcomes 
Hypopituitarism, or being deficient of one or more anterior pituitary hormones (growth 
hormone, follicle-stimulating hormone, luteinizing hormone, adrenocorticotrophic hormone, 
or thyroid-stimulating hormone), can occur as a result of the cancer directly or the treatment 
used201. Survivors of teenage and young adult cancer in Canada were approximately 60% 
more likely to be hospitalized for an endocrine condition than controls234.  The most common 
chronic endocrine conditions in survivors of teenage and young adult cancers were growth 
hormone deficiency, gonadal dysfunction, decreased fertility, and thyroid gland 
abnormalities236,237.  Total body irradiation, cranial or spinal irradiation, and irradiation to the 
neck, abdomen, pelvis, and testes were associated with chronic endocrine conditions in 
teenage and young adult cancer survivors243.  Hypothyroidism and hyperthyroidism, however, 
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were also common among teenage and young adult survivors of CNS tumors, acute 
lymphoblastic leukemia, and Hodgkin lymphoma194,235.  Currently, chronic endocrine 
conditions among teenage and young adult cancer survivors are an understudied topic and 
further investigation is necessary.     
 
2.2.3.3.4. Neurologic Outcomes 
Neurologic complications among teenage and young adult survivors have not been 
investigated widely, but the limited literature published has identified specific groups to be at 
an increased risk of neurologic sequelae196.  For example, in a study assessing American 
teenage and young adult survivors aged 15 to 21 years, individuals treated with cranial 
radiotherapy were found to be at an increased risk for neurologic complications, such as 
seizure disorders, coordination and motor control problems, hearing impairments, and 
cataracts194,238.  Survivors of testicular cancer treated with cisplatin-based chemotherapy 
agents have also been shown to be at an increased risk of sensory neurologic complications, 
with 29% reporting paresthesia of the hands or feet, 22% reporting tinnitus, and 21% 
reporting hearing impairments244.  Finally, increased risk of stroke has been associated with 
cranial irradiation in CNS tumor and leukemia survivors and mantle field irradiation in 
Hodgkin lymphoma survivors136,239.  Further studies are needed to assess neurologic outcomes 
in teenage and young adult populations in order to make more suitable evidence-based 
recommendations for survivors.   
 
2.2.3.4. Psychosocial Outcomes & Behaviors 
Individuals treated for a cancer as a teenager or young adult face different psychosocial 
outcomes than survivors of cancer diagnosed in childhood or mature adulthood245,246.  In 
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particular, survivors treated in teenage and young adulthood need to cope with having cancer 
and its treatment whilst developing their personal and sexual identity, maintaining their peer 
involvement, and establishing their autonomy161,247.  Due to the fact that cancer is associated 
with lengthy treatments, cancer can often disrupt these developmental milestones, which in 
return may impact school, work, and relationships, and ultimately cause negative 
consequences for long-term financial status and career opportunities196,248.  Cancer-related 
issues, such as loss of fertility or confrontation with potential mortality, may also lead to 
emotional distress and psychiatric symptoms196.  Recent studies assessing emotional issues 
found that psychological distress was significantly higher among teenage and young adult 
cancer survivors compared with survivors of cancer diagnosed in older adulthood249–251 or 
age-matched peers252.  Psychological problems were also associated with an increased risk for 
obesity and other poor health-related behaviors, such as tobacco, alcohol, or substance use196.  
Thus, psychosocial counseling and support is necessary across the life course in order to assist 
teenage and young adult survivors of cancer with accepting cancer, maintaining an active and 
independent life, coping with treatment-side effects and stress, and maintaining a positive 
attitude196,248. 
 
2.3. Study Populations 
2.3.1. British Childhood Cancer Survivor Study  
The British Childhood Cancer Survivor Study (BCCSS) is a large, population-based study of 
childhood cancer survivors who survived at least five years.  The cohort was ascertained by 
using the population-based National Registry of Childhood Tumours (NRCT), which has 
approximately a 99% ascertainment rate253.  Demographic, cancer, and treatment-related 
factors were provided for all survivors by NRCT.  The BCCSS was established as a 
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consequence of the improvements in childhood cancer survival rates across recent decades, 
which has led to a growing population of living childhood cancer survivors.  As it is 
internationally recognized that survivors of childhood cancer are a high-risk population with 
specific health care needs254, it was imperative that these individuals be monitored for long-
term outcomes, especially as these survivors have many decades of life remaining due to their 
young age at diagnosis.  Thus, the main objective of the BCCSS is to assess adverse health 
and social outcomes following childhood cancers255.  Ethical and legal approval for the 
BCCSS was given by a Multi-Centre Research Ethics Committee and every Local Research 
Ethics Committee in Britain.  
 
Originally, to be eligible for inclusion, survivors had to be diagnosed with cancer in Britain 
before the age of 15 years, between January 1, 1940 and December 31, 1991, and to have 
survived at least five years from their original cancer diagnosis.  The overall eligible 
population-based cohort comprised 17,980 survivors.  These individuals were then linked to 
the Health and Social Care Information Centre, which are maintained at Southport (England 
and Wales) and Edinburgh (Scotland)255.  Through this linkage, three critically important 
types of information were obtained for all individuals in the BCCSS cohort.  Firstly, the vital 
status of each survivor was obtained by linking with the national death registration system.  
Secondly, all SPNs were identified by linking with the national cancer registration system.  
And, finally, the current general practitioner practice was identified for all survivors who were 
alive.   
 
By ascertaining each survivor’s National Health Service status, the Study Coordinating Center 
was then able to identify the survivor’s current primary care physician.  Using the primary 
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care physician’s details, a study package was then sent to all survivors who were alive, a 
British resident, and aged at least 16 years at time of questionnaire send out (median year 
2002).  The study package to the primary care physician contained the following items: (1) a 
covering letter indicating the need for the study and seeking their cooperation, (2) a consent 
form for the primary care physician to give their permission for their patient, the survivor, to 
be included in the study together with a reply paid enveloped addressed to the Study 
Coordinating Center, (3) a suggested draft letter for the primary care physician to send to the 
survivor with the study questionnaire inviting participating, and (4) a postage-paid package to 
be mailed to the survivor by the primary care physician after the inclusion of the suggested 
draft letter255.  The package of documents sent to the survivors contained the following items: 
(1) the suggested covering letter from the primary care physician inviting participation, (2) a 
covering letter from the Study Coordinating Center, (3) a short explanatory leaflet for the 
survivor, (4) a personalized copy of the study questionnaire in either the male or female 
version depending on the sex of the survivor, and (5) a reply paid envelope for the survivor to 
return the completed questionnaire to the Study Coordinating Center255.  Ethical approval for 
the questionnaire send-out was obtained from a Multi-Centre Research Ethics Committee and 
every Local Research Ethics Committee in England, Wales, and Scotland. 
 
Of the 17,980 total survivors in the BCCSS cohort, 14,880 (82.8%) were alive, a British 
resident, and aged at least 16 years at questionnaire send out.  Of those who were ineligible 
for a questionnaire, 2,780 (15.5%) had died subsequent to surviving at least five years, 245 
(1.4%) had emigrated, and 75 (0.4%) were alive, a British resident and under 16 years age255.   
An additional 45 survivors were excluded from receiving a questionnaire because they were 
not traced with the Health and Social Care Information Centre (n=24), adopted subsequent to 
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diagnosis of childhood cancer (n=16), or had indicated as part of a pilot study that they did 
not want to be contacted again (n=5)255.  Thus, ultimately, 14,835 survivors were available to 
receive a postal questionnaire survey255. 
 
In total, 10,488 completed questionnaires were returned to the Study Coordinating Center, 
which equated to a response rate of 70.7%.  Each questionnaire contained a range of questions 
relating to the survivor’s life, including topics such as health status, marriage, pregnancies and 
children, family history, smoking and alcohol use, educational attainment, employment, life 
and medical insurance, and personal concerns.  The full male and female questionnaires can 
be found in Appendix 1 and Appendix 2, respectively. 
 
In 2014 the BCCSS was subsequently extended to include individuals diagnosed with 
childhood cancer from January 1, 1992 to December 31, 2006 in Britain and who had 
survived at least five years from their childhood cancer.  Ethical and legal approval was given 
by the National Research Ethics Service (NRES) and national Confidentiality Advisory 
Group (CAG).  With the extension, the BCCSS comprises 34,489 five-year survivors of 
childhood cancer.  Information relating to vital status and SPNs is available for all survivors 
in the cohort.  Information on social, economic, and health outcomes is available for only the 
survivors who completed the questionnaire survey (n=10,488).  This thesis includes analyses 
on the BCCSS both before and after the extension; however, the study population under 
investigation will be described in the methods section of each of the subsequent chapters.  




2.3.2. Teenage and Young Adult Cancer Survivor Study  
The Teenage and Young Adult Cancer Survivor Study (TYACSS) is a large, population based 
study of individuals diagnosed with cancers between the ages of 15 to 39 and who have 
survived at least five years256.  The cohort was established in collaboration with the Office for 
National Statistics (ONS) and Welsh Cancer Registry due to the international 
acknowledgement of the need for survivorship and late effects studies relating to individuals 
diagnosed with cancer as teenagers and young adults6,256–261.  As cancer incidence rates take 
up to five years after the end of a given calendar year to reach 100%262, ascertainment for this 
cohort is expected to be essentially complete as the upper limit for diagnosis inclusion was 
2006.  Ethical and legal approval for the TYACSS was given by the National Research Ethics 
Committee and Confidentiality Advisory Group. 
 
In order to be included in the TYACSS cohort, individuals had to be diagnosed with a teenage 
or young adult cancer from January 1, 1971 to December 31, 2006 in England or Wales and 
survive at least five years.  The total eligible population-based cohort comprises 200,945 
survivors. These individuals were then linked to the Health and Social Care Information 
Centre, which provided the vital status of each survivor, via the national death registration 
system, and all cancer registrations, via the national cancer registration system.  Baseline 
characteristics of the TYACSS cohort can be found in Appendix 4. 
 
2.4. Thesis Outline and Aims 
This thesis aims to expand upon the current understanding of late adverse effects among five-
year survivors of childhood, teenage, and young adult cancers through the investigation of 
five studies using the two cohorts described above.  Such large population-based 
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investigations of risks of a wide spectrum of fatal and non-fatal adverse health outcomes 
provide the most reliable, unbiased, and comprehensive evidence base for (i) counseling, 
educating, and empowering survivors, (ii) providing educational material for healthcare 
professionals, (iii) constructing survivorship care plans, (iv) providing risk stratification 
evidence to inform decisions on amending (childhood cancer) and developing (teenage and 
young adult cancer) clinical follow-up guidelines, (v) advising the Department of Health in 
relation to groups at sufficiently elevated risk to consider recall for counseling, screening, or 
other interventions, (vi) identifying low risk groups for discharge from hospital follow-up, 
(vii) evaluating risks and benefits of proposals for future treatment protocols, and (viii) health 
economic evaluations. 
 
The specific aims of this thesis are: 
1. Study 1:  To assess a wide range of adverse health (mortality, SPNs, 
hospitalizations/healthcare usage, quality-of-life) and social (educational attainment, 
marital status, alcohol and smoking habits) outcomes among five-year survivors of 
childhood bone sarcoma within the BCCSS cohort. 
2. Study 2:  To assess aspects of mental health dysfunction among five-year survivors of 
childhood cancer within the BCCSS cohort. 
3. Study 3:  To quantify the risk of late cause-specific mortality among five-year 
survivors of childhood cancer within the BCCSS extended cohort. 
4. Study 4:  To quantify the risk of cardiac mortality among five-year survivors of 
childhood cancer within the BCCSS extended cohort. 
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5. Study 5:  To quantify the risk of respiratory mortality among five-year survivors of 
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STUDY 1:  
Long-term adverse outcomes in survivors of 






Purpose:  With improved survival, more bone sarcoma survivors are approaching middle age 
making it crucial to investigate the late effects of their cancer and its treatment.  We 
investigated the long-term risks of adverse outcomes among five-year bone sarcoma survivors 
within the British Childhood Cancer Survivor Study. 
 
Material and Methods:  Cause-specific mortality and risk of subsequent primary neoplasms 
(SPNs) were investigated for 664 bone sarcoma survivors.  Use of health services, health and 
marital status, alcohol and smoking habits, and educational qualifications were investigated 
for survivors who completed a questionnaire.  
 
Results:  Survivors were seven-times more likely to experience all-cause mortality than 
expected, and there were substantial differences in risk depending on tumor type.  Beyond 25 
years follow-up the risk of dying from all-causes was comparable to the general population.  
This is in contrast to dying before 25 years where the risk was 13-fold that expected.  
Survivors were also four-times more likely to develop a SPN than expected, the excess 
restricted to 5-24 years post-diagnosis.  Increased healthcare usage and poor health status 
were also found.  Nonetheless, for some psychosocial outcomes survivors were better off than 
expected.   
 
Conclusions:  Up to 25 years after five-year survival, bone sarcoma survivors are at 
substantial risk of death and SPNs, but this is greatly reduced thereafter.  As 95% of all excess 
deaths before 25 years follow-up were due to recurrences and SPNs, increased monitoring of 
survivors could prevent mortality.  Furthermore, bone and breast SPNs should be a particular 
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concern.  Since there are variations in the magnitude of excess risk depending on the specific 
adverse outcome under investigation and whether the survivors were initially diagnosed with 
osteosarcoma or Ewing sarcoma, risks need to be assessed in relation to these factors.  These 




Primary malignant bone sarcomas account for 4.8% of all childhood cancers in the UK1.  
Approximately 65 cases occur each year, of which the principal tumor types are osteosarcoma 
(53%) and Ewing sarcoma (39%)1.  Although the incidence is low, survival after bone 
sarcoma has increased substantially. Since the 1970s five-year survival has risen from 23% to 
64% mainly due to the introduction of modern chemotherapy1.  Consequently, as the number 
of individuals treated for childhood bone sarcomas increases, it becomes ever more important 
to investigate the risk of the long-term effects of this childhood cancer and its treatment. 
 
This study assessed adverse outcomes among bone sarcoma survivors diagnosed between the 
ages of 0-14 years within the British Childhood Cancer Survivor Study (BCCSS).  Key 
advantages of the BCCSS compared to other studies are that it is a large, population-based 
cohort with 30.4% of individuals diagnosed with bone sarcoma surviving to age 45 years at 
least.  Therefore, adverse health and social outcomes beyond 35 years post-diagnosis in these 
childhood cancer survivors can be examined much more satisfactorily than has been possible 
in previous smaller or non-population based studies with limited follow-up2–6.  In this study, 
we investigated the long-term risk of premature mortality, developing a subsequent primary 
neoplasm, healthcare usage, health and marital status, alcohol and smoking habits, and 
educational attainment among five-year childhood bone sarcoma survivors.  
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Material and Methods  
British Childhood Cancer Survivor Study 
The BCCSS, which has been described previously in detail7, is a population-based cohort 
comprised of 17,980 individuals; it includes 664 bone sarcoma survivors diagnosed with 
cancer before the age of 15, between 1940-1991 in Great Britain, and who have survived at 
least five years.  The cohort was ascertained through the National Registry of Childhood 
Tumours, which has a high estimated level of completeness (~99%)8.  Ethical approval for the 
study was obtained from a Multi-Centre Research Ethics Committee and every Local 
Research Ethics Committee in Britain.   
 
When treatment exposures within this cohort were investigated across five-year calendar year 
bands, we found that prior to 1976, where our radiotherapy and chemotherapy treatment 
completeness was 98.4% and 88.4% respectively, the majority of bone sarcoma survivors 
received radiotherapy (76.3%), with only a small proportion receiving chemotherapy.  A 
distinct change in treatment practice was then observed from 1976 onwards where broadly all 
survivors received chemotherapy and Ewing sarcoma survivors additionally received 
radiotherapy.  Thus, in order to address the incompleteness of treatment information in more 
recent diagnosis years, which was due to decreasing availability of recorded radiotherapy and 
chemotherapy details at the National Registry of Childhood Tumours during this period, our 
analyses were undertaken for bone sarcoma survivors overall and separately for osteosarcoma 
and Ewing sarcoma, which serve as proxies for treatment exposures.  Therefore, osteosarcoma 
survivors were likely to have received radiotherapy if diagnosed prior to 1976 and only 
chemotherapy if diagnosed from 1976 onwards, whereas all Ewing sarcoma survivors were 
likely to have received radiotherapy, with only those diagnosed after 1976 additionally 
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receiving chemotherapy.  Consequently, those surviving beyond 25 years from five-year 
survival were likely to have only received radiotherapy, whilst those with less than 25 years 
follow-up were likely to have received only chemotherapy or chemotherapy and radiotherapy 
depending on tumor type. 
 
Record Linkage Ascertained Outcomes 
Deaths and subsequent primary neoplasms (SPNs) were ascertained for the entire BCCSS 
cohort through record linkage with the Health and Social Care Information Centre, which 
includes the population-based national death and cancer registries.  This linkage ensures that 
the BCCSS is notified whenever a survivor has died or developed a SPN.  To determine the 
expected number of deaths or incident cancers, person-years for each sex-specific, age-
specific (five-year bands), and calendar year-specific (one-year bands) stratum were 
multiplied by the corresponding general population rates for specific cause(s)-of-death and 
incident cancers occurring throughout England and Wales.  
  
Cause-specific Mortality 
For our mortality analysis, the death certificate and underlying cause-of-death, as coded by 
the Office for National Statistics using the relevant International Classification of Disease, 
were obtained.  The underlying cause-of-death was then confirmed by a clinician using 
available medical records; very little disagreement was observed and thus the underlying 
cause-of-death listed on the death certificate was utilized.  Time at risk started at five-year 
survival and continued until individuals exited from risk at the first occurrence of emigration, 
death, or December 31, 2010, which was the date of the most recent vital status update on the 
entire cohort from the National Health Service Information Centre.  The standardized 
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mortality ratio (SMR) was defined as the ratio of observed to expected number of deaths.  The 
absolute excess risk (AER) was defined as the observed minus the expected number of deaths 
divided by person-years at risk multiplied by 10,000.  Cumulative mortality for a specific 
cause-of-death was calculated by treating other causes-of-death as competing risks.   
 
Subsequent Primary Neoplasms  
Confirmation of all SPNs was undertaken by writing to the relevant clinician(s) to obtain 
diagnostic reports to confirm site, type, and date of diagnosis.  Irrespective of further clinical 
input or information, the SPN site and type coded at cancer registration was used.  Time at 
risk for a SPN began at five-year survival and individuals exited from risk at the first 
occurrence of an SPN, emigration, death, or December 31, 2006 which was the most recent 
date up to which all potential SPNs had been ascertained and validated.  Standardized 
incidence ratios (SIRs) were calculated as the ratio of observed to expected number of 
neoplasms.  AERs were calculated as described previously for the mortality analyses.  
Cumulative incidence for the first occurrence of a SPN was computed treating death as a 
competing risk. 
 
Questionnaire Ascertained Outcomes 
Healthcare usage, health and marital status, alcohol and smoking habits, and educational 
attainment were obtained via the BCCSS questionnaire.  To be eligible to receive the BCCSS 
questionnaire survivors in the cohort had to be alive and aged at least 16 years at 
questionnaire send-out (median year 2002).  Of the 664 bone sarcoma survivors, 506 
survivors met this eligibility criteria and were contacted; amongst survivors who were 
ineligible, the majority had died prior to questionnaire send-out (n=106).  Ultimately, 411 
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(81.2%) returned a completed questionnaire.  All comparisons with the general population 
were adjusted for age and sex.  Some outcomes were adjusted further – see tables for details. 
 
Healthcare Usage 
Four types of healthcare usage were assessed: talking to a doctor, attending the hospital 
outpatient department, being hospitalized as a day patient, and being hospitalized as an 
inpatient.  In order to compare healthcare use with the general population, the 2002 General 
Household Survey (GHS) served as the general population sample9.  Multivariable 
generalized estimating equation (GEE) logistic regression modeling was used to calculate 
odds ratios (OR) for healthcare usage among bone sarcoma survivors compared to that 
expected from the general population sample10.  
 
Psychosocial Outcomes 
The survivors' education level, smoking history, and alcohol consumption were compared to 
the general population using the 2002 GHS9 as the reference sample, whereas marital status 
was compared to the National Marriage Registry11.  Multivariable GEE logistic regression 
was used to compare educational attainment, smoking status, and alcohol use between 
survivors and the general population sample12–14.  ORs were calculated using pooled Mantel-
Haenszel tests to compare marital status between survivors and the general population sample.   
 
Health Status   
Version one of the Short Form 36 (SF-36) Health Survey was used to measure self-reported 
health status by the following eight scales: physical function, role-physical, role-emotional, 
social functioning, mental health, vitality, pain, and general health perception.  External 
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comparisons were conducted using the Oxford Healthy Life Survey (OHLS) as the general 
population sample.  Multivariable linear regression and direct standardization were used to 
compare bone sarcoma survivors and the OHLS population.   
 
All analyses were undertaken using Stata 12.115.  Statistical significance was defined as a 




Of the 664 bone sarcoma survivors, 309 (46.5%) were diagnosed with osteosarcoma, 260 
(39.2%) were diagnosed with Ewing sarcoma, 26 (3.9%) were diagnosed with 
chondrosarcoma, 48 (7.2%) were diagnosed with other specified bone sarcomas (e.g. 
fibromatous neoplasms, giant cell tumors, chordomas, miscellaneous bone tumors), and 21 
(3.2%) were diagnosed with an unspecified bone sarcoma.  The mean age at diagnosis was 
10.8 and the average attained age was 39.4 years (Table 3.1).  Osteosarcoma survivors were 
older at diagnosis and had a higher attained age compared to Ewing sarcoma survivors.  
Excluding missing information, 60.2% and 60.0% of survivors received radiotherapy and 
chemotherapy, respectively.  In general, characteristics of the 411 survivors who returned a 
questionnaire were similar both overall and by tumor type to the entire BCCSS bone sarcoma 
cohort, except that only 3.7% had died by December 31, 2010 subsequent to completing a 
questionnaire. 
 
Record Linkage Ascertained Data 
Cause-specific Mortality 
Overall, bone sarcoma survivors experienced seven-times (SMR:7.0, 95%CI:5.9-8.3) the 
number of deaths expected from the general population with 72 (95%CI:57.2-85.8) excess 
deaths per 10,000 person-years (Table 3.2). The largest excess was for neoplastic-related 
causes in both relative and absolute terms; recurrences and SPNs accounted for 71.2% and 
22.6% of all excess deaths, respectively.  When the SMR was assessed by follow-up, a 
striking difference was observed; the overall SMR was 12.7-times (95%CI:10.5-15.2) that 
expected during 0-24 years follow-up and only 1.7-times (95%CI:1.0-2.7) that expected 
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beyond 25 years.  Notably, there was an eight-fold decrease in SMRs from 0-24 years to 
beyond 25 years follow-up for SPN-related deaths.  Compared to the general population, the 
SMR for all-causes was significantly higher (P<0.001) for Ewing sarcoma survivors, who had 
approximately double the SMR and AER of osteosarcoma survivors.  Although recurrence 
and SPN related deaths accounted for approximately 93% of all excess deaths in both tumor 
types, there was heterogeneity in the proportion of recurrence and SPN excess deaths; 
recurrences accounted for 59.0% and 80.2% of excess deaths in osteosarcoma and Ewing 
sarcoma survivors respectively, whilst the corresponding excess SPN deaths were 34.7% and 
13.1%.   
 
There was a steep increase in mortality during the initial five years following five-year 
survival where the cumulative mortality reached 10.4% (95%CI:8.3-13.0) (Figure 3.1).  
Subsequently, there was a more gradual incline to 20.6% (95%CI:17.3-24.3) at 35 years post-
diagnosis.  When stratified by tumor type (Figure 3.2) a significant difference (P=0.004) in 
cumulative mortality was observed for recurrences, where Ewing sarcoma survivors had 
nearly double the cumulative mortality at 35 years post-diagnosis (osteosarcoma:8.5% vs. 
Ewing sarcoma:16.7%).  Conversely, the cumulative mortality due to SPNs was twice as high 
for osteosarcoma compared to Ewing sarcoma survivors at the same point 
(osteosarcoma:6.7% vs. Ewing sarcoma:3.2%).   
 
Subsequent Primary Neoplasms 
Bone sarcoma survivors were 4.4-times (95%CI:3.3-5.8) more likely to experience a SPN 
than expected and had 29.3 (95%CI:18.7-39.9) excess SPNs per 10,000 person-years (Table 
3.3).  By SPN cancer type, survivors overall and by tumor type were at a considerably higher 
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risk of developing a subsequent bone neoplasm and to a lesser extent a breast neoplasm.  
Specifically overall, survivors were 136.3- (95%CI:79.2-234.8) and 4.5-times (95%CI:2.6-
8.0) more at risk than the general population for bone and breast cancers, respectively.  When 
the SIRs were assessed by follow-up, a 8.4-fold (95%CI:6.1-11.2) increased risk was 
observed during 0-24 years, where the SIR for subsequent breast and bone cancer were 10.8 
(95%CI:5.2-19.9) and 154.3 (95%CI:82.2-263.8) respectively.  Beyond 25 years of follow-up, 
the SIR for any SPN was not significantly higher in survivors than expected from the general 
population. 
   
There was a continuous and steady increase in cumulative incidence for SPNs over follow-up, 
ultimately reaching 8.3% (95%CI:5.9-11.2) at 30 years post-diagnosis (Figure 3.3).  When 
stratified by tumor type, the cumulative incidence curves were nearly identical to each other 
and to bone sarcoma survivors overall (P>0.05).   
 
Questionnaire Ascertained Data 
Healthcare Usage 
Compared to the general population sample, bone sarcoma survivors were almost three times 
(OR:2.9, 95%CI:2.3-3.7) more likely to have visited an outpatient hospital department in the 
previous three months (Table 3.4).  Survivors were also over twice (OR:2.4, 95%CI:1.7-3.4) 
more likely to be hospitalized as an inpatient during the previous year than the general 
population sample.  When analyzed by tumor type, both osteosarcoma and Ewing sarcoma 
survivors had significantly higher odds of attending the hospital as an outpatient or inpatient 





Bone sarcoma survivors overall were comparable to the general population sample for being 
ever-married, a current drinker, or consuming harmful amounts of alcohol (Table 3.4).  
Survivors were, however, significantly less likely to be a current smoker (OR:0.6, 95%CI:0.5-
0.8) and consume alcohol over recommendations (OR:0.7, 95%CI:0.5-0.9) than the general 
population sample.  Compared to that expected, survivors performed well in obtaining 
educational qualifications and were 70% more likely to have obtained at least O-levels 
(OR:1.7, 95%CI:1.3-2.1).  When analyzed by tumor type, the odds for each psychosocial 
outcome were comparable to the overall finding.   
 
Health Status 
Compared to the general population sample, bone sarcoma survivors overall were 
significantly more limited in all SF-36 scales with the exception of role-emotional (Figure 
3.4).  The most notable differences occurred in physical function, role-physical, and pain.  For 
the individual components of the physical function scale (Figure 3.5), 54% and 61% of 
survivors were limited in “moderate activities” and “walking more than one mile” compared 
to the 8% and 11% expected from the general population sample respectively.  In the role-
physical scale (Figure 3.6), the largest difference between the survivors and general 
population sample was in “being limited in the kind of work and activities,” although all 
component questions reported at least a 10% deficit.  Finally, for the pain scale (Figure 3.7), 
survivors reported more bodily pain (12% vs. 5%) and more pain interference (16% vs. 5%) 
during the past four weeks compared to the general population sample.   
 
 75 
When stratified by tumor type, osteosarcoma survivors were assessed additionally by 
amputation status, where only arm or leg amputations as a form of initial treatment for the 
first primary tumor were included.  Compared to the general population sample, osteosarcoma 
amputee survivors reported being the most limited in all scales relative to osteosarcoma non-
amputees and Ewing sarcoma survivors, with a significantly (P<0.001) higher disadvantage in 
physical function (Figure 3.4).   
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Discussion 
This is the first large scale population-based study to provide a comprehensive description of 
long-term health and social outcomes among a large cohort of five-year bone sarcoma 
survivors, both overall and by tumor type, beyond 35-years post-diagnosis.  Mortality 
estimates in this cohort were elevated seven-times that expected and varied significantly 
between tumor types, which were consistent with previous findings of a large-scale US 
study2.  Past studies have also shown the principal cause-of-death was neoplastic-related16–18.  
However, to our knowledge, this is the first study that has shown substantial differences when 
comparing excess and cumulative mortality between tumor types; osteosarcoma survivors had 
double the cumulative mortality for SPNs compared to Ewing sarcoma and Ewing sarcoma 
survivors had double the cumulative mortality for recurrences compared to osteosarcoma at 
35 years post-diagnosis.  The osteosarcoma survivors in this study were much more likely to 
have an amputation than Ewing sarcoma, which may partially explain why osteosarcoma 
survivors were less likely to have recurred19.  Additionally, due to the extended follow-up 
available, this is the first study to show that beyond 25 years follow-up the risk of dying from 
all-causes is comparable to the general population and unlikely to exceed 2.7-fold that 
expected.  This is in contrast to dying before 25 years of follow-up, where the risk is 12.7-fold 
that expected.  This provides important evidence for clinicians who monitor survivors treated 
in similar decades to those included in the BCCSS.  A possible explanation for this striking 
absence or low risk of excess mortality with extended follow-up may relate to our previous 
observation that, as the overall cohort of childhood cancer survivors ages, a large proportion 
of excess deaths are attributed to SPNs20, particularly breast, digestive, genitourinary, and 
lung carcinomas.  Although carcinomas of these sites are common cancers of adulthood in the 
general population, in childhood cancer survivors they are principally caused by direct 
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radiotherapy exposure20.  As 80% of the bone sarcomas included here were diagnosed in the 
limb, there is unlikely to have been much direct exposure from radiotherapy to tissues of these 
sites due to the lack of proximity of the radiotherapy fields.   
 
The overall and tumor type-specific SIRs for SPNs were consistent with previous studies3,21–
23.  Additionally, our findings are consistent with previous literature in that the most common 
SPN was breast cancer for osteosarcoma survivors and bone cancer for Ewing sarcoma 
survivors22.  Due to the extended follow-up available, this is the first study to show that the 
risk of developing SPNs was 9.9-fold the expected during 0-24 years follow-up and 
comparable to the general population beyond 25 years follow-up, where it was unlikely to 
exceed 2.0-fold that expected.  Notably, all 13 bone cancers occurred before 25 years follow-
up, nine of which developed inside or on the edge of tissue directly irradiated to treat the 
original bone sarcoma and one in a survivor diagnosed with a p53 mutation.  This corresponds 
with our previous work that found that bone cancer is the most common SPN after a first 
primary bone sarcoma20, which is principally attributable to exposure of the SPN site to 
radiation during treatment for the first cancer24–26.  Of the two breast cancers observed 
subsequent to 25 years follow-up, both developed in survivors previously treated for a bone 
sarcoma of a lower limb with unknown p53 status.  
 
Consistent with other studies27–29, we reported that survivors were severely limited in health 
status, in particular physical function and pain.  While previous studies have suggested that 
health status among amputees is generally similar to non-amputees30–35, we found that 
osteosarcoma amputees reported the worst health status for all scales, with significantly 
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higher limitations in physical function relative to osteosarcoma non-amputees and Ewing 
sarcoma (95% of which were non-amputees) survivors.   
 
Although we report here on appreciable proportions of the bone sarcoma survivors 
experiencing detrimental effects to their health, many of their social outcomes were favorable.  
In fact, our findings suggest that survivors were more likely than expected to obtain some 
types of educational qualification and less likely to be a current smoker than expected from 
the general population. 
 
Current Guidelines & Recommendations  
The Bone Cancer Research Trust currently recommends yearly follow-up after five-year 
survival36,37.  From the evidence presented here, 74% and 21% of all excess deaths before 25 
years of follow-up were due to recurrence and SPN respectively, and therefore monitoring of 
survivors for recurrences and SPNs, particularly during the period 5-10 years post-diagnosis 
where risk of recurrence is highest, could help prevent premature mortality.  Bone and breast 
SPNs should also be a particular concern and regular follow-up should be provided, 
particularly in the period 0-24 years following five-year survival for bone SPNs.  Factsheets 
given to childhood cancer survivors could further expand upon the risk of recurrence and 
SPNs and the potential for early diagnosis by detailing more precisely signs and symptoms 
relating to bone and breast neoplasms.  Furthermore, the substantial excess risks of specific 
physical limitations and pain are likely to be useful for risk stratification and possible 
interventions that seek to reduce morbidity and the practical difficulties that survivors may 




Although the findings in this paper may not be generalizable for children diagnosed after 
1991, the purpose of this study was to address the long-term, beyond 35 years post-diagnosis, 
outcomes that childhood bone sarcoma survivors are currently facing.  We acknowledge 
reassessment is necessary and recommend further analyses to be conducted on the recently 
extended BCCSS cohort, which includes five-year survivors diagnosed from 1992-2006.  
Furthermore, as a large proportion of bone sarcoma diagnoses occur in individuals aged over 
14 years, we recommend further analyses on adverse outcomes to be assessed using the 
Teenage and Young Adult Cancer Survivor Study (TYACSS), which we have established 
recently and includes all five-year survivors diagnosed from age 15-39 in England and Wales 
between 1970-2006.  Finally, a potential limitation of our study is the lack of detailed 
treatment information.  Although we report a large reduction in excess mortality and SPNs 
beyond 25 years follow-up, those followed-up for less than 25 years are more likely to be 
treated differently due to the introduction of chemotherapy.  Thus, reassessment of these more 
recently diagnosed individuals is essential in order to determine whether the decreases in risk 
reported in this study remain with newer treatment practices.  Nevertheless, due to our 
population-based design, the evidence presented here provides a reliable and unbiased basis to 
update clinical follow-up guidelines in relation to bone sarcoma survivors diagnosed before 
age 15 and treated before 1992 in Great Britain by using cancer diagnosis as a proxy.  
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Conclusions 
In conclusion, childhood bone sarcoma survivors diagnosed between 1940 and 1991 in this 
cohort are at substantial risk of death and SPNs up to 25 years after five-year survival, but the 
risk is greatly reduced thereafter.  Survivors additionally face difficulties in daily life due to 
their excess prevalence of poor physical health-status.  As there are variations in the degree of 
excess depending on the specific outcome and whether they survived osteosarcoma or Ewing 
sarcoma, risk needs to be assessed in a stratified way.  These findings should provide useful 
evidence for risk stratification, updating clinical follow-up guidelines, and possible 




Available Survivors for Data Linkage  
(N=664) 

















Sex       
Male 345 (52.0) 150 (48.5) 138 (53.1) 200 (48.7) 96 (47.8) 74 (48.1) 
Female 319 (48.0) 159 (51.5) 122 (46.9) 211 (51.3) 105 (52.2) 80 (52.0) 
Cancer Site       
Upper limbs 92 (13.9) 34 (11.0) 48 (18.5) 56 (13.7) 21 (10.5) 32 (20.8) 
Lower limbs 436 (65.7) 262 (84.8) 132 (50.8) 273 (66.5) 170 (84.6) 75 (48.7) 
Bones of skull and face 42 (6.4) 5 (1.6) 10 (3.9) 26 (6.3) 4 (2.0) 6 (3.9) 
Vertebral column 24 (3.6) 3 (1.0) 15 (5.8) 13 (3.2) 3 (1.5) 7 (4.6) 
Rib, sternum, clavicle 28 (4.2) 1 (0.3) 25 (9.6) 20 (4.9) 1 (0.5) 17 (11.0) 
Pelvic, sacrum, coccyx 33 (5.0) 2 (0.7) 27 (10.4) 19 (4.6) 2 (1.0) 15 (9.7) 
Other  9 (1.4) 2 (0.7) 3 (1.2) 4 (1.0) 0 (0) 2 (1.3) 














0-4 years 40 (6.0) 8 (2.6) 22 (8.5) 22 (5.4) 4 (2.0) 13 (8.4) 
5-9 years 185 (27.9) 74 (24.0) 84 (32.3) 122 (29.7) 46 (22.9) 58 (37.7) 
10-14 years 439 (66.1) 227 (73.5) 154 (59.2) 267 (65.0) 151 (75.1) 83 (53.9) 














16-24 years 89 (13.4) 31 (10.0) 47 (18.1) 71 (17.3) 23 (11.4) 43 (27.9) 
25-34 years 155 (23.3) 62 (20.1) 78 (30.0) 169 (41.1) 83 (41.3) 72 (46.8) 
35-44 years 218 (32.8) 108 (35.0) 90 (34.6) 92 (22.4) 53 (26.4) 25 (16.2) 
45+ years 202 (30.4) 108 (35.0) 45 (17.3) 79 (19.2) 42 (20.9) 14 (9.1) 
Radiotherapy†       
No 201 (39.8) 150 (59.3) 17 (9.9) 125 (40.3) 98 (58.3) 10 (10.5) 
Yes 304 (60.2) 103 (40.7) 154 (90.1) 185 (59.7) 70 (41.7) 85 (89.5) 
Chemotherapy†       
No 195 (40.0) 93 (37.5) 40 (23.8) 109 (36.7) 58 (35.6) 16 (17.2) 
Yes 292 (60.0) 155 (62.5) 128 (76.2) 188 (63.3) 105 (64.4) 77 (82.8) 
Surgery†       
No 160 (31.3) 34 (13.2) 109 (63.4) 93 (29.4) 19 (11.1) 62 (64.6) 
Yes 352 (68.8) 223 (86.8) 63 (36.6) 223 (70.6) 152 (88.9) 34 (35.4) 
Vital Status‡       
Alive 533 (80.3) 256 (82.9) 203 (78.1) 396 (96.4) 193 (96.0) 150 (97.4) 
Dead 131 (19.7) 53 (17.2) 57 (21.9) 15 (3.7) 8 (4.0) 4 (2.6) 
Table 3.1:  Characteristics of bone sarcoma study population overall and by tumor type 
†Missing data: Radiotherapy(all data-linkage)=139, Radiotherapy(all questionnaire)=101; Chemotherapy(all data-linkage)=157, 
Chemotherapy(all questionnaire)=114; Surgery(all data-linkage)=152, Surgery(all questionnaire)=95 
‡Age at December 31, 2010 or death/embarkation (if before December 31, 2010) – relevant to the mortality analyses 
§Age at questionnaire completion – relevant to outcomes measured by the questionnaire
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All Bone Sarcoma Survivors Osteosarcoma Survivors Ewing Sarcoma Survivors P§ 
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Cause of Death 





























































































































































































Table 3.2:  All cause and cause-specific† standardized mortality ratios and absolute excess risk for bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS) overall and by tumor type 
SMRs and AERs where there are less than 5 observed events should be interpreted with caution 
Abbreviations: O-observed number, E-expected number, CI-confidence intervals, SMR-standardized mortality ratios, AER-absolute excess risk, NA-not applicable, NP-not possible to reliably calculate due to very 
small expected number 
†Results are only reported for underlying causes-of-deaths with at least five observed events overall.  Other causes-of-death were: 4 genitourinary, 1 digestive, 1 infection, 1 unknown 
‡Per 10,000 person-years 
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Table 3.3: Overall and site-specific† standardized incidence ratios and absolute excess risks of second primary neoplasms for bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS) 
SIRs and AERs where there are less than 5 observed events should be interpreted with caution  
Abbreviations: O-observed number, E-expected number, CI-confidence intervals, SIR-standardized incidence ratios, AER-absolute excess risk, NA-not applicable, NP-not possible to reliably calculate due to very small 
expected number 
†Results are only reported for site-specific SPNs with at least five observed events overall.  Other SPNs were: 4 genitourinary, 4 bladder, 3 digestive, 3 connective and soft tissue, 3 malignant neoplasms with 
unspecified sites, 2 gliomas, 2 Hodgkin lymphoma, 2 NHL, 2 leukemia, 1 respiratory, 1 eye, 1 thyroid 
‡AER is shown per 10,000 person-years 




 UK Norms (ref) 






Marital Status†     
Males Ever-married 1.0 0.7 (0.5,1.0) 1.0 (0.6,1.6) 0.7 (0.4,1.3) 
Females Ever-married 1.0 0.8 (0.6,1.1) 0.8 (0.5,1.2) 0.9 (0.6,1.4) 
Education‡     
University degree or higher 1.0 1.2 (1.0,1.6) 1.5 (1.1,2.1) 1.0 (0.8,1.5) 
Teaching qualification or higher 1.0 1.1 (0.9,1.4) 1.3 (1.0,1.7) 1.0 (0.7,1.4) 
A-levels or higher 1.0 1.2 (1.0,1.5) 1.2 (0.9,1.6) 1.1 (0.8,1.5) 
O-levels or higher 1.0 1.7 (1.3,2.1) 1.8 (1.2,2.6) 2.0 (1.2,3.1) 
Alcohol§     
Current drinker 1.0 0.8 (0.6,1.1) 1.0 (0.6,1.6) 0.8 (0.5,1.3) 
Consuming over recommendations 1.0 0.7 (0.5,0.9) 0.7 (0.5,1.1) 0.5 (0.3,0.9) 
Consuming harmful amounts 1.0 0.7 (0.4,1.1) 0.6 (0.3,1.4) 0.7 (0.3,1.5) 
Smoking§      
Current smoker 1.0 0.6 (0.5,0.8) 0.7 (0.5,1.0) 0.6 (0.4,0.9) 
Use of Health Services||     
Talked to a doctor¶ 1.0 1.2 (0.9,1.6) 1.3 (0.9,1.8) 1.2 (0.8,1.8) 
Attended as outpatient¶ 1.0 2.9 (2.3,3.7) 2.9 (2.1,4.0) 3.2 (2.2,4.7) 
Attended as day patient* 1.0 1.1 (0.7,1.5) 1.2 (0.7,1.9) 1.0 (0.6,1.8) 
Attended as inpatient* 1.0 2.4 (1.7,3.4) 2.5 (1.6,3.9) 2.8 (1.7,4.7) 
Table 3.4:  Percentages and odds ratios (with corresponding 95% confidence intervals) for the likelihood of use of health services and psychosocial outcomes in bone sarcoma survivors within the British Childhood 
Cancer Survivor Study (BCCSS) compared with the general population of Britain 
Abbreviations: OR-odds ratio, CI-confidence interval 
†From a pooled Mantel Haenszel model controlling for attained age 
‡From a GEE multivariate logistic regression controlling for age at questionnaire completion and sex (taking into account the GHS weighting factor) 
§From a GEE multivariate logistic model adjusting for attained age (<69 years), sex, marital status, socioeconomic classification, educational attainment, and region (taking into account the GHS weighting factor) 
||From a GEE multivariate logistic model adjusting for age at questionnaire completion, sex, and educational attainment 
¶Excluding women who were pregnant at time of survey 




Figure 3.1:  Cumulative mortality of recurrence and second primary neoplasms among childhood bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS) by tumor type 
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Figure 3.3:  Observed cumulative incidence of a subsequent primary neoplasm among bone sarcoma survivors within the British Childhood Cancer Survivor Study (BCCSS) overall and by tumor type  
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Figure 3.4:  Sex and age adjusted regression coefficients and corresponding 95% confidence intervals for differences in SF-36 health status scales between bone sarcoma, osteosarcoma amputees, osteosarcoma non-
amputees, and Ewing sarcoma survivors versus UK norms 
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Figure 3.5:  Directly (age and sex) standardized prevalence and corresponding 95% confidence intervals, of reporting being limited† in specific daily activity or other problem related to physical function 
score of SF-36 
†Limited defined as reporting “yes, limited a lot” or “yes, limited a little” for relevant question of BCCSS questionnaire 
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Figure 3.6:  Directly (age and sex) standardized prevalence and corresponding 95% confidence intervals, of reporting being limited† in specific daily activity or other problem related to role limitation 
physical score of SF-36 
†Limited defined as reporting “yes” for relevant question of BCCSS questionnaire  
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Figure 3.7:  Directly (age and sex) standardized prevalence and corresponding 95% confidence intervals, of reporting being limited† in specific daily activity or other problem related to pain score of SF-
36 
†Limited defined as reporting “severe/very severe” or “quite a bit/ extremely” for relevant question of BCCSS questionnaire 
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STUDY 2:  
Aspects of mental health dysfunction among 
survivors of childhood cancer  
  97 
Abstract  
Purpose:  Some previous studies have reported that survivors of childhood cancer are at an 
increased risk of developing long-term mental health morbidity, whilst others have reported 
that this is not the case. Therefore, we analyzed five-year survivors of childhood cancer using 
the British Childhood Cancer Survivor Study (BCCSS) to determine the risks of aspects of 
long-term mental health dysfunction.  
 
Material and Methods:  Within the BCCSS, 10,488 survivors completed a questionnaire that 
ascertained mental health-related information via ten questions from the Short From-36 
survey.   Internal analyses were conducted using multivariate logistic regression to determine 
risk factors for mental health dysfunction.  External analyses were undertaken using direct 
standardization to compare mental health dysfunction in survivors to UK norms.     
 
Results:  This study has shown that overall, childhood cancer survivors had a significantly 
higher prevalence of mental health dysfunction for 6/10 questions analyzed compared to UK 
norms.  CNS and bone sarcoma survivors reported the greatest dysfunction, compared to 
expected, with significant excess dysfunction in nine and six questions, respectively; the 
excess ranged from 4.4%-22.3% in CNS survivors and 6.9%-15.9% in bone sarcoma 
survivors.  Compared to expected, excess mental health dysfunction increased with attained 
age; this increase was greatest for reporting “limitations in social activities due to health,” 
where the excess rose from 4.5% to 12.8% in those aged 16-24 and 45+, respectively.  Within 
the internal analyses, higher levels of educational attainment and socioeconomic classification 
were protective against mental health dysfunction. 
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Conclusions:  Based on the findings of this large population-based study, childhood cancer 
survivors report significantly higher levels of mental health dysfunction than those in the 
general population, where deficits were observed particularly among CNS and bone sarcoma 
survivors.  Limitations were also observed to increase with age, and thus it is important to 
emphasize the need for mental health evaluation and services across the entire lifespan.  There 
is evidence that low educational attainment and being unemployed or having never worked 
adversely impacts long-term mental health.  These findings provide an evidence base for risk 
stratification and planning interventions.   
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Introduction  
Although five-year survival from childhood cancer has risen substantially to approximately 
80%1, long-term survival is accompanied by an excess risk of adverse outcomes due to late 
effects of the cancer and its treatment.  Consequently, as the number of survivors increases, it 
becomes ever more important to investigate the risk of such adverse effects in order to 
identify vulnerable subgroups.  While previous studies have investigated health status among 
childhood cancer survivors, mental health sequelae remains a concern as psychological 
limitations or distress have been reported in both adolescent and adult survivors of childhood 
cancer2–5.  Additionally, conflicting findings on mental health have been reported5,6.  By 
identifying survivors at risk for mental health dysfunction, appropriate monitoring and early 
interventions within long-term care can be undertaken through risk stratification to ensure that 
young people and adults achieve the best possible outcomes in terms of health and social 
welfare, whilst optimizing the expenditure of limited resources. 
 
The goal of this study was to investigate specific aspects of mental health dysfunction among 
childhood cancer survivors diagnosed between the ages of 0-14 years within the British 
Childhood Cancer Survivor Study (BCCSS) by assessing responses to specific questions 
within the Short Form-36 (SF-36) survey.  Although studies have assessed aspects of mental 
health using this survey previously5–10, this is the first study to our knowledge to 
comprehensively analyze the ten questions comprising the role-emotional, social functioning, 
and mental health scales, which have been shown to be the most valid among the scales as 
mental health measures11,12.  By looking at specific questions, one can better determine the 
effect of various aspects of mental health dysfunction, which may have been previously 
undetected in a composite score or individual scale.  The potential impact of demographic, 
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cancer, treatment, social, and economic explanatory factors on mental health were explored 
and external analyses comparing survivors to general population norms were conducted.  In 
doing so, this large, population-based study provides further evidence on mental health 
morbidity among childhood cancer survivors, which may have important implications for 
clinicians, family members, and survivors with regard to minimizing mental health adverse 
late effects. 
  101 
Material and Methods 
Study Population 
The BCCSS is a population-based cohort of 17,980 individuals diagnosed with cancer before 
the age of 15, between 1940-1991 in Great Britain, and who have survived at least five 
years13.  The cohort was ascertained through the National Registry of Childhood Tumours, 
which has a high estimated level of completeness (~99%)14.  Ethical approval for the study 
was obtained from a Multi-Centre Research Ethics Committee and every Local Research 
Ethics Committee in Britain (N = 212 in total). 
 
Short Form-36 Survey 
It was important to measure both health and social impacts on quality-of-life to understand the 
effect of childhood cancer treatment on long-term mental health.  In order to ascertain health 
and social outcomes, a questionnaire was sent to all survivors in the BCCSS cohort who were 
alive and aged at least 16 years. Of the 14,836 survivors who were eligible to receive the 
questionnaire, 10,488 (70.7%) completed the survey13.  Included in the questionnaire was the 
SF-36, which is a generic health survey that contains 36 questions, which measure eight 
dimensions of health status.  From our previous work, which studied the psychometric 
properties of the SF-36 in the BCCSS population, we know that this survey exhibits good 
validity and reliability when used in long-term survivors of childhood cancer15.   
 
Using the available information from the SF-36, we assessed specific aspects of mental health 
dysfunction, henceforth only referred to as mental health dysfunction, by looking at the ten 
individual questions that comprise the role-emotional, social functioning, and mental health 
scales11,12.  In order to assess mental health dysfunction from the responses to each question, 
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we dichotomized the responses (Figure 4.1).  For the mental health scale (questions 9b, 9c, 
9d, 9f, 9h) and one question relating to social functioning (question 9j), we dichotomized the 
responses based upon whether the sentence was positively or negatively worded, where 
survivors were considered to be reporting dysfunction if they answered ‘all,’ ‘most,’ ‘a good 
bit,’ or ‘some’ of the time to the negatively worded questions and ‘some,’ ‘a little,’ or ‘none 
of the time’ to the positively worded questions.  The second social functioning question 
(question 6), which assessed physical or emotional interference in normal social activities, 
was dichotomized by categorizing responses of  ‘not at all’ or ‘slightly’ as not reporting 
dysfunction and responses of ‘moderately,’ ‘quite a bit,’ or ‘extremely’ as reporting 
dysfunction.  For the role-emotional scale (questions 5a, 5b, 5c), survivors who reported ‘yes’ 
were considered to be reporting mental health dysfunction.  These dichotomized groupings 
were utilized in order to avoid the problems associated with having almost all survivors 
occupying one level of the dichotomy for responses to any question. 
 
Comparison Group 
In order to compare responses to the ten questions between survivors and the general 
population, the SF-36 responses from the Oxford Healthy Life Survey (OHLS) served as the 
reference general population sample16,17. The OHLS was conducted contemporaneously with 
the BCCSS and included 13,042 individuals aged 18-64 who were randomly sampled from 
the Family Health Services Authority registers for Berkshire, Buckinghamshire, 
Northamptonshire and Oxfordshire.  The OHLS sample resembles the UK general population 
with regard to socio-demographic characteristics17, and the characteristics of the OHLS have 
been compared to BCCSS survivors previously with only slight differences being observed6.  
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OHLS responses to the SF-36 were dichotomized as described above so that responses from 
survivors and the general population sample were treated identically. 
 
Statistical Analyses – Internal Comparison 
Internal analyses, using multivariate logistic regression, were conducted in order to determine 
risk factors for mental health dysfunction among five-year childhood cancer survivors within 
each of the ten questions.  All models adjusted for the following factors: age at diagnosis, sex, 
first primary neoplasm (FPN) diagnosis, age at questionnaire completion, marital status, 
socioeconomic classification (SEC), and educational attainment.  We decided a priori to use 
leukemia survivors as the referent group because previously published literature on health 
status has been conducted in this manner18.  Odds ratios (ORs) and 95% confidence intervals 
(CIs) were reported.  Likelihood ratio tests were used to assess the significance of fitted 
models and trends.   
 
Statistical Analyses – External Comparison 
In order to compare the prevalence of mental health dysfunction between survivors and the 
general population, external analyses were completed using direct (age and sex) 
standardization.  For these analyses, the general population sample acted as the reference 
group and survivors were compared overall and separately by FPN diagnosis and attained age.  
Prevalence of mental health dysfunction was reported as percentages with corresponding 95% 
CIs. 
  
All analyses were undertaken using Stata 12.119.  Statistical significance was defined as a 
two-sided P-value less than 0.05.  
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Results  
Study Characteristics  
Survivors who were female, treated for a FPN of a central nervous system (CNS) tumor, 
unemployed or having never worked, or educationally unqualified were found to consistently 
report the highest prevalence of dysfunction across all ten questions (Table 4.1).  Survivors 
who were separated, divorced, or widowed also generally reported more dysfunction than 
those who were single, cohabiting, or married.  Mental health dysfunction within the ten 
questions did not appear to differ substantially by age at diagnosis, treatment modalities 
(radiotherapy, chemotherapy, surgery), or age at questionnaire completion. 
 
Internal Comparison  
Risk factors associated with reporting mental health dysfunction within the role-
emotional scale 
Table 4.2 presents the multivariate models for the three mental health questions within the 
role-emotional scale.  Females were significantly more likely to be limited in all three 
questions (Pheterogeneity<0.0001).  Across FPN diagnoses there were statistically significant 
heterogeneity for all three questions where, compared to leukemia survivors, survivors of 
non-Hodgkin lymphoma (NHL), CNS tumors, and bone sarcoma were significantly more 
likely to be limited for all questions (Pheterogeneity<0.05).  Also, compared to leukemia 
survivors, heritable retinoblastoma survivors reported significantly more mental health 
dysfunction in “the amount of time spent on work/activities” (OR:1.7,95%CI:1.1-2.4) and 
“accomplishing as much as desired” (OR:1.7,95%CI:1.2-2.3), whereas Hodgkin lymphoma 
(HL) survivors reported significantly more dysfunction in “doing work or other activities as 
carefully as usual” (OR:1.4,95%CI:1.0-1.8).  Compared to individuals aged 16-24 at 
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questionnaire completion, the risk for reporting mental health dysfunction in all three 
questions increased linearly with age (Ptrend<0.005).  An analysis by marital status showed 
for all three questions that, relative to single survivors, those who were separated were most at 
risk of reporting dysfunction, whereas those who were married were significantly less likely 
to report dysfunction.  An association was found for educational attainment, where increased 
qualifications were associated with decreased odds of reporting dysfunction in all three 
questions.  For all three questions, relative to students, survivors who had never worked or 
were unemployed were significantly more likely to report mental health dysfunction, whereas 
those who were in managerial or professional positions were significantly less likely to report 
dysfunction.   
 
Risk factors associated with reporting mental health dysfunction within the social 
functioning scale 
In the multivariate models assessing the two questions within the social functioning scale, 
females were again significantly more likely to report dysfunction compared to males (Table 
4.3).  An analysis by FPN diagnosis showed that compared to those diagnosed with leukemia, 
CNS (OR:1.6,95%CI:1.4-1.9), neuroblastoma (OR:1.5,95%CI:1.1-2.0), bone sarcoma 
(OR:2.0,95%CI:1.5-2.7), and soft tissue sarcoma (STS) (OR:1.3,95%CI:1.0-1.7) survivors 
were all significantly more likely to report mental health dysfunction due to “physical health 
or emotional problems interfering with normal activities.”  NHL, CNS, neuroblastoma, 
heritable retinoblastoma, bone sarcoma, and STS survivors also reported significantly higher 
dysfunction in “social activities due to their health”, compared to leukemia survivors, with 
bone sarcoma (OR:3.0,95%CI:2.3-4.0) and CNS survivors (OR:2.5,95%CI:2.1-2.9) being the 
most limited.  Age at questionnaire completion was significantly associated with reporting 
  106 
dysfunction in both questions where those aged 25-34, 35-44, and 45+ reported more 
dysfunction compared to those aged 16-24 (Ptrend<0.0001).  Relative to single survivors, 
married survivors were significantly less likely to report dysfunction in either question 
(Pheterogeneity<0.001); no significant difference was found between single survivors and 
those who were cohabiting, separated, divorced, or widowed.  An analysis by educational 
attainment showed that, compared to survivors with no qualifications, the odds of reporting 
mental health dysfunction decreased with higher levels of qualifications for both questions.  
SEC was also found to be significantly related to reporting dysfunction in both questions 
where, compared to students, those who never worked or were unemployed were significantly 
more likely report dysfunction (Pheterogeneity<0.001) and those in managerial or 
professional positions were significantly less likely to report dysfunction 
(Pheterogeneity<0.001). 
 
Risk factors associated with reporting mental health dysfunction within the 
mental health scale 
Survivors who were female or who had never worked or were unemployed were significantly 
more likely to report mental health dysfunction in all five questions within in the mental 
health scale relative to males and students, respectively (Table 4.4).  Conversely, survivors 
who achieved an O-level, A-level, teaching qualification, or degree were significantly less 
likely to report dysfunction in all questions compared to students.  Age at questionnaire 
completion was also found to be significantly associated with reporting dysfunction in 4/5 
questions, but a consistent trend was not observed within the subgroups compared to those 
aged 16-24.  When analyzed by marital status, survivors who were married were found to 
report significantly less mental health dysfunction in 4/5 of the questions, compared to those 
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who were single.  Survivors who were cohabiting also reported significantly less mental 
health dysfunction for the question relating to “being a very nervous person” 
(OR:0.8,95%CI:0.7-1.0).  Survivors who were separated, conversely, reported a 70% increase 
in mental health dysfunction compared to single survivors (OR:1.7,95%CI:1.2-2.4).   When 
asked if the survivor had “been a very nervous person”, those diagnosed with CNS 
(OR:1.3,95%CI:1.1-1.5), compared to leukemia, were significantly more likely to agree with 
this statement.  Furthermore, in the multivariate model assessing whether survivors have 
“been a happy person”, an analysis by FPN diagnosis showed that HL (OR:1.3,95%CI:1.0-
1.6), NHL (OR:1.4,95%CI:1.1-1.8), CNS (OR:1.4,95%CI:1.2-1.6), neuroblastoma 
(OR:1.3,95%CI:1.0-1.7), non-heritable retinoblastoma (OR:1.4,95%CI:1.0-1.8), and bone 
sarcoma (OR:1.5,95%CI:1.1-1.9) survivors reported significantly higher dysfunction 
compared to leukemia survivors.   
  
External Comparison 
Compared to the general population sample, survivors overall reported more mental health 
dysfunction in 6/10 questions that were examined (Table 4.5).  When further assessed by 
FPN diagnosis, CNS and bone sarcoma survivors were found to report the greatest 
dysfunction, compared to that expected, with significant differences in ten and six questions, 
respectively; the excess of dysfunction ranged from 4.4%-22.3% in CNS survivors, whereas 
bone sarcoma survivors were limited from 6.9%-15.9%.  Both diagnostic groups were most 
disadvantaged by their health limiting their social activities.  Conversely, survivors of 
neuroblastoma, heritable retinoblastoma, non-heritable retinoblastoma, Wilms, and other 
(those that did not conform to one of the ten FPN groups used) were not significantly different 
in any of the questions analyzed when compared to the general population sample.    
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An analysis by age at questionnaire completion showed that the prevalence of mental health 
dysfunction was comparable or better for 7/10 questions among survivors aged 16-24, 
compared to that expected from the general population sample (Table 4.6); survivors in this 
age group did however report a higher prevalence of “being a nervous person” (30.7% vs. 
23.7% expected) “feeling down in the dumps” (25.3% vs. 21.2% expected) and “being limited 
in their social activities due to their health” (15.7% vs. 11.2% expected).  Among those aged 
25-34 and 35-44 at questionnaire completion, significantly higher mental health dysfunction 
was reported, compared to the general population sample, in relation to 6 questions (questions 
5a, 6, 9b, 9c, 9f, 9j).  Similarly, survivors aged 45 and older reported significantly higher 
dysfunction in 5 questions compared to that expected.  Notably, the percent difference in 
mental health dysfunction between survivors and the general population increased with age at 
questionnaire completion for both questions from the social functioning scale and the question 
relating to “feeling downhearted and low”; this increase was most noticeable among those 
reporting “limitations in social activities due to their health”, where the excess rose from 4.5% 
to 12.8% in those aged 16-24 and 45+, respectively.  Statistically significant variation in the 
excess by age at questionnaire completion was not observed in four questions, which related 
to problems with work or daily activities and feeling calm, peaceful, or happy. 
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Discussion 
The findings from this large population-based study indicate that the prevalence of mental 
health dysfunction among survivors of childhood cancer in the BCCSS was substantially 
higher than that expected from the general population sample in over half of the questions 
assessed, with survivors of CNS and bone sarcoma being the most vulnerable; these findings 
are generally consistent with other studies that have used the SF-367 or similar psychological 
measures5,18,20, although some studies have suggested that mental health status was similar 
between survivors and comparative populations5,6,21.  While the North American Childhood 
Cancer Survivor Study (CCSS) found significantly higher limitations in the role-emotional 
and social functioning scales for survivors overall, survivors of CNS and bone sarcoma were 
reported as having significantly less problems on the mental health scale compared to that 
expected from the US population reference10; this finding does not correspond with our 
results as CNS and bone sarcoma survivors were found to be significantly more limited in 5/5 
and 3/5 of the questions that comprise the mental health scale, respectively.  The same study10 
also reported significantly higher limitations in regards to the role-emotional and social 
functioning scales for HL, NHL, Wilms, and neuroblastoma survivors, compared to US 
norms, which conflicts with the results presented in this study as these survivors were not 
significantly more limited in any of the questions comprising these scales compared to the 
general population sample.  These inconsistencies with our study might reflect differences in 
study demographics, cohort design, or therapeutic practice between North America and Great 
Britain.   
 
Another important finding in this study was that, although younger survivors (16-24 years) 
perceived their mental health as broadly similar to the general population, significant mental 
  110 
health dysfunction was reported in at least half of the questions among those aged 25 years 
and older.  A particular concern was found among the questions relating to social functioning 
as significant mental health dysfunction was reported for all age groups.  Furthermore, the 
extent of the excess among survivors increased with age at questionnaire completion for both 
questions within the social functioning scale.  This finding corresponds with another study 
that reported significantly more disadvantage in the social functioning scale in those assessed 
10-14 and 15-19 years from diagnosis compared to a control group7.  A possible explanation 
as to why mental health dysfunction increased with age may be due to the fact that the risk of 
complex and multiple late effects emerging increases as time since treatment increases22–25.  
Although late effects may not immediately affect survivors, they may become more important 
with maturity and influence life decisions and experiences later on.  For example, infertility 
may become a greater concern and impact mental health when survivors want to start a 
family.  Living with chronic health conditions, such as infertility, cardiovascular disease, 
diabetes, blindness, physical disability, and epilepsy, which can often be managed but not 
cured, may have long-term consequences on both physical and psychological health, stressing 
the importance for life course care and services.    
 
The internal analyses similarly revealed that CNS and bone sarcoma survivors reported higher 
levels of mental health dysfunction compared to other types of childhood cancer, with CNS 
survivors being limited in all questions assessed and bone sarcoma survivors being limited in 
all questions relating to the social functioning and role-emotional scales.  Broadly, this 
finding conflicts with an analysis by the CCSS, which found no significant difference among 
childhood cancer survivors by FPN diagnosis18; however, it is worth noting that in the CCSS 
the Brief Symptom Inventory 18 survey was used and thus results are not directly 
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comparable.  Other risk factors for mental health dysfunction included being female, 
separated from a spouse/partner, and unemployed or having never worked, which corresponds 
with previous reports using the SF-365,10 or similar measures to predict psychological 
distress18.  Low educational attainment, unemployment, and other socioeconomic 
disadvantages are recognized risks to mental health in the general population26.  However, the 
effects of these determinants may be even more detrimental among childhood cancer 
survivors as these individuals, when assessed with comparative norms, experience an even 
greater risk of morbidity and adverse psychosocial outcomes22–25,27–30.  Conversely, survivors 
who received some educational qualifications or worked in a managerial/professional position 
were found to exhibit less mental health dysfunction compared to their respective referents, 
which also generally corresponds with previous reports10. 
 
Limitations 
Response bias due to selective responses should be minimal due to our reasonably good 
response rate and the fact that there was not a substantial difference in cancer and socio-
demographic characteristics between responders and non-responders of our questionnaire6.  
There is potentially selection bias due to survival, particularly among the group of older 
survivors, as they may be healthier than their counterparts who did not survive until 
questionnaire send-out.  Another limitation in our study is our comparison data, which may 
differ from our study population in terms of socio-economic status.  However, as the results 
from our internal and external analyses broadly correspond with one another, confounding by 
this factor should be limited.  Finally, although the findings from this paper may not be 
generalizable for children diagnosed with cancer after 1991, they are still highly relevant to 
children treated more recently for whom treatment intensity and long-term morbidity may be 
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greater.  We acknowledge reassessment is necessary and recommend further analyses to be 
conducted on the recently extended BCCSS cohort, which includes five-year survivors 
diagnosed from 1992-2006, and other long-term follow-up studies.   
 
Clinical Recommendations  
Although the need for long-term psychological assessment and care is recognized5,31–33, there 
remain uncertainties as to how these individuals should be assessed.  A previous study 
reported that approximately only 35% of childhood cancer survivors in the UK were on 
hospital follow-up34.  Consequently, as general practitioners provide health care for the 
majority of these survivors35, routine psychological assessment, preferably using a 
standardized and validated measure, should be integrated into both long-term hospital follow-
up clinics and general practitioner visits, especially for the vulnerable subgroup of survivors 
identified in this study.  To date, psychological provisions are lacking in late effects services 
and are rare in the primary care setting.  In order to improve mental health, it is essential that 
recommendations for risk-based care are readily available for general practitioners and 
ongoing communication is coordinated across all sites and services involved.  Furthermore, 
surveillance for mental health dysfunction and recommended interventions should be included 
in the development of clinical guidelines, treatment summaries, and patient care plans.  As the 
results from this study suggest mental health dysfunction is a concern across the lifespan for 
survivors, it is imperative that equitable psychological support is continuously available 
within general practices or specialist late effects services, irrespective of the amount of time 
that has passed since initial diagnosis, and that funding is allocated to allow for interventions.  
Finally, the findings presented in this study also stress the importance of educational 
attainment and employment on long-term mental health.  Educational support and career 
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advisors should be provided during and after treatment to ensure that childhood cancer 
survivors achieve their full educational and employment potential and have the same 
likelihood of academic and professional success as their peers.  By continually improving the 
standard of care for mental health in childhood cancer survivors, we work towards meeting 
the goal of psychosocial oncology research, which is to facilitate patients’ adjustment to the 
short- and long-term consequences of their treatment, recovery, and survivorship so that 
quality-of-life is not reduced36. 
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Conclusions  
Based on the findings of this large population-based study, childhood cancer survivors report 
significantly higher levels of mental health dysfunction than those in the general population, 
where excesses were observed particularly among CNS and bone sarcoma survivors.  
Limitations were also observed to increase with age, and thus it is important to emphasize the 
need for mental health evaluation and services across the entire lifespan.  There is evidence 
that low educational attainment and being unemployed or having never worked adversely 
impacts long-term mental health.  These findings provide an evidence base for risk 
stratification and planning interventions. 
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 ROLE EMOTIONAL SCALE SOCIAL FUNCTIONING SCALE MENTAL HEALTH SCALE 
 
Cut down on the 
amount of time you 
spent on work or 
other activities?  
(Question 5a) 
Accomplished 
less than you 
would like? 
(Question 5b) 






Has your physical 
health or emotional 
problems interfered 
with your normal 
social activities? 
(Question 6) 








Have you felt so 
down in the 
dumps that 
nothing could 
cheer you up? 
(Question 9c) 











































Male 610/5222 (11.7) 903/5221 (17.3) 670/5212 (12.9) 796/5300 (15.0) 847/5249 (16.1) 1328/5271 (25.2) 1018/5279 (19.3) 2000/5278 (37.9) 1530/5258 (29.1) 1139/5274 (21.6) 
Female 846/4999 (16.9) 1155/4996 (23.1) 934/4974 (18.8) 1022/5081 (20.1) 1075/5026 (21.4) 1626/5065 (32.1) 1425/5064 (28.1) 2527/5062 (49.9) 1975/5050 (39.1) 1283/5065 (25.3) 
First Primary Neoplasm Type 
Leukemia 321/2811 (11.4) 478/2812(17.0) 368/2801 (13.0) 410/2852 (14.4) 374/2821 (13.3) 848/2833 (29.9) 686/2842 (24.1) 1190/2836 (42.0) 977/2827 (34.6) 559/2836 (19.7) 
Hodgkin Lymphoma 93/732 (12.7) 132/730 (18.1) 113/731 (15.5) 104/737 (14.1) 101/734 (13.8) 197/736 (26.8) 144/738 (19.5) 316/739 (42.8) 231/738 (31.3) 182/737 (24.7) 
NHL 75/527 (14.2) 110/530 (20.8) 90/525 (17.1) 85/531 (16.0) 84/527 (15.9) 133/531 (25.1) 110/530 (20.8) 236/530 (44.5) 160/528 (30.3) 133/530 (25.1) 
CNS 437/2153 (20.3) 585/2153 (27.2) 455/2145 (21.2) 575/2230 (25.8) 717/2190 (32.7) 771/2213 (34.8) 643/2212 (29.1) 1091/2216 (49.2) 887/2201 (40.5) 666/2219 (30.0) 
Neuroblastoma 55/424 (13.0) 79/425 (18.6) 59/423 (14.0) 72/426 (16.9) 66/423 (15.6) 100/426 (23.5) 107/426 (25.1) 177/424 (41.8) 145/425 (34.1) 98/406(23.2) 
Non-Heritable 
Retinoblastoma 
47/407 (11.6) 69/405 (17.0) 51/405 (12.6) 53/407 (13.0) 53/404 (13.1) 109/406 (26.9) 86/406 (21.2) 174/406 (42.9) 132/406 (32.5) 94/406 (23.2) 
Heritable 
Retinoblastoma 
43/288 (14.9) 68/290 (23.5) 42/288 (14.6) 48/293 (16.4) 49/291 (16.8) 66/292 (22.6) 62/292 (21.2) 111/293 (37.9) 88/292 (30.1) 65/293 (22.2) 
Wilms 119/939 (12.7) 153/935 (16.4) 132/934 (14.1) 139/945 (14.7) 129/935 (13.8) 244/941 (25.8) 197/941 (20.9) 396/941 (41.9) 276/940 (29.3) 186/938 (19.8) 
Bone Sarcoma 75/404 (18.6) 97/403 (24.1) 74/401 (18.5) 100/410 (24.4) 114/407 (28.0) 107/409 (26.2) 96/409 (23.5) 199/410 (48.5) 139/408 (34.1) 113/410 (27.6) 
Soft Tissue Sarcoma 100/697 (14.4) 138/696 (19.8) 120/696 (17.2) 117/702 (16.7) 122/701 (17.4) 179/703 (25.5) 145/703 (20.6) 299/701 (42.7) 229/699 (32.8) 156/701 (22.3) 
Other 91/839(10.9) 149/838 (17.8) 100/837 (12.0) 115/848 (13.6) 113/842 (13.4) 200/846 (24.6) 167/844 (19.8) 338/844 (41.1) 241/844 (28.9) 170/844 (20.1) 
Age at Diagnosis 
Mean (range) 7.1(0-14.9) 7(0-14.9) 6.9(0-14.9) 7.0(0-14.9) 7.2(0-14.9) 6.5(0-14.9) 6.5(0-14.9) 6.8(0-14.9) 6.7(0-14.9) 7(0-14.9) 
0-4 years 595/4711 (12.6) 837/4707 (17.8) 687/4697 (14.6) 762/4781 (15.9) 768/4736 (16.2) 1361/4764 (28.6) 1136/4767 (23.8) 1983/4761 (41.7) 1555/4752 (32.7) 1024/4766 (21.5) 
5-9 years 403/2710 (14.9) 578/2708 (21.3) 427/2703 (15.8) 497/2754 (18.1) 537/2720 (19.7) 805/2731 (29.5) 644/2734 (23.6) 1216/2739 (44.4) 941/2723 (34.6) 646/2730 (23.7) 
10-14 years 458/2800 (16.4) 643/2802 (23.0) 490/2786 (17.6) 559/2846 (19.6) 617/2819 (21.9) 788/2841 (27.7) 663/2842 (23.3) 1328/2840 (46.8) 1009/2833 (35.6) 752/2843 (26.5) 
Radiotherapy 
No 313/2206 (14.2) 455/2210 (20.6) 336/2203 (15.3) 381/2233 (17.1) 430/2214 (19.4) 617/2232 (27.6) 534/2229 (24.0) 989/2227 (44.4) 770/2225 (34.6) 548/2226 (24.6) 
Yes 782/5144 (15.2) 1079/5140 (21.0) 837/5119 (16.4) 999/5249 (19.0) 1060/5188 (20.4) 1500/5213 (28.8) 1263/5224 (24.2) 2329/5221 (44.6) 1828/5203 (35.1) 1255/5219 (24.1) 
Chemotherapy 
No 535/3249 (16.5) 745/3248 (22.9) 556/3240 (17.2) 674/3322 (20.3) 802/3279 (24.5) 941/3309 (28.4) 809/3305 (24.5) 1505/3303 (45.6) 1186/3295 (36.0) 873/3305 (26.4) 
Yes 510/7122 (13.2) 722/3872 (18.7) 574/3854 (14.9) 638/3918 (16.3) 612/3886 (15.8) 1104/3901 (28.3) 921/3910 (23.6) 1684/3907 (43.1) 1315/3895 (33.8) 843/3901 (21.6) 
Surgery 
No 438/3353 (13.1) 625/3353 (18.6) 486/3340 (14.6) 864/4286 (20.2) 968/4235 (22.9) 980/3386 (28.9) 820/3393 (24.2) 1485/3390 (43.8) 1186/3383 (35.1) 1090/4268 (25.5) 
Yes 679/4202 (16.2) 944/4200 (22.5) 713/4186 (17.0) 548/3402 (16.1) 546/3369 (16.2) 1198/4266 (28.1) 1018/4266 (23.9) 1928/4264 (45.2) 1478/4251 (34.8) 762/3384 (22.5) 
Table 4.1:  Frequency of reporting mental health dysfunction in the ten questions under investigation among survivors of childhood cancer in the British Childhood Cancer Survivor Study  
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 ROLE EMOTIONAL SCALE SOCIAL FUNCTIONING SCALE MENTAL HEALTH SCALE 
 
Cut down on the 
amount of time 
you spent on 




less than you 
would like? 
(Question 5b) 
Didn't do work 
or other activities 
as carefully as 
usual? 
(Question 5c) 
Has your physical  
health or emotional  
problems  
interfered with  
your normal social 
 activities? 
(Question 6) 
Has your health 
limited your social 
activities? 
(Question 9j) 
Have you felt so  
down in the  
dumps that  
nothing could  
cheer you up? 
(Question 9c) 
Have you felt calm 
and peaceful? 
(Question 9d) 










































Age at Questionnaire Completion 
Mean (range) 31.7(16.0-66.1) 31.5(16.0-66.1) 31.0(16.0-66.1) 31.5(16.0-70.0) 32.4(16.0-7.0) 29.7(16.0-70.0) 29.9(16.0-66.1) 30.6(16.0-70.0) 30.6(16.0-66.1) 31.5(16.1-70.0) 
16-24 years 435/3704 (11.7) 643/3695 (17.4) 521/3693 (14.1) 549/3741 (14.7) 518/3705 (14.0) 1113/3727 (29.9) 864/3724 (23.2) 1505/3728 (40.4) 1182/3716 (31.8) 744/3726 (20.0) 
25-34 years 523/3531 (14.8) 714/3529 (20.2) 562/3519 (16.0) 657/3587 (18.3) 705/3552 (19.9) 1038/3567 (29.1) 894/3579 (25.0) 1626/3572 (45.5) 1265/3564 (35.5) 862/3572 (24.1) 
35-44 years 325/1976 (16.5) 456/1981 (23.0) 349/1973 (17.7) 400/2024 (19.8) 443/2008 (22.1) 533/2021 (26.4) 496/2023 (24.5) 956/2021 (47.3) 712/2013 (35.4) 538/2021 (26.6) 
45+ years 173/1010 (17.1) 245/1012 (24.2) 172/1001 (17.2) 212/1029 (20.6) 256/1010 (25.4) 270/1021 (26.4) 189/1017 (18.6) 440/1019 (43.2) 346/1015 (34.1) 278/1020 (27.3) 
Marital Status 
Single 785/5629 (14.0) 1125/5629 (20.0) 908/5619 (16.2) 1026/5741 (17.9) 1070/5674 (18.9) 1756/5705 (30.8) 1423/5717 (24.9) 2437/5712 (42.7) 1967/5695 (34.5) 1318/5715 (23.1) 
Cohabiting 166/1034 (16.1) 229/1029 (22.3) 170/1029 (16.5) 192/1043 (18.4) 187/1036 (18.1) 264/1043 (25.3) 254/1043 (24.4) 492/1041 (47.3) 375/1042 (36.0) 269/1038 (25.9) 
Married 338/2703 (12.5) 473/2702 (17.5) 345/2689 (12.8) 408/2723 (15.0) 451/2704 (16.7) 645/2720 (23.7) 500/2717 (18.4) 1172/2717 (43.1) 792/2711 (29.2) 561/2716 (20.7) 
Separated 35/149 (23.5) 50/150 (33.3) 39/148 (26.4) 36/150 (24.0) 36/148 (24.3) 54/150 (36.0) 51/149 (34.2) 81/150 (54.0) 79/148 (53.4) 49/149 (32.9) 
Divorced 86/440 (19.6) 118/442 (26.7) 93/438 (21.2) 104/447 (23.3) 112/442 (25.3) 145/444 (32.6) 132/441 (29.9) 217/444 (48.9) 182/444 (41.0) 144/445 (32.4) 
Widowed 6/32 (18.8) 8/32 (25.0) 9/32 (28.1) 8/32 (25.0) 13/33 (39.4) 10/33 (30.3) 13/33(39.4) 17/33 (51.5) 13/32 (40.6) 11/33 (33.3) 
Educational Attainment 
No qualifications 328/1433 (22.9) 416/1434 (29.0) 334/1418 (23.6) 453/1518 (29.8) 530/1475 (35.9) 544/1491 (36.5) 505/1489 (33.9) 761/1493 (51.0) 635/1482 (42.9) 456/1491 (30.6) 
Other qualifications 219/1424 (15.4) 297/1421 (20.9) 231/1414 (16.3) 289/1447 (20.0) 312/1432 (21.8) 4991435 (34.8) 417/1441 (28.9) 649/1439 (45.1) 541/1433 (37.8) 375/1440 (26.0) 
O-level 357/2836 (12.6) 516/2839 (18.2) 419/2837 (14.8) 433/2858 (15.2) 467/2835 (16.5) 780/2860 (27.3) 662/2855 (23.2) 1204/2858 (42.1) 972/2851 (34.1) 635/2853 (22.3) 
A-level 236/1919 (12.3) 358/1921 (18.6) 258/1917 (13.5) 274/1928 (14.2) 244/1916 (12.7) 493/1923 (25.6) 370/1928 (19.2) 786/1926 (40.8) 581/1922 (30.2) 400/1925 (20.8) 
Teaching 
qualification 
111/919 (12.1) 158/917 (17.2) 128/917 (14.0) 124/919 (13.5) 136/913 (14.9) 236/914 (25.8) 177/918 (19.3) 392/918 (42.7) 282/914 (30.9) 195/916 (21.3) 
Degree 151/1416 (10.7) 248/1416 (17.5) 173/1416 (12.2) 176/1423 (12.4) 156/1415 (11.0) 299/1426 (21.0) 225/1423 (15.8) 610/1425 (42.8) 390/1420 (27.5) 290/1424(20.4) 
Socioeconomic Classification  
Student 206/1728 (11.9) 315/1725 (18.3) 241/1720 (14.0) 249/1738 (14.3) 232/1725 (13.5) 524/1733 (30.2) 351/1733 (20.3) 679/1734 (39.2) 512/1724 (29.7) 313/1733 (18.1) 
Never worked/ 
Unemployed 
130/576 (22.6) 179/579 (30.9) 125/576 (21.7) 174/603 (28.9) 191/600 (31.8) 231/60 (38.5) 244/604 (40.4) 295/603 (48.9) 252/601 (41.9) 203/601 (33.8) 
Routine/Manual 435/3086 (14.1) 598/3080 (19.4) 501/3071 (16.3) 540/3121 (17.3) 589/3083 (19.1) 944/3105 (30.4) 799/3103 (25.8) 1353/3102 (43.6) 1134/3102 (36.6) 754/3106 (24.3) 
Intermediate 253/1840 (13.8) 365/1842 (19.8) 264/1838(14.4) 307/1847 (16.6) 316/1834 (17.2) 485/1844(26.3) 388/1843 (21.1) 807/1846 (43.7) 621/1836 (33.8) 423/1843 (23) 
Managerial/ 
Professional 
236/2344 (10.1) 376/2345 (16.0) 276/2343 (11.8) 279/2353 (11.9) 275/2334 (11.8) 500/2354 (21.2) 382/2352 (16.2) 985/2352 (41.9) 645/2346 (27.5) 478/2349 (20.4) 
Table 4.1 (continued):  Frequency of reporting mental health dysfunction in the ten questions under investigation among survivors of childhood cancer in the British Childhood Cancer Survivor Study 
Abbreviations: NHL: non-Hodgkin lymphoma, CNS: central nervous system  
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Cut down on the amount of time you spent on work  
or other activities? (Question 5a) 
Accomplished less than you would like?  
(Question 5b) 
Didn’t do work or other activities as carefully as usual?  
(Question 5c) 
Characteristic OR (95%CI) P 
Pheterogeneity†  
(Ptrend‡) OR (95%CI) P 
Pheterogeneity† 




Male 1.0   1.0   1.0   
Female 1.6 (1.4,1.8) <0.001 <0.0001 1.5 (1.3,1.7) <0.001 <0.0001 1.8 (1.6,2.0) <0.001 <0.0001 
First Primary Neoplasm Type 
Leukemia 1.0   1.0   1.0   
Hodgkin Lymphoma 1.2 (0.9,1.5) 0.317  1.0 (0.8,1.3) 0.723  1.4 (1.0,1.8) 0.024  
NHL 1.4 (1.1,1.9) 0.019  1.4 (1.1,1.7) 0.019  1.6 (1.2,2.1) 0.001  
CNS 1.6 (1.4,2.0) <0.001  1.5 (1.2,1.7) <0.001  1.5 (1.2,1.8) <0.001  
Neuroblastoma 1.4 (1.0,1.9) 0.055  1.3 (1.0,1.7) 0.077  1.1 (0.8,1.6) 0.437  
Non-Heritable Retinoblastoma 1.1 (0.8,1.6) 0.496  1.1 (0.8,1.5) 0.687  1.0 (0.7,1.4) 0.967  
Heritable Retinoblastoma 1.7 (1.1,2.4) 0.011  1.7 (1.2,2.3) 0.002  1.3 (0.9,1.9) 0.205  
Wilms 1.2 (1.0,1.6) 0.105  1.0 (0.8,1.3) 0.838  1.1 (0.9,1.5) 0.256  
Bone Sarcoma 1.7 (1.2,2.4) 0.001  1.4 (1.1,1.9) 0.014  1.5 (1.1,2.1) 0.008  
Soft Tissue Sarcoma 1.5 (1.1,1.9) 0.006  1.2 (1.0,1.5) 0.082  1.5 (1.1,1.9) 0.003  
Other 0.9 (0.7,1.2) 0.673 <0.0001 1.0 (0.8,1.3) 0.693 <0.0001 1.0 (0.8,1.3) 0.927 0.0005 
Age at Diagnosis 
0-4 years 1.0   1.0   1.0   
5-9 years 1.2 (1.0,1.4) 0.029  1.3 (1.1,1.5) 0.001  1.1 (0.9,1.2) 0.530  
10-14 years 1.2 (1.0,1.5) 0.026 0.0462 (0.0282) 1.3 (1.1,1.5) 0.003 0.0019 (0.0029) 1.1 (1.0,1.4) 0.147 0.3433 (0.1380) 
Age at Questionnaire Completion 
16-24 years 1.0   1.0   1.0   
25-34 years 1.4 (1.1,1.7) 0.001  1.3 (1.1,1.5) 0.001  1.3 (1.1,1.5) 0.009  
35-44 years 1.6 (1.2,2.0) <0.001  1.6 (1.3,2.0) <0.001  1.4 (1.2,1.8) 0.001  
45+ years 1.4 (1.1,1.9) 0.012 0.0016 (0.0004) 1.6 (1.2,2.0) <0.001 <0.0001 (<0.0001) 1.2 (0.9,1.6) 0.124 0.0087 (0.0054) 
Marital Status 
Single 1.0   1.0   1.0   
Cohabiting 1.1 (0.9,1.4) 0.226  1.1 (0.9,1.4) 0.166  1.0 (0.8,1.2) 0.971  
Married 0.7 (0.6,0.9) 0.002  0.7 (0.6,0.8) <0.001  0.7 (0.5,0.8) <0.001  
Separated 1.5 (1.0,2.4) 0.047  1.6 (1.1,2.4) 0.013  1.6 (1.0,2.3) 0.031  
Divorced 1.2 (0.9,1.6) 0.333  1.1 (0.8,1.4) 0.495  1.1 (0.8,1.4) 0.613  
Widowed 0.7 (0.2,2.2) 0.603 0.0001 0.8 (0.3,2.0) 0.583 <0.0001 1.1 (0.4,2.9) 0.817 <0.0001 
Educational Attainment 
No qualifications 1.0   1.0   1.0   
Other qualifications 0.7 (0.6,0.9) 0.010  0.8 (0.6,0.9) 0.010  0.8 (0.6,1.0) 0.040  
O-level 0.7 (0.5,0.8) <0.001  0.7 (0.6,0.8) <0.001  0.8 (0.6,0.9) 0.005  
A-level 0.7 (0.6,0.9) 0.001  0.7 (0.6,0.9) 0.002  0.7 (0.6,0.9) 0.003  
Teaching qualification 0.6 (0.5,0.8) 0.002  0.7 (0.5,0.8) 0.001  0.8 (0.6,1.0) 0.037  
Degree 0.6 (0.5,0.8) <0.001 0.0004 0.7 (0.6,0.9) 0.003 0.0044 0.7 (0.5,0.9) 0.002 0.0030 
Socioeconomic Classification 
Student 1.0   1.0   1.0   
Never worked/Unemployed 1.5 (1.2,2.0) 0.003  1.4 (1.1,1.8) 0.003  1.3 (1.0,1.8) 0.030  
Routine/Manual 0.9 (0.7,1.1) 0.424  0.8 (0.7,1.0) 0.030  1.0 (0.8,1.2) 0.893  
Intermediate 0.9 (0.7,1.1) 0.290  0.8 (0.7,1.0) 0.060  0.8 (0.7,1.1) 0.155  
Managerial/Professional 0.7 (0.5,0.9) 0.005 <0.0001 0.7 (0.5,0.8) <0.001 <0.0001 0.8 (0.6,1.0) 0.025 0.0004 
Table 4.2:  Multivariable logistic regression models* reporting odds ratios and 95% confidence intervals for reporting mental health dysfunction within the three questions comprising the role emotional scale of the SF-
36 survey, by specific potential demographic, cancer, social, and economic factors 
Abbreviations: NHL: non-Hodgkin lymphoma, CNS: central nervous system, OR: odds ratio, CI: confidence intervals 
*Adjusted for age at diagnosis, diagnosis, sex, age at questionnaire completion, marital status, educational attainment, and socioeconomic classification 
†The Pheterogeneity (two-sided) is from the likelihood ratio test for heterogeneity in the probability of reporting mental health dysfunction within this specific question, across different levels of the specified 
explanatory factor with adjustment for all other factors in the multivariate model.  The threshold for statistical significant was 0.05. 
‡The Ptrend (two-sided) is from the test for trend, where the threshold for statistical significant was 0.05. 
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Has your physical health or emotional problems interfered with 
your normal social activities? (Question 6) 
Has your health limited your social activities? 
(Question 9j) 
Characteristic OR (95%CI) P 
Pheterogeneity† 
(Ptrend‡) OR (95%CI) P 
Pheterogeneity† 
(Ptrend‡) 
        
Sex   
Male 1.0   1.0   
Female 1.5 (1.3,1.7) <0.001 <0.0001 1.5 (1.4,1.7) <0.001 <0.0001 
First Primary Neoplasm Type  
Leukemia 1.0   1.0   
Hodgkin Lymphoma 0.9 (0.7,1.2) 0.703  1.2 (0.9,1.5) 0.284  
NHL 1.3 (1.0,1.7) 0.079  1.5 (1.1,2.0) 0.004  
CNS 1.6 (1.4,1.9) <0.001  2.5 (2.1,2.9) <0.001  
Neuroblastoma 1.5 (1.1,2.0) 0.011  1.5 (1.1,2.0) 0.020  
Non-Heritable Retinoblastoma 1.0 (0.7,1.4) 0.812  1.0 (0.7,1.5) 0.864  
Heritable Retinoblastoma 1.3 (0.9,1.9) 0.197  1.5 (1.0,2.2) 0.037  
Wilms 1.1 (0.8,1.3) 0.896  1.1 (0.9,1.5) 0.275  
Bone Sarcoma 2.0 (1.5,2.7) <0.001  3.0 (2.3,4.0) <0.001  
Soft Tissue Sarcoma 1.3 (1.0,1.7) 0.036  1.6 (1.2,2.0) <0.001  
Other 1.0 (0.7,1.2) 0.692 <0.0001 1.2 (0.9,1.5) 0.224 <0.0001 
Age at Diagnosis   
0-4 years 1.0   1.0   
5-9 years 1.1 (0.9,1.3) 0.377  1.1 (0.9,1.2) 0.462  
10-14 years 1.1 (1.0,1.4) 0.137 0.3297 (0.1368) 1.1 (0.9,1.3) 0.258 0.5227 (0.2821) 
Age at Questionnaire Completion   
16-24 years 1.0   1.0   
25-34 years 1.5 (1.3,1.8) <0.001  1.8 (1.5,2.2) <0.001  
35-44 years 1.6 (1.3,1.8) <0.001  2.0 (1.6,2.5) <0.001  
45+ years 1.5 (1.2,2.0) 0.002 <0.0001 (<0.0001) 2.1 (1.6,2.7) <0.001 <0.0001 (<0.0001) 
Marital Status   
Single 1.0   1.0   
Cohabiting 1.1 (0.9,1.3) 0.419  1.0 (0.8,1.2) 0.940  
Married 0.7 (0.6,0.9) <0.001  0.7 (0.6,0.8) <0.001  
Separated 1.3 (0.9,2.0) 0.176  1.2 (0.8,1.8) 0.447  
Divorced 1.1 (0.9,1.5) 0.339  1.0 (0.8,1.3) 0.969  
Widowed 1.2 (0.5,2.9) 0.709 0.0001 1.6 (0.7,3.8) 0.255 0.0001 
Educational Attainment   
No qualifications 1.0   1.0   
Other qualifications 0.7 (0.6,0.9) <0.001  0.7 (0.6,0.8) <0.001  
O-level 0.6 (0.5,0.7) <0.001  0.5 (0.4,0.6) <0.001  
A-level 0.6 (0.5,0.7) <0.001  0.4 (0.4,0.5) <0.001  
Teaching qualification 0.5 (0.4,0.7) <0.001  0.5 (0.4,0.6) <0.001  
Degree 0.5 (0.4,0.6) <0.001 <0.0001 0.4 (0.3,0.5) <0.001 <0.0001 
Socioeconomic Classification (SEC)   
Student 1.0   1.0   
Never worked/Unemployed 1.6 (1.3,2.1) <0.001  1.7 (1.3,2.2) <0.001  
Routine/Manual 0.9 (0.7,1.1) 0.384  0.9 (0.7,1.1) 0.402  
Intermediate 0.9 (0.7,1.1) 0.329  0.9 (0.7,1.1) 0.224  
Managerial/Professional 0.7 (0.5,0.9) 0.001 <0.0001 0.7 (0.5,0.9) <0.001 <0.0001 
Table 4.3:  Multivariable logistic regression models* reporting odds ratios and 95% confidence intervals for reporting mental health dysfunction 
within the two questions comprising the social functioning scale of the SF-36 survey, by specific potential demographic, cancer, social, and 
economic factors  
Abbreviations: NHL: non-Hodgkin lymphoma, CNS: central nervous system, OR: odds ratio, CI: confidence intervals 
*Adjusted for age at diagnosis, diagnosis, sex, age at questionnaire completion, marital status, educational attainment, and socioeconomic 
classification 
†The Pheterogeneity (two-sided) is from the likelihood ratio test for heterogeneity in the probability of reporting mental health dysfunction within 
this specific question, across different levels of the specified explanatory factor with adjustment for all other factors in the multivariate model.  
The threshold for statistical significant was 0.05. 
‡The Ptrend (two-sided) is from the test for trend, where the threshold for statistical significant was 0.05. 
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Have you been a very nervous person? 
(Question 9b) 
Have you felt so down in the dumps that  
nothing could cheer you up? (Question 9c) 
Have you felt calm and peaceful?  
(Question 9d) 
Have you felt downhearted and low?  
(Question 9f) 




























Sex                               
Male 1.0     1.0     1.0     1.0     1.0     
Female 1.4 (1.3,1.6) <0.001 <0.0001 1.7 (1.5,1.9) <0.001 <0.0001 1.6 (1.5,1.8) <0.001 <0.0001 1.6 (1.4,1.7) <0.001 <0.0001 1.2 (1.1,1.4) <0.001 <0.0001 
















Leukemia 1.0     1.0     1.0     1.0     1.0     
Hodgkin 
Lymphoma 
1.1 (0.9,1.3) 0.433   1.0 (0.8,1.2) 0.732   1.1 (0.9,1.3) 0.468   1.0 (0.8,1.2) 0.617   1.3 (1.0,1.6) 0.021   
NHL 1.0 (0.8,1.2) 0.863   1.1 (0.8,1.4) 0.620   1.2 (1.0,1.5) 0.086   0.9 (0.8,1.2) 0.615   1.4 (1.1,1.8) 0.003   
CNS 1.3 (1.1,1.5) 0.001   1.2 (1.0,1.4) 0.036   1.2 (1.0,1.3) 0.024   1.1 (1.0,1.3) 0.080   1.4 (1.2,1.6) <0.001   
Neuroblastoma 0.8 (0.6,1.1) 0.116   1.2 (0.9,1.6) 0.124   1.1 (0.9,1.3) 0.535   1.1 (0.9,1.4) 0.432   1.3 (1.0,1.7) 0.041   
Non-Heritable 
Retinoblastoma 
1.1 (0.8,1.3) 0.884   1.0 (0.8,1.4) 0.737   1.1 (0.9,1.4) 0.373   1.1 (0.8,1.3) 0.681   1.4 (1.0,1.8) 0.024   
Heritable 
Retinoblastoma 
0.8 (0.6,1.1) 0.242   1.1 (0.8,1.5) 0.518   0.8 (0.6,1.1) 0.242   0.9 (0.7,1.2) 0.612   1.2 (0.9,1.6) 0.311   
Wilms 0.9 (0.8,1.1) 0.249   0.9 (0.8,1.2) 0.586   1.0 (0.9,1.2) 0.896   0.8 (0.7,1.0) 0.065   1.0 (0.8,1.2) 0.989   
Bone Sarcoma 1.0 (0.8,1.3) 0.881   1.2 (0.9,1.6) 0.229   1.2 (1.0,1.6) 0.071   1.0 (0.8,1.3) 0.737   1.5 (1.1,1.9) 0.005   
Soft Tissue 
Sarcoma 
0.9 (0.7,1.1) 0.398   1.0 (0.8,1.2) 0.853   1.1 (0.9,1.3) 0.491   1.0 (0.8,1.2) 0.877   1.2 (1.0,1.5) 0.085   
Other 0.9 (0.7,1.1) 0.174 0.0022 0.9 (0.8,1.1) 0.481 0.2762 0.9 (0.8,1.1) 0.379 0.1254 0.8 (0.7,1.0) 0.015 0.0273 1.0 (0.8,1.2) 0.898 0.0004 
















0-4 years 1.0     1.0     1.0     1.0     1.0     
5-9 years 1.1 (0.9,1.2) 0.412   1.0 (0.9,1.2) 0.527   1.0 (0.9,1.2) 0.423   1.1 (1.0,1.2) 0.200   1.0 (0.9,1.2) 0.618   
10-14 years 1.0 (0.9,1.2) 0.708 0.7132 (0.7301) 1.1 (0.9,1.3) 0.334 0.6190 (0.3569) 1.1 (1.0,1.3) 0.094 0.2444 (0.1029) 1.1 (1.0,1.3) 0.098 0.2266 (0.1072) 1.1 (1.0,1.3) 0.132 0.2990 (0.1519) 
















16-24 years 1.0     1.0     1.0     1.0     1.0     
25-34 years 1.1 (1.0,1.3) 0.131   1.2 (1.0,1.4) 0.21   1.2 (1.0,1.3) 0.010   1.3 (1.1,1.5) <0.001   1.3 (1.1,1.5) 0.001   
35-44 years 1.0 (0.9,1.2) 0.852   1.2 (1.0,1.4) 0.103   1.3 (1.1,1.5) 0.002   1.3 (1.1,1.6) 0.001   1.5 (1.3,1.9) <0.001   
45+ years 1.0 (0.8,1.2) 0.666 0.2051 (0.8380) 0.8 (0.6,1.0) 0.050 0.0001 (0.7357) 1.0 (0.8,1.3) 0.731 0.0021 (0.0415) 1.2 (1.0,1.5) 0.078 0.0013 (0.0015) 1.6 (1.2,2.0) <0.001 <0.0001 (<0.0001) 
Table 4.4:  Multivariable logistic regression models* reporting odds ratios and 95% confidence intervals for reporting mental health dysfunction within the five questions comprising the mental health 
scale of the SF-36 survey, by specific potential demographic, cancer, social, and economic factors 
Abbreviations: NHL: non-Hodgkin lymphoma, CNS: central nervous system, OR: odds ratio, CI: confidence intervals 
*Adjusted for age at diagnosis, diagnosis, sex, age at questionnaire completion, marital status, educational attainment, and socioeconomic classification 
†The Pheterogeneity (two-sided) is from the likelihood ratio test for heterogeneity in the probability of reporting mental health dysfunction within this specific question, across different levels of the 
specified explanatory factor with adjustment for all other factors in the multivariate model.  The threshold for statistical significant was 0.05. 
‡The Ptrend (two-sided) is from the test for trend, where the threshold for statistical significant was 0.05. 
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Have you been a very nervous person? 
 (Question 9b) 
Have you felt so down in the dumps that 
nothing could cheer you up?  
(Question 9c) 
Have you felt calm and peaceful? 
(Question 9d) 
Have you felt downhearted and low? 
(Question 9f) 




























Marital Status                               
Single 1.0     1.0     1.0     1.0     1.0     
Cohabiting 0.8 (0.7,1.0) 0.018   1.0 (0.8,1.2) 0.700   1.1 (1.0,1.3) 0.159   1.0 (0.8,1.2) 0.879   1.1 (0.9,1.3) 0.519   
Married 0.7 (0.6,0.8) <0.001   0.6 (0.5,0.7) <0.001   0.9 (0.8,1.0) 0.091   0.7 (0.6,0.8) <0.001   0.7 (0.6,0.8) <0.001   
Separated 1.2 (0.8,1.7) 0.305   1.3 (0.9,1.9) 0.149   1.3 (0.9,1.9) 0.098   1.7 (1.2,2.4) 0.003   1..3 (0.9,1.9) 0.175   
Divorced 1.0 (0.8,1.3) 0.916   1.1 (0.8,1.4) 0.588   1.0 (0.8,1.3) 0.822   1.0 (0.8,1.2) 0.872   1.1 (0.9,1.4) 0.469   

















No qualifications 1.0     1.0     1.0     1.0     1.0     
Other qualifications 1.0 (0.9,1.2) 0.719   0.9 (0.7,1.0) 0.123   0.9 (0.7,1.0) 0.054   0.9 (0.8,1.1) 0.230   0.9 (0.7,1.1) 0.218   
O-level 0.8 (0.7,0.9) 0.001   0.7 (0.6,0.8) <0.001   0.8 (0.7,0.9) 0.004   0.8 (0.7,1.0) 0.013   0.8 (0.7,0.9) 0.010   
A-level 0.7 (0.6,0.9) <0.001   0.6 (0.5,0.8) <0.001   0.8 (0.7,0.9) 0.004   0.7 (0.6,0.9) <0.001   0.8 (0.6,0.9) 0.005   
Teaching qualification 0.8 (0.6,1.0) 0.029   0.6 (0.5,0.8) <0.001   0.8 (0.7,1.0) 0.031   0.8 (0.6,0.9) 0.006   0.7 (0.6,0.9) 0.009   
Degree 0.6 (0.5,0.8) <0.001 <0.0001 0.5 (0.4,0.6) <0.001 <0.0001 0.8 (0.7,1.0) 0.047 0.0646 0.7 (0.6,0.8) <0.001 <0.0001 0.7 (0.6,0.9) 0.002 0.0007 
















Student 1.0     1.0     1.0     1.0     1.0     
Never worked/ 
Unemployed 
1.3 (1.1,1.6) 0.008   2.6 (2.1,3.2) <0.001   1.3 (1.1,1.6) 0.006   1.5 (1.2,1.8) <0.001   1.8 (1.5,2.3) <0.001   
Routine/ 
Manual 
1.0 (0.9,1.2) 0.892   1.4 (1.2,1.7) <0.001   1.1 (0.9,1.2) 0.417   1.3 (1.1,1.5) 0.004   1.2 (1.0,1.4) 0.091   
Intermediate 0.9 (0.7,1.0) 0.153   1.1 (0.9,1.4) 0.245   1.0 (0.9,1.2) 0.986   1.1 (0.9,1.3) 0.195   1.1 (0.9,1.3) 0.430   
Managerial/ 
Professional 
0.8 (0.6,0.9) 0.009 <0.0001 1.0 (0.8,1.3) 0.766 <0.0001 1.0 (0.8,1.2) 0.816 0.0339 0.9 (0.8,1.1) 0.527 <0.0001 1.0 (0.8,1.2) 0.973 <0.0001 
Table 4.4 (continued):  Multivariable logistic regression models* reporting odds ratios and 95% confidence intervals for reporting mental health dysfunction within the five questions comprising the 
mental health scale of the SF-36 survey, by specific potential demographic, cancer, social, and economic factors.  
Abbreviations: NHL: non-Hodgkin lymphoma, CNS: central nervous system, OR: odds ratio, CI: confidence intervals 
*Adjusted for age at diagnosis, diagnosis, sex, age at questionnaire completion, marital status, educational attainment, and socioeconomic classification 
†The Pheterogeneity (two-sided) is from the likelihood ratio test for heterogeneity in the probability of reporting mental health dysfunction within this specific question, across different levels of the 
specified explanatory factor with adjustment for all other factors in the multivariate model.  The threshold for statistical significant was 0.05. 
‡The Ptrend (two-sided) is from the test for trend, where the threshold for statistical significant was 0.05. 
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Table 4.5:  Percentage of individuals and corresponding 95% confidence intervals reporting mental health dysfunction among the general health population sample (OHLS) and childhood cancer 
survivors within the British Childhood Cancer Survivor Study, adjusting for sex and age  
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 Age at SF-36 Completion 

















All Survivors  
Cut down on the amount of time you spent  
on work or other activities? (Question 5a) 
14.4(12.5,16.3) 12.9 (11.6,14.2) 12.1(10.7,13.4) 15.4(14.2,16.7) 12.1(10.7,13.5) 17.2(15.4,18.9) 12.8(11.6,13.9) 17.5(14.6,20.3) 
Accomplished less than you would like? 
 (Question 5b) 
22.6(20.4,24.9) 19.0(17.5,20.6) 20.6(18.9,22.3) 20.8(19.5,22.2) 21.6(19.9,23.3) 23.6(21.7,25.6) 21.8(20.4,23.2) 24.9(21.7,28.1) 
Didn't do work or other activities as carefully  
as usual?(Question 5c) 
21.6(19.4,23.8) 14.8(13.5,16.2) 17.5(16.0,19.1) 16.7(15.4,17.9) 18.1(16.5,19.7) 18.1(16.3,19.9) 15.6(14.3,16.8) 18.1(15.1,21.0) 
Has your physical health or emotional problems  
interfered with your normal social activities?  
(Question 6) 
16.9(14.9,18.9) 16.1(14.7,17.5) 13.5(12.1,15.0) 18.9(17.6,20.2) 14.1(12.6,15.5) 20.4(18.5,22.2) 15.1(13.9,16.3) 21.8(18.7,24.9) 
Has your health limited your social  
activities? (Question 9j) 
11.2(9.6,12.9) 15.7(14.2,17.1) 11.2(9.9,12.5) 20.5(19.1,21.8) 13.4(12.0,14.8) 22.9(20.9,24.8) 15.3(14.1,16.5) 28.1(24.7,31.5) 
Have you been a very nervous person? 
(Question 9b) 
23.7(21.4,25.9) 30.7(28.9,32.5) 20.3(18.6,21.9) 29.7(28.1,31.2) 20.9(19.2,22.6) 26.8(24.8,28.8) 19.5(18.2,20.8) 27.5(24.2,30.8) 
Have you felt so down in the dumps that 
 nothing could cheer you up? (Question 9c) 
21.2(19.1,23.4) 25.3(23.6,26.9) 17.6(16.0,19.2) 25.7(24.2,27.1) 18.1(16.5,19.6) 24.5(22.6,26.5) 17.6(16.3,18.9) 18.7(15.9,21.6) 
Have you felt calm and peaceful?  
(Question 9d) 
44.8(42.2,47.5) 43.2(41.3,45.1) 45.0(42.9,47.0) 46.8(45.1,48.4) 47.1(45.1,49.2) 47.7(45.4,49.9) 39.1(37.5,40.8) 43.1(39.4,46.7) 
Have you felt downhearted and low? 
(Question 9f) 
31.1(28.7,33.6) 35.1(33.3,37.0) 29.4(27.5,31.3) 36.4(34.8,38.0) 28.4(26.6,30.3) 35.7(33.5,37.9) 26.4(24.9,27.9) 34.1(30.6,37.6) 
Have you been a happy person? 
(Question 9h) 
22.0(19.8,24.2) 21.5(19.9,23.1) 24.1(22.3,25.9) 24.5(23.1,26.0) 27.1(25.2,28.9) 27.1(25.0,29.1) 26.2(24.7,27.7) 27.8(24.5,31.1) 
Table 4.6:  Percentage of individuals and corresponding 95% confidence intervals reporting mental health dysfunction by attained age among the general health population sample (OHLS) and childhood 
cancer survivors within the British Childhood Cancer Survivor Study, adjusting for sex and age  
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Figure 4.1:  SF-36v1 questions assessed for mental health dysfunction (as portrayed in the questionnaire).   
Checked boxes denote responses that were considered as ‘reporting mental health dysfunction.’
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Population-based long-term cause-specific mortality 
among 34,489 five-year survivors of childhood cancer 
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Abstract 
Purpose:  The recent extension of the British Childhood Cancer Survivor Study (BCCSS) to 
include five-year survivors of childhood cancer diagnosed between 1940 and 2006 provides an 
opportunity to investigate risk of death in relation to era of treatment, and, in particular, to 
address whether more modern treatments are associated with net increased or decreased risk of 
death from neoplastic and non-neoplastic causes.   
 
Material and Methods:  The BCCSS is a population-based cohort of 34,489 five-year survivors of 
childhood cancer diagnosed between 1940-2006 before the age of 15 in Britain, and to date is the 
largest cohort to assess late mortality.  Standardized mortality ratios (SMRs) and absolute excess 
risks (AERs) were investigated for all deaths.   
 
Results:  Overall, 4,483 deaths were observed, which was 9.1-times the number expected.  The 
SMR declined significantly with increasing attained age, but significant excess mortality 
remained even after age 65 (AER: 139.4;95%CI: 41.2-237.6).   All types of childhood cancer, 
except non-heritable retinoblastoma, had increased mortality relative to that expected, with the 
greatest SMRs observed among CNS and leukemia survivors.  With respect to cause-specific 
deaths, survivors were 27.0-times and 2.9-times more at risk of neoplastic and non-neoplastic 
death than expected, respectively.  As attained age increased, the AERs significantly decreased 
for neoplastic causes and significantly increased for non-neoplastic causes (both Ptrend<0.0001).  
Both neoplastic and non-neoplastic AERs significantly decreased with more recent treatment 
decades (both Ptrend<0.0001); specifically, the neoplastic and non-neoplastic AERs in those 
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treated from 1990-2006 were less than a third and half of that observed in those treated before 
1970 after multivariate adjustment, respectively. 
 
Conclusions:  Among five-year British survivors of childhood cancer, this study shows that the 
net effect of more modern treatment, screening and treatment of late effects, and supportive care 
is to reduce the excess numbers of both neoplastic and non-neoplastic deaths observed among 
five-year survivors.  
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Introduction 
Over the past several decades, five-year survival rates from childhood cancer have increased 
significantly due to improvements in treatment therapies.  Nonetheless, long-term survivors of 
childhood cancer remain at an increased risk of mortality compared to that expected1–6.  Previous 
reports on late mortality have shown that the principal cause of excess mortality in the short-term 
is due to progression or recurrence of the initial cancer1–3,7.  However, as follow-up increases, 
studies have shown that a shift occurs where subsequent primary neoplasm and non-neoplastic 
causes account for the majority of excess deaths among survivors later1,2,5.   
 
Nonetheless, it remains unclear the extent to which cause-specific mortality subsequent to five-
year survival has changed following treatment in more recent eras, where increasingly therapeutic 
intensity has been guided by risk stratification.  On one hand, treatment intensity has typically 
decreased for survivors diagnosed with a relatively good prognosis neoplasms in order to prevent 
premature morbidity and mortality from treatment related side-effects. On the other hand, 
treatment regimens have intensified for neoplasms with poor prognosis in order to improve five-
year survival rates.  Although previous studies have aimed to address late mortality across time 
periods1,4,7,8, previous investigations have been restricted due to limited treatment era timespans, 
low person-years at risk, or relatively small numbers of deaths, which limited statistical power 
and inhibited detailed classification and investigation of cause-specific deaths.   
 
In this study we aimed to address these previous limitations by investigating the risk of late 
cause-specific mortality following treatment across almost seven decades (1940-2006) within the 
recently extended British Childhood Cancer Survivor Study (BCCSS) cohort.  The main 
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objective of this study was to determine whether excess late mortality declined for neoplastic and 
non-neoplastic deaths among those treated more recently.  Non-neoplastic deaths were 
investigated overall and for specific causes including circulatory and respiratory. This current 
study includes an additional 7,846, 12,505, and 14,006 five-year survivors than that included in 
previous studies investigating late mortality from SEER7, the CCSS1, and Nordic countries3, 
respectively; additionally, due to fact that our cohort was substantially larger than previous 
studies, we also observed 1,662, 2,159, and 2,407 more deaths than that reported previously by 
SEER7, the CCSS1, and Nordic countries3, respectively.  Thus, this is the largest population-
based study to date to comprehensively examine late mortality and address whether more recent 
treatment eras are associated with a net increased or decreased risk of death.   
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Material and Methods 
British Childhood Cancer Survivor Study  
The BCCSS is the largest population-based cohort to date to comprehensively examine the late 
effects of childhood cancer and its treatment in relation to mortality.  The cohort comprises 
34,489 five-year survivors of childhood cancer diagnosed under the age of 15 years from 1940-
2006 in Britain.  The cohort was identified using the National Registry of Childhood Tumors, 
which has a high estimated level of ascertainment (~99%)9.  Ethical approval for the study was 
obtained from the National Research Ethics Committee and Confidentiality Advisory Group. 
 
Death Ascertainment 
In order to ascertain each survivor’s vital and embarkation status, the entire BCCSS cohort was 
linked to the Health and Social Care Information Centre, which includes the national population-
based death registration system.  An attempt was then made for each death to obtain the death 
certificate and underlying cause-of-death as coded by the Office of National Statistics (England 
and Wales) and General Registrar Office (Scotland) using the relevant International 
Classification of Diseases (ICD) used at time of death.  These ICD codes were also used to 
classify the underlying causes-of-death by using the principal chapters of the relevant ICD 
revision.  Follow-up for mortality commenced at the date of five-year survival and continued 
until the first instance of emigration, death, or February 28, 2014. 
 
Statistical Analyses 
Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated using 
standard cohort techniques10.  The SMR was defined as the ratio of the observed over expected 
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number of deaths.  The AER was defined as the observed minus the expected number of deaths 
divided by person-years at risk multiplied by 10,000.  Expected numbers were calculated by 
multiplying the person-years for each sex-specific, age-specific (five-year bands), and calendar 
year-specific (one-year bands) stratum by the corresponding mortality rate for the population of 
England and Wales and then summing the expected numbers across the strata11.  SMRs are useful 
in determining the multiplicative excess risk, whereas the AER is an additive measure for 
calculating the excess number of deaths in survivors compared to the background mortality per 
10,000 person-years.  In order to test for heterogeneity or trend in SMRs or AERs, likelihood-
ratio tests within Poisson regression models were used10.  Multivariable Poisson regression 
models for the SMRs and AERs were used to evaluate the simultaneous effect of the following 
demographic- and cancer-related factors: sex, first primary neoplasm (FPN) type, age at cancer 
diagnosis (0-4, 5-9, 10-14 years), treatment era (<1970, 1970-1979, 1980-1989, 1990-2006), and 
attained age (5-19, 20-29, 30-39, 40-49, 50-59, 60+ years).   
 
Cumulative mortality, as a function of follow-up (years since diagnosis), was estimated by using 
the stcompet command in Stata12.  Causes-of-death other than the one under study were treated as 
competing risks13.   
 
All analyses were completed using Stata 12.1 statistical software12 where the criterion for 
statistical significance was a two-sided P-value less than 0.05.  
  135 
Results 
Study Characteristics 
The cohort was followed up for a total of 620,758 person-years, with a mean follow-up of 18.0 
(range:0.0-68.7) years from five-year survival and to a mean attained age of 29.6 (range:5.5-85.6) 
years.  When assessed by follow-up, 57,979 and 15,835 person-years were observed beyond 35 
and 45 years, respectively.  With regards to attained age, 41,527 person-years were observed 
beyond age 45 years. Survivors of central nervous system (CNS) tumors, including primitive 
neuroectodermal tumors (PNET), and leukemia, including acute myeloid leukemia (AML), 
accounted for over 50% of the cohort.  Of the 34,489 survivors, 4,483 (13.0%) had died by the 
study exit date (Table 5.1).  Death certifications were obtained for 4,460 of 4,483 (99.5%) of 
survivors.  In order to determine the cause-of-death for individuals without a death certificate, all 
medical information available was assessed manually to determine the likely cause; all transpired 
to be due to neoplastic causes.  
 
All Causes-of-Death 
Overall, survivors experienced 9.1-times (95%CI:8.9-9.4) more deaths than that expected from 
the general population, which equated to 64.3 (95%CI:62.2-66.4) excess deaths per 10,000 
person-years (Table 5.2).  The risk was substantially raised (SMR>10.0) for survivors of CNS 
PNET (SMR:23.3), leukemia (excluding AML) (SMR:15.5), AML (SMR:13.2), and CNS 
(excluding PNET) (SMR:11.6) (Table 5.3).  With regards to AERs, over 50 excess deaths were 
observed for survivors of CNS (excluding PNET), CNS PNET, leukemia (excluding AML), 
AML, Hodgkin lymphoma (HL), heritable retinoblastoma, bone sarcoma, and soft tissue 
sarcoma.  The SMR significantly decreased as follow-up (Ptrend<0.0001) and attained age 
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(Ptrend<0.0001) increased.  Nonetheless, significant excess mortality remained even beyond age 
60, where 108.1 (95%CI:63.7-152.5) excess deaths were observed.  When assessed by treatment 
era, the SMRs and AERs decreased significantly (both Ptrend<0.0001) among those diagnosed 
more recently.  After adjusting for sex, FPN type, age at diagnosis, and attained age, individuals 
diagnosed from 1990-2006 experienced 30% (EMR:0.3,95%CI:0.3-0.4) of the excess deaths 
observed among those diagnosed before 1970 (Table 5.4, Figure 5.1).  When treatment era was 
further assessed, a statistically significant decline in excess mortality among those diagnosed 
more recently was observed for the following FPN types, after adjusting for sex, age at diagnosis, 
and attained age: CNS (excluding PNET) (Ptrend<0.0001), CNS PNET (Ptrend<0.0001), 
leukemia (excluding AML) (Ptrend<0.0001), AML (Ptrend=0.0279), HL (Ptrend<0.0001), non-
Hodgkin lymphoma (NHL) (Ptrend=0.0257), heritable retinoblastoma (Ptrend=0.0399), and 
other FPN types (individuals who did not confirm to one of the finer categories of interest) 
(Ptrend=0.0001) (Table 5.5).  The greatest decrease in excess risk was observed for survivors of 
leukemia (excluding AML) and HL, where survivors diagnosed in 1990-2006 experienced 92% 
and 91% less excess deaths than those diagnosed before 1970, respectively, after adjustment.  A 
decrease in excess deaths among Wilms survivors was also observed, but the trend was slightly 
above that deemed as statistical significance (Ptrend=0.0509). 
 
Further investigations into cause-specific mortality were conducted for all causes-of-death with at 
least 150 observed events, which were as follows: neoplastic causes overall, non-neoplastic 
causes overall, circulatory causes, respiratory cases, and external causes. 
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Cause-Specific Mortality  
The SMR was significantly increased for all causes-of-death, except for deaths due to a mental 
disorder (Table 5.2).  Substantial excesses in mortality (SMR>5.0) were observed for neoplastic-, 
stroke-, respiratory-, infection-, genitourinary-, musculoskeletal-, and blood-related deaths.  The 
mortality was greatest for neoplastic causes at 27.0-fold (95%CI:26.1-27.9) that expected, which 
accounted for 82.7% of the excess deaths among survivors.  Circulatory and respiratory causes-
of-death were the next largest contributors for excess deaths, accounting for 9.2% of the excess 
when combined.  When assessed by attained age, neoplastic causes-of-death accounted for the 
majority of excess mortality until approximately 60 years age, at which point non-neoplastic 
causes were the majority (Table 5.6); the percentage of excess deaths attributable to non-
neoplastic causes rose rapidly with attained age from 7.7% among those aged 5-19 years to 
53.0% among those aged beyond 60 years.  The proportion of excess death due to circulatory 
causes also increased with attained age; the largest proportion of excess mortality among those 
aged beyond 60 years was due to circulatory causes, accounting for 36.8% of the total excess 
mortality and 69.4% of the excess non-neoplastic mortality.  The proportion of excess death due 
to respiratory causes also increased with attained age.   
 
Neoplastic Causes-of-Death 
There were 3,427 neoplastic deaths observed in the cohort, accounting for 76.4% of the deaths 
(Table 5.3).  All FPN types were at a statistically significant increased risk of premature 
neoplastic death, where the SMR ranged from 2.2-fold in survivors of non-heritable 
retinoblastoma to 152.2-fold in survivors of CNS PNET.  As follow-up and attained age 
increased, the SMR significantly declined (both Ptrend<0.0001).  From age 5-19 to beyond age 
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60 the SMR declined from 200.0 (95%CI:191.3-208.9) to 2.1 (95%CI:1.5-2.8), respectively.  
Nonetheless, over 50 (AER:50.8,95%CI:20.6-81.1) excess neoplastic deaths were observed 
beyond age 60.  With regards to treatment era, the AER significantly decreased among those 
treated more recently (Ptrend<0.0001) (Table 5.4, Figure 5.1).  Compared to survivors 
diagnosed before 1970, those diagnosed between 1990-2006 experienced 30% 
(EMR:0.3,95%CI:0.3-0.4) of the excess neoplastic deaths, after adjusting for sex, FPN type, age 
at diagnosis, and attained age (Table 5.3).  When treatment era was assessed by FPN type, 
survivors of CNS (excluding PNET) (Ptrend<0.0001), CNS PNET (Ptrend<0.0001), leukemia 
(excluding AML) (Ptrend<0.0001), AML (Ptrend=0.0035), HL (Ptrend<0.0001), NHL 
(Ptrend=0.0411), and other FPN types (Ptrend<0.0001) were found to have significantly less 
excess mortality among those diagnosed most recently (Table 5.5).  Again, this decrease was 
greatest for leukemia (excluding AML) and HL survivors who were both found to have 93% less 
excess deaths in those diagnosed between 1990-2006 compared to those diagnosed before 1970.  
Nonetheless, all FPN types reporting a significant trend with treatment era were found to have an 
EMR of at least 0.6 for those diagnosed from 1990-2006, which equated to approximately a 40% 
decrease in excess risk among those diagnosed from 1990-2006 compared to those diagnosed 
before 1970.  
 
Non-Neoplastic Causes-of-Death  
Survivors of childhood cancer were 2.9-times (95%CI:2.7-3.1) more likely to die from a non-
neoplastic cause-of-death than expected in the general population, which equated to 11.1 
(95%CI:10.1-12.2) excess non-neoplastic deaths per 10,000 person-years (Table 5.3).  Survivors 
of AML, CNS PNET, and CNS (excluding PNET) were at greatest risk of non-neoplastic death 
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with SMRs of 5.1 (95%CI:3.3-7.5), 4.7 (95%CI:3.5-6.2), and 4.6 (95%CI:4.1-5.1), respectively.  
Survivors of non-heritable retinoblastoma, heritable retinoblastoma, and bone sarcoma were not 
found to be at a significantly increased risk of non-neoplastic death.  The SMR was not observed 
to have significant heterogeneity or trend as follow-up increased (both P>0.05), although the 
AER did significantly increase as follow-up increased (Ptrend<0.0001).  The SMR declined 
(Ptrend=0.0040) and the AER increased (Ptrend<0.0001) significantly as attained age increased, 
with 57.3 (95%CI:24.8-89.7) excess non-neoplastic deaths occurring beyond age 60.  The 
number of excess non-neoplastic deaths among survivors was also observed to decrease with 
more recent treatment eras (Ptrend=0.0016) (Table 5.4, Figure 5.1); survivors diagnosed 
between 1990-2006 experienced 60% (EMR:0.6,95%CI:0.4-0.8) of the excess numbers of non-
neoplastic deaths than observed among survivors diagnosed before 1970.  When treatment era 
was further assessed by FPN type, only CNS (excluding PNET) (Ptrend=0.0229) and HL 
(Ptrend=0.0237) survivors were found to have a significant decrease in excess non-neoplastic 
mortality among those treated more recently (Table 5.5).  Fifty percent (EMR:0.5,95%CI:0.3-
0.9) of the excess number of deaths from non-neoplastic causes was observed among CNS 
(excluding PNET) survivors diagnosed from 1990-2006 compared to those diagnosed before 
1970, whilst the corresponding figure among HL survivors was 30% (EMR:0.3,95%CI:0.1-1.1).  
Decreases in excess non-neoplastic deaths were also observed for NHL and neuroblastoma 





  140 
  Circulatory Causes-of-Death 
In absolute terms, circulatory causes accounted for the largest proportion of non-neoplastic deaths 
with 302 observed events (Table 5.3).  Survivors were 3.9-times (95%CI:3.4-4.3) more at risk of 
circulatory death than expected, which equated to 3.6 (95%CI:3.1-4.2) excess circulatory deaths 
per 10,000 person-years.  The risk of circulatory death was substantially raised (SMR>5.0) for 
survivors of AML (SMR:16.6), CNS PNET (SMR:6.8), Wilms (SMR:5.8), and HL (SMR:5.1).  
As follow-up since diagnosis increased, the SMRs significantly decreased (Ptrend=0.0011) and 
AER significantly increased (Ptrend<0.0001).  Similarly, the SMRs significantly decreased 
(Ptrend=0.0002) and AERs significantly increased (Ptrend<0.0001) as attained age increased; 
even after 60 years age the SMR was significantly elevated at 2.4 (95%CI:1.6-3.5), which 
equated to 39.8 (95%CI:14.8-64.8) excess circulatory deaths per 10,000 person-years.  Although 
a significant decline was observed when assessing the cumulative mortality of circulatory deaths 
by treatment era (Figure 5.1), no effect for treatment era was found in the multivariate Poisson 
model (Ptrend=0.1572), which took into account the expected rates of circulatory death and 
adjusted for sex, FPN type, age at diagnosis, and attained age (Table 5.4).   
 
     Respiratory Causes-of-Death 
Respiratory-related deaths were the second largest cause of non-neoplastic death with 164 
observed events, which was 6.8-times (95%CI:5.8-7.9) that expected from the general population 
(Table 5.3).  A substantial excess risk (SMR>5) was observed among survivors of CNS PNET 
(SMR:22.6), AML (SMR:12.6), CNS (excluding PNET) (SMR:11.9), leukemia (excluding 
AML) (SMR:8.5), neuroblastoma (SMR:7.2), and soft tissue sarcoma (SMR:5.4).  The SMRs 
significantly declined (Ptrend=0.0049) and the AER significantly increased (Ptrend=0.0006) as 
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follow-up increased.  Similarly, the SMR significantly declined (Ptrend=0.0001) and AER 
significantly increased (Ptrend=0.0386) with attained age.  When treatment era was assessed, a 
statistically significant decline (Ptrend=0.0127) in excess mortality was observed among those 
treated more recently, after adjusting for sex, FPN type, age at diagnosis, and attained age (Table 
5.4, Figure 1); compared to survivors diagnosed before 1970, survivors diagnosed from 1990-
2006 experienced 40% (EMR:0.6,95%CI:0.2-1.4) less excess respiratory deaths.   
 
  External Causes-of-Death 
Survivors of childhood cancer had a slight increased risk of death due to external causes 
compared to that expected with an SMR of 1.2 (95%CI:1.1-1.4) (Table 5.3).   Only survivors of 
CNS (excluding PNET) (SMR:2.0,95%CI:1.5-2.6) and neuroblastoma (SMR:2.2,95%CI:1.1-3.9) 
had a significant increased risk compared to that expected.  The SMRs and AERs were not found 
to vary across follow-up nor attained age (all Pheterogeneity>0.05 & all Ptrend>0.05), 
suggesting the risk of death due to external causes was constant throughout follow-up and the 
lifespan.  With regards to treatment era, the number of excess deaths due to external causes 
significantly declined among those treated more recently (Table 5.3, Figure 1).   
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Discussion 
Due to our study’s wide period of diagnosis, long follow-up time, large number of observed 
events, and population-based design, this is the first study to comprehensively investigate late 
mortality among five-year childhood cancer survivors beyond 50 years age, whilst also assessing 
treatment era effects in cause-specific mortality.  Previously we have reported the risk of cause-
specific death after childhood cancer within the same cohort2.  However, this updated analysis 
includes an additional 16,509 survivors and adds a further 1,434 deaths and 250,733 person-
years, ultimately providing more precise risk estimates of late mortality among childhood cancer 
survivors.  Furthermore, this study additionally expands upon previous findings from the 
Childhood Cancer Survivor Study (CCSS)1, Surveillance, Epidemiology and End Results 
Program (SEER)7, and the Nordic countries3, by including a further 7,846, 12,505, and 14,006 
five-year survivors and 2,407, 2,159, and 1,662 deaths, respectively.  
   
The findings from our study support that the net effect of more modern treatment, increased 
screening and treatment of late effects, and improved supportive care, which was available for 
survivors more recently diagnosed, was to reduce excess mortality for all, neoplastic, non-
neoplastic, respiratory, and external causes.  These findings complement previous literature that 
has suggested that late mortality was higher in earlier treatment eras (before 1970) than in more 
recent times (1970 to present), a period where multimodal therapy has been available, among 
five-year survivors of childhood cancer14–17.  Three previous large cohorts from SEER7, the 
Nordic countries3, and the CCSS 1 have reported on treatment era effects among childhood cancer 
survivors.  In the first publication, SEER assessed survivors diagnosed from 1974-2000 and 
reported that all cause late mortality improved among those treated more recently, largely due to 
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a reduction of excess deaths attributable to recurrence/progression of the original cancer7.  
Similarly, the Nordic cohort, which assessed five-year survivors diagnosed from 1960-1989, 
found that the cumulative mortality from all causes, recurrence/progression of the primary 
cancer, and other causes excluding subsequent cancers declined significantly among those more 
recently treated (all P<0.001)3.  Finally, the CCSS found that among 20,483 survivors (2,821 
deaths), the mortality rate remained stable over the treatment period of 1970-19861.  Our findings 
complement the SEER and Nordic studies, as well as smaller reports that investigated treatment 
era trends in Scotland4 and British Columbia, Canada8, as we too found a decline in excess 
mortality for all causes and neoplastic-related deaths; however, this study also further expands 
upon the knowledge in the field of treatment era effects among childhood cancer survivors as we 
have identified significant decreases in excess mortality for non-neoplastic causes overall, 
respiratory causes, and external causes, after taking into account the background expected risks 
and potential confounders.  
 
This study also illustrates treatment era effects by each FPN type for all causes-of-death.  To our 
knowledge, only one other study by SEER has assessed treatment era by FPN7; in this study, 
significant declines (P<0.05) in ten-year all cause cumulative mortality was observed for 
survivors of all leukemias, acute lymphoblastic leukemia, HL, NHL, Ewing sarcoma, and 
rhabdoymosarcoma7.  These findings broadly correspond with our study as we too found 
significant declines with treatment era for leukemia (excluding AML), AML, HL, and NHL when 
assessing all cause mortality via multivariate Poisson models.  However, our finding build upon 
the Armstrong et al. study by additionally finding significant declines in excess all cause 
mortality for CNS (excluding PNET), CNS PNET, heritable retinoblastoma, and other FPNs.  A 
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potential explanation for the differences between our studies may be the fact that the SEER study 
investigated treatment era effects for the diagnosis period of 1974-2000, whilst our study 
included diagnoses from 1940-2006.  Due to our wide diagnosis period, we were able to compare 
multimodal treatment eras to pre-chemotherapy (1940-1959) and first-generation chemotherapy 
(1960-1974) eras, whereas the SEER study covers a diagnosis period where multimodal treatment 
was generally available for all survivors.  Thus, as our study spans a diagnosis period with more 
variable treatment regimens, it is expected that we would be able to better discern decreases in 
excess mortality as substantial improvements in treatment and care have occurred from the 1940s 
to 1970s. 
 
Furthermore, this is the first study to our knowledge to illustrate significant declines in excess 
mortality by treatment era for both neoplastic and non-neoplastic causes for some FPN types.  
Previously, SEER reported significant declines in cumulative mortality for 
recurrence/progression of the primary cancer for some FPN types, but was unable to identify 
significant declines in non-recurrence non-external deaths among survivors more recently 
diagnosed 7.   Our study, however, was able to identify significant declines in neoplastic deaths 
for CNS (excluding PNET), CNS PNET, leukemia (excluding AML), AML, HL, NHL, and other 
FPNs.  Survivors of CNS (excluding PNET) and HL were also found to have significantly less 
excess non-neoplastic deaths among individuals diagnosed more recently.  Although 
chemotherapy generally is not used to treat CNS (excluding PNET) tumors, increased precision 
in the removal and resection of the tumor, smaller and more accurate radiotherapy fields, risk-
stratified driven levels of radiotherapy exposure, and increased awareness of adverse late effects 
have likely contributed to the significant decline in excess neoplastic and non-neoplastic 
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mortality.  Chemotherapy has, however, played an important role in survivors of CNS PNET; 
based upon the findings of the UK PNET-3 trial, survivors treated with surgery, chemotherapy, 
then radiotherapy have been found to have improved event-free and overall survival compared to 
individuals treated with only surgery and radiotherapy18.  This trial highlights the importance of 
removing as much of the tumors as possible and further treating any residual tumor cells with 
chemotherapy and radiotherapy18; this, in addition to improved surgical precision, may have led 
to decreased neoplastic mortality among CNS PNET survivors more recently diagnosed.  For 
leukemia survivors, a large decline in excess mortality was observed from 1970-1979 where, 
compared to individuals diagnosed before 1970, the excess mortality decreased by 40% 
(EMR:0.6); this finding likely corresponds with the introduction of combination chemotherapy, 
which was introduced in the early 1970s and intensified during the 1980s19.  Further reductions in 
excess neoplastic mortality may also relate to radiotherapy use, as CNS irradiation to treat 
leukemia was diminished by the late 1980s, reducing the risk of treatment-induced subsequent 
cancers20,21.  A key factor associated with improved prognosis for AML survivors was the 
relatively recent identification of cytogenetics, which have been shown through the Medical 
Research Council AML 10 trial to be useful for providing the framework for a stratified treatment 
approach22; this approach may have in return decreased excess neoplastic mortality by reducing 
the likelihood of a relapse occurring, which to date still has a poor prognosis.  With regards to HL 
survivors, multimodal therapy with reduced radiation doses among individuals more recently 
diagnosed likely contributed to the large decrease in excess mortality during the diagnosis period 
of 1970-1979 period where, compared to those treated before 1970, a 60% (EMR:0.4) decrease in 
excess mortality was observed.  Further decreases in excess mortality among those diagnosed 
from 1980-1989 and 1990-2006 may be associated with lower cumulative doses of anthracyclines 
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to reduce cardiotoxicity and increased awareness and screening of late adverse effects7,23–25.  
Finally, prior to the 1970s, few children survived NHL26.  However, in the mid-1970s, reports 
began to appear suggesting improved survival and outcomes due to intensive regimens including 
multiple chemotherapy drugs, irradiation to involved fields, and prophylactic treatment of the 
CNS26.  Treatment intensity of NHL then subsequently decreased for individuals with a good 
prognosis, in order to reduce acute toxicities and late adverse effects, and intensified among 
individuals with a poor prognosis26.  These treatment changes over time for NHL survivors 
increased five-year survival from a largely fatal disease and likely contributed to the significant 
decline in excess neoplastic deaths.    
 
And, finally, this study expands upon our previous work on late mortality by extending the 
mortality analysis to beyond 60 years follow-up2.  In doing so, we identified a persistence of 
excess death even beyond 50 years age, suggesting that childhood cancer survivors will likely 
remain at an elevated risk of premature mortality for the majority, if not entirety, of their lifespan.  
Although neoplastic-related deaths were the principal cause of excess mortality overall, excess 
non-neoplastic deaths increased rapidly with attained age, ultimately becoming the more 
prominent concern among older survivors.  Excess non-neoplastic mortality is likely attributable 
to late complications of treatment, as radiotherapy and chemotherapy have been associated with 
adverse circulatory27–31, respiratory32–34, endocrine35,36, neurologic37–39, and other chronic health 
conditions35,40.  Although the change in the proportion of excess deaths attributable to neoplastic 
causes with extending follow-up or attained age is not new, with our previous study2 and the 
CCSS reporting the same transition towards non-neoplastic causes1,41, this is the first study to 
satisfactorily assess late mortality among a population of childhood cancer survivors in their fifth 
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and sixth decades of life.  In doing so, this study provides the initial findings for late mortality 
among childhood cancer survivors who have reached late adulthood.  These results will be useful 
for informing older survivors and clinicians about the persisting increased risks of premature 
mortality, despite the many decades that may have passed since the original childhood cancer 
diagnosis.  Additionally, our results will also serve as a predictor of the future changes and trends 
of late mortality that may occur with on-going follow-up as this population of childhood cancer 
survivors reaches elderly age.  
 
Limitations 
A limitation of our study is the high level of missing treatment information, which prohibited any 
examination of patterns of treatment exposures in relation to cause specific mortality risk.  
Another possible limitation of this study is that our classification of deaths relied upon the 
underlying cause-of-death as coded on the death certificate.  Death certificates have been 
previously shown to have imperfect accuracy in regards to the cause-of-death, and thus some 
degree of misclassification is inherent in our data42–45.  Nonetheless, it is more likely that we have 
under-ascertained non-neoplastic deaths, which were largely the outcomes of interest for the 
cause-specific analysis in this study, as childhood cancer survivors are more likely to be coded as 
having a neoplastic-related death due to their previous medical history46.    Thus, our results 
likely underestimated the risk of non-neoplastic deaths among survivors of childhood cancer, and 
in doing so should still be useful for identifying individuals with increased risks of premature 
mortality. 
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Conclusions 
In conclusion, the findings from this large-scale, population-based study provide evidence that 
excess deaths among five-year British survivors of childhood cancer increase significantly with 
attained age, with a substantial number of survivors dying prematurely even beyond 50 years age.  
Nonetheless, there is evidence that the net effect of more modern treatments, screening and 
detection of late effects, and improvements in supportive care translates into a reduction in the 
excess numbers of both neoplastic and non-neoplastic deaths among five-year survivors.  These 
findings provide unbiased and reliable estimates of late mortality among childhood cancer 
survivors, which will be useful for informing clinicians and survivors regarding the increased risk 
of premature mortality. 
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Patient Characteristic Dead % Alive % Total % 
       
Overall 4,483 13.0 30,006 87.0 34,489 100.0 
Sex             
Male 2,635 13.9 16,304 86.1 18,939 100.0 
Female 1,848 11.9 13,702 88.1 15,550 100.0 
First Primary Neoplasm Type             
CNS (excluding PNET) 1,335 19.2 5,634 80.8 6,970 100.0 
CNS PNET 341 28.5 857 71.5 1,198 100.0 
Leukemia (excluding AML) 1,103 11.6 8,390 88.4 9,493 100.0 
AML 82 8.4 899 91.6 981 100.0 
Hodgkin Lymphoma 335 15.0 1,899 85.0 2,234 100.0 
Non-Hodgkin Lymphoma 131 8.5 1,418 91.5 1,549 100.0 
Neuroblastoma 144 9.4 1,391 90.6 1,535 100.0 
Non-Heritable Retinoblastoma 31 3.1 975 96.9 1,006 100.0 
Heritable Retinoblastoma 139 18.5 611 81.5 750 100.0 
Wilms 184 7.7 2,204 92.3 2,388 100.0 
Bone Sarcoma 198 16.6 997 83.4 1,195 100.0 
Soft Tissue Sarcoma 253 11.8 1,894 88.2 2,147 100.0 
Other 206 6.8 2,837 93.2 3,043 100.0 
Age at Diagnosis             
0-4 1,662 10.6 14,035 89.4 15,697 100.0 
5-9 1,355 14.6 7,909 85.4 9,264 100.0 
10-14 1,466 15.4 8,062 84.6 9,528 100.0 
Treatment Era             
1940-1969 1,333 35.6 2,413 64.4 3,746 100.0 
1970-1979 1,251 23.3 4,128 76.7 5,379 100.0 
1980-1989 941 13.2 6,206 86.8 7,147 100.0 
1990-1999 703 7.0 9,328 93.0 10,031 100.0 
2000-2006 255 3.1 7,931 96.9 8,186 100.0 
Years Follow-Up             
Mean (SD) 12 13.3 18.9 12.5 18 12.8 
5-9 2,720 23.4 8,921 76.6 11,641 100.0 
10-19 699 7.2 9,047 92.8 9,746 100.0 
20-29 491 7.5 6,049 92.5 6,540 100.0 
30-39 325 7.8 3,830 92.2 4,155 100.0 
40-49 209 11.3 1,642 88.7 1,851 100.0 
50-59  34 6.5 490 93.5 524 100.0 
60+ 5 15.6 27 84.4 32 100.0 
Attained Age              
Mean (SD) 24.3 13.8 30.4 13.1 29.6 13.4 
5-9 416 48.9 435 51.1 851 100.0 
10-19 1,834 21.7 6,611 78.3 8,445 100.0 
20-29 1,005 9.4 9,728 90.6 10,733 100.0 
30-39 536 8.1 6,082 91.9 6,618 100.0 
40-49 366 7.5 4,484 92.5 4,850 100.0 
50-59  238 11.3 1,859 88.7 2,097 100.0 
60+ 88 9.8 807 90.2 895 100.0 
Table 5.1:  Cohort characteristics of the British Childhood Cancer Survivor Study 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia 
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 O/E SMR (95%CI) AER (95%CI) 
All Causes 4483/490.9 9.1 (8.9,9.4) 64.3 (62.2,66.4) 
 Neoplastic 3427/126.9 27.0 (26.1,27.9) 53.2 (51.3,55.0) 
 Non-Neoplastic 1056/364.0 2.9 (2.7,3.1) 11.1 (10.1,12.2) 
 Circulatory 302/78.0 3.9 (3.4,4.3) 3.6 (3.1,4.2) 
   Cardiac 182/53.1 3.4 (2.9,4.0) 2.1 (1.6,2.5) 
   Stroke 78/15.2 5.1 (4.1,6.4) 1.0 (0.7,1.3) 
 Respiratory 164/24.2 6.8 (5.8,7.9) 2.3 (1.8,2.7) 
 Nervous 98/23.0 4.3 (3.5,5.2) 1.2 (0.9,1.5) 
 Infection 67/9.1 7.4 (5.7,9.4) 0.9 (0.7,1.2) 
 Digestive 63/30.6 2.1 (1.6,2.6) 0.5 (0.3,0.8) 
 Perinatal 42/9.5 4.4 (3.2,6.0) 0.5 (0.3,0.7) 
 Endocrine 32/10.5 3.1 (2.1,4.3) 0.3 (0.2,0.5) 
 Genitourinary 30/3.3 9.2 (6.2,13.2) 0.4 (0.3,0.6) 
 Musculoskeletal 18/3.0 6.0 (3.5,9.4) 0.2 (0.1,0.4) 
 Mental 15/13.3 1.1 (0.6,1.9) 0.0 (-0.1,0.1) 
 Blood 16/2.1 7.5 (4.3,12.2) 0.2 (0.1,0.3) 
 External 188/151.7 1.2 (1.1,1.4) 0.6 (0.2,1.0) 
 Other 21/5.7 3.7 (2.3,5.7) 0.2 (0.1,0.4) 
Table 5.2:  Observed and expected deaths, standardized mortality ratio, and absolute excess risk of specific causes-of-death 
Abbreviation:  O: observed; E: expected; SMR: standardized mortality ratio; CI: confidence interval; AER: absolute excess risk
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All Causes Neoplastic Causes Non-Neoplastic Causes 
 Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Overall 620,758 4483/490.9 9.1 (8.9,9.4) 64.3 (62.2,66.4) 3427/126.9 27.0 (26.1,27.9) 53.2 (51.3,55.0) 1056/364.0 2.9 (2.7,3.1) 11.1 (10.1,12.2) 
Sex 
Male 336,802 2635/332.7 7.9 (7.6,8.2) 68.4 (65.4,71.3) 1995/66.6 30.0 (28.7,31.3) 57.3 (54.7,59.9) 640/266.1 2.4 (2.2,2.6) 11.1 (9.6,12.6) 
Female 283,955 1848/158.3 11.7 (11.1,12.2) 59.5 (56.5,62.5) 1432/60.3 23.7 (22.5,25.0) 48.3 (45.7,50.9) 416/97.9 4.2 (3.8,4.7) 11.2 (9.8,12.6) 
Pheterogeneity   <0.0001a 0.0004a  0.2999a <0.0001a  <0.0001a 0.8155a 
First Primary Neoplasm Type 
CNS (excluding PNET) 124,750 1336/115.5 11.6 (11.0,12.2) 97.8 (92.1,103.6) 957/32.7 29.3 (27.5,31.2) 74.1 (69.2,79.0) 379/82.9 4.6 (4.1,5.1) 23.7 (20.7,26.8) 
CNS PNET 18,699 341/14.6 23.3 (20.9,26.0) 174.6 (155.2,193.9) 288/3.3 86.3 (76.6,96.8) 152.2 (134.4,170.0) 53/11.3 4.7 (3.5,6.2) 22.3 (14.7,29.9) 
Leukemia (excluding 
AML) 145,237 1103/71.2 15.5 (14.6,16.4) 71.0 (66.6,75.5) 955/12.7 75.1 (70.4,80.0) 64.9 (60.7,69.0) 148/58.5 2.5 (2.1,3.0) 6.2 (4.5,7.8) 
AML 13,029 82/6.2 13.2 (10.5,16.4) 58.2 (44.5,71.8) 56/1.1 50.7 (38.3,65.8) 42.1 (30.9,53.4) 26/5.1 5.1 (3.3,7.5) 16.0 (8.4,23.7) 
Hodgkin Lymphoma 42,600 335/47.3 7.1 (6.3,7.9) 67.5 (59.1,75.9) 243/11.5 21.1 (18.5,23.9) 54.3 (47.2,61.5) 92/35.8 2.6 (2.1,3.2) 13.2 (8.8,17.6) 
Non-Hodgkin Lymphoma 30,343 131/31.9 4.1 (3.4,4.9) 32.7 (25.3,40.1) 79/8.2 9.7 (7.6,12.0) 23.3 (17.6,29.1) 52/23.7 2.2 (1.6,2.9) 9.3 (4.7,14.0) 
Neuroblastoma 28,500 144/16.8 8.5 (7.2,10.1) 44.6 (36.4,52.9) 107/4.2 25.7 (21.1,31.1) 36.1 (29.0,43.2) 37/12.7 2.9 (2.1,4.0) 8.5 (4.3,12.7) 
Non-Heritable 
Retinoblastoma 26,167 31/23.2 1.3 (0.9,1.9) 3.0 (-1.2,7.2) 15/6.8 2.2 (1.2,3.6) 3.1 (0.2,6.0) 16/16.4 1.0 (0.6,1.6) , 0.1 (-3.1,2.9) 
Heritable Retinoblastoma 20,162 139/16.9 8.2 (6.9,9.7) 60.6 (49.1,72.0) 121/4.7 25.6 (21.3,30.6) 57.7 (47.0,68.4) 18/12.2 1.5 (0.9,2.3) 2.9 (-1.2,7.0) 
Wilms 51,519 184/33.8 5.4 (4.7,6.3) 29.1 (24.0,34.3) 101/8.1 12.5 (10.2,15.1) 18.0 (14.2,21.9) 83/25.7 3.2 (2.6,4.0) 11.1 (7.6,14.6) 
Bone Sarcoma 21,798 198/24.6 8.0 (7.0,9.2) 79.5 (66.9,92.2) 172/7.4 23.1 (19.8,26.8) 75.5 (63.7,87.3) 26/17.2 1.5 (1.0,2.2) 4.0 (-0.5,8.6) 
Soft Tissue Sarcoma 42,062 253/39.2 6.5 (5.7,7.3) 50.8 (43.4,58.2) 199/10.9 18.3 (15.8,21.0) 44.7 (38.1,51.3) 54/28.3 1.9 (1.4,2.5) 6.1 (2.7,9.5) 
Other 55,891 206/49.5 4.2 (3.6,4.8) 28.0 (23.0,33.0) 134/15.2 8.8 (7.4,10.5) 21.3 (17.2,25.3) 72/34.4 2.1 (1.6,2.6) 6.7 (3.8,9.7) 
Pheterogeneity   <0.0001a <0.0001a  <0.0001a <0.0001a  <0.0001a <0.0001a 
Age at Diagnosis 
0-4 years 291,564 1662/167.9 9.9 (9.4,10.4) 51.2 (48.5,54.0) 1283/38.6 33.2 (31.4,35.1) 42.7 (40.3,45.1) 379/129.3 2.9 (2.6,3.2) 8.6 (7.3,9.9) 
5-9 years 163,195 1355/128.6 10.5 (10.0,11.1) 75.2 (70.7,79.6) 1055/31.1 33.9 (31.9,36.1) 62.7 (58.8,66.6) 300/97.5 3.1 (2.7,3.4) 12.4 (10.3,14.5) 
10-14 years 165,999 1466/194.4 7.5 (7.2,7.9) 76.6 (72.1,81.1) 1089/57.2 19.0 (17.9,20.2) 62.2 (58.3,66.1) 377/137.2 2.7 (2.5,3.0) 14.4 (12.2,16.7) 
Pheterogeneity   <0.0001a <0.0001a  <0.0001a <0.0001a  0.0723a 0.7330a 
Ptrend   <0.0001a <0.0001a  <0.0001a <0.0001a  0.0307 a 0.4311a 
Table 5.3:  Standardized mortality ratios and absolute excess risks for deaths due to all, neoplastic, non-neoplastic, circulatory, respiratory, and external causes, by potential explanatory factors  
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk 
aPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
bPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and follow-up 
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  All Causes Neoplastic Causes Non-Neoplastic Causes 
 Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Treatment Era 
<1970 135,884 1333/228.1 5.8 (5.5,6.2) 81.3 (76.0,86.6) 936/79.7 11.8 (11.0,12.5) 63.0 (58.6,67.4) 397/148.5 2.7 (2.4,3.0) 18.3 (15.4,21.2) 
1970-1979 152,278 1251/125.0 10.0 (9.5,10.6) 73.9 (69.4,78.5) 951/26.9 35.4 (33.2,37.7) 60.7 (56.7,64.7) 300/98.1 3.1 (2.7,3.4) 13.3 (11.0,15.5) 
1980-1989 155,375 941/85.0 11.1 (10.4,11.8) 55.1 (51.2,59.0) 728/13.1 55.7 (51.7,59.9) 46.0 (42.6,49.4) 213/71.9 3.0 (2.6,3.4) 9.1 (7.2,10.9) 
1990-2006 177,221 958/52.9 18.1 (17.0,19.3) 51.1 (47.7,54.5) 812/7.3 110.8 (103.3,118.7) 45.4 (42.3,48.6) 146/45.5 3.2 (2.7,3.8) 5.7 (4.3,7.0) 
Pheterogeneity   <0.0001a <0.0001a  <0.0001a <0.0001a  0.7912a 0.0031a 
Ptrend   <0.0001a <0.0001a  <0.0001a <0.0001a  0.7150 a 0.0016a 
Years Follow-Up 
5-19 years 390,711 3120/156.8 19.9 (19.2,20.6) 75.8 (73.0,78.6) 2695/21.2 126.9 (122.2,131.8) 68.4 (65.8,71.0) 425/135.5 3.1 (2.8,3.4) 7.4 (6.4,8.4) 
20-29 years 132,085 547/101.7 5.4 (4.9,5.8) 33.7 (30.2,37.2) 317/19.8 16.0 (14.3,17.9) 22.5 (19.9,25.1) 230/82.0 2.8 (2.5,3.2) 11.2 (9.0,13.5) 
30-39 years 66,379 420/98.9 4.2 (3.9,4.7) 48.4 (42.3,54.4) 220/29.8 7.4 (6.4,8.4) 28.6 (24.3,33.0) 200/69.1 2.9 (2.5,3.3) 19.7 (15.5,23.9) 
40-49 years 24,972 277/83.5 3.3 (2.9,3.7) 77.5 (64.4,90.5) 134/33.5 4.0 (3.3,4.7) 40.2 (31.2,49.3) 143/50.0 2.9 (2.4,3.4) 37.2 (27.9,46.6) 
50-59 years 6,102 103/43.0 2.4 (2.0,2.9) 98.3 (65.7,130.9) 54/19.5 2.8 (2.1,3.6) 56.5 (32.9,80.1) 49/23.5 2.1 (1.5,2.8) 41.8 (19.3,64.3) 
60+ years 508 16/7.0 2.3 (1.3,3.7) 177.4 (23.0,331.9) 7/3.0 2.3 (0.9,4.8) 78.3 (-23.9,180.4) 9/4.0 2.3 (1.0,4.3) 99.1 (-16.7,215.0) 
Pheterogeneity   <0.0001b <0.0001
b  <0.0001b <0.0001b  0.5209b <0.0001b 
Ptrend   <0.0001b <0.0001
b  <0.0001
b <0.0001b  0.2465b <0.0001b 
Attained Age 
5-19 years 243,035 2250/70.5 31.9 (30.6,33.3) 89.7 (85.9,93.5) 2022/10.1 200.0 (191.3,208.9) 82.8 (79.2,86.4) 228/60.4 3.8 (3.3,4.3) 6.9 (5.7,8.1) 
20-29 years 195,584 1005/111.2 9.0 (8.5,9.6) 45.7 (42.5,48.9) 739/13.7 54.1 (50.2,58.1) 37.1 (34.4,39.8) 266/97.5 2.7 (2.4,3.1) 8.6 (7.0,10.2) 
30-39 years 108,573 536/94.8 5.7 (5.2,6.2) 40.6 (36.5,44.8) 324/20.2 16.0 (14.3,17.8) 28.0 (24.7,31.2) 212/74.6 2.8 (2.5,3.3) 12.7 (10.0,15.3) 
40,49 years 51,869 366/95.1 3.9 (3.5,4.3) 52.2 (45.0,59.5) 184/30.5 6.0 (5.2,7.0) 29.6 (24.5,34.7) 182/64.6 2.8 (2.4,3.3) 22.6 (17.5,27.7) 
50-59 years 17,552 238/76.1 3.1 (2.7,3.6) 92.2 (75.0,109.5) 117/32.5 3.6 (3.0,4.3) 48.2 (36.1,60.2) 121/43.6 2.8 (2.3,3.3) 44.1 (31.8,56.4) 
60+ years 4,144 88/43.2 2.0 (1.6,2.5) 108.1 (63.7,152.5) 41/19.9 2.1 (1.5,2.8) 50.8 (20.6,81.1) 47/23.3 2.0 (1.5,2.7) 57.3 (24.8,89.7) 
Pheterogeneity   <0.0001
a <0.0001a  <0.0001
a <0.0001a  0.0172
a <0.0001a 
Ptrend   <0.0001
a <0.0001a  <0.0001
a <0.0001a  0.0040
a <0.0001a 
Table 5.3 (continued):  Standardized mortality ratios and absolute excess risks for deaths due to all, neoplastic, non-neoplastic, circulatory, respiratory, and external causes, by potential explanatory 
factors  
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk 
aPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
bPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and follow-up 




Circulatory Causes Respiratory Causes External Causes 
 Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Overall 620,758 302/78.0 3.9 (3.4,4.3) 3.6 (3.1,4.2) 164/24.2 6.8 (5.8,7.9) 2.3 (1.8,2.7) 188/151.7 1.2 (1.1,1.4) 0.6 (0.2,1.0) 
Sex           
Male 336,802 178/56.8 3.1 (2.7,3.6) 3.6 (2.8,4.4) 98/14.9 6.6 (5.3,8.0) 2.5 (1.9,3.0) 133/122.9 1.1 (0.9,1.3) 0.3 (-0.4,1.0) 
Female 283,955 124/21.2 5.9 (4.9,7.0) 3.6 (2.9,4.4) 66/9.3 7.1 (5.5,9.0) 2.0 (1.4,2.6) 55/28.8 1.9 (1.4,2.5) 0.9 (0.4,1.4) 
Pheterogeneity   <0.0001a 0.6211a  0.6059a 0.1717a  0.0013a 0.3063a 
First Primary Neoplasm 
CNS (excluding PNET) 124,750 90/20.1 4.5 (3.6,5.5) 5.6 (4.1,7.1) 72/6.1 11.9 (9.3,15.0) 5.3 (4.0,6.6) 64/31.9 2.0 (1.5,2.6) 2.6 (1.3,3.8) 
CNS PNET 18,699 15/2.2 6.8 (3.8,11.2) 6.8 (2.8,10.9) 15/0.7 22.6 (12.7,37.4) 7.7 (3.6,11.7) 7/5.1 1.4 (0.6,2.8) 1.0 (-1.7,3.8) 
Leukemia (excluding 
AML) 145,237 22/7.1 3.1 (1.9,4.7) 1.0 (0.4,1.7) 23/2.7 8.5 (5.4,12.7) 1.4 (0.7,2.0) 29/30.4 1.0 (0.6,1.4) -0.1 (-0.8,0.6) 
AML 13,029 11/0.7 16.6 (8.3,29.7) 7.9 (2.9,12.9) 3/0.2 12.6 (2.6,36.7) 2.1 (-0.5,4.7) 4/2.6 1.5 (0.4,3.9) 1.1 (-2.0,4.1) 
Hodgkin Lymphoma 42,600 43/8.5 5.1 (3.7,6.8) 8.1 (5.1,11.1) 7/2.3 3.1 (1.2,6.4) 1.1 (-0.1,2.3) 15/14.8 1.0 (0.6,1.7) 0.0 (-1.7,1.8) 
Non-Hodgkin 
Lymphoma 30,343 24/5.7 4.2 (2.7,6.2) 6.0 (2.9,9.2) 5/1.6 3.1 (1.0,7.4) 1.1 (-0.3,2.6) 11/9.6 1.1 (0.6,2.0) 0.4 (-1.7,2.6) 
Neuroblastoma 28,500 8/2.5 3.3 (1.4,6.4) 1.9 (-0.0,3.9) 6/0.8 7.2 (2.6,15.7) 1.8 (0.1,3.5) 12/5.4 2.2 (1.1,3.9) 2.3 (-0.1,4.7) 
Non-Heritable 
Retinoblastoma 26,167 2/4.1 0.5 (0.1,1.8) -0.8 (-1.9,0.3) 1/1.3 0.8 (0.0,4.3) -0.1 (-0.9,0.6) 4/5.9 0.7 (0.2,1.7) -0.7 (-2.2,0.8) 
Heritable 
Retinoblastoma 20,162 5/2.8 1.8 (0.6,4.2) 1.1 (-1.1,3.3) 4/0.9 4.5 (1.2,11.4) 1.5 (-0.4,3.5) 2/4.8 0.4 (0.1,1.5) -1.4 (-2.7,0.0) 
Wilms 51,519 27/4.7 5.8 (3.8,8.4) 4.3 (2.4,6.3) 7/1.6 4.4 (1.8,9.1) 1.1 (0.0,2.1) 16/11.4 1.4 (0.8,2.3) 0.9 (-0.6,2.4) 
Bone Sarcoma 21,798 12/4.6 2.6 (1.4,4.6) 3.4 (0.3,6.5) 1/1.4 0.7 (0.0,4.1) -0.2 (-1.1,0.7) 5/6.1 0.8 (0.3,1.9) -0.5 (-2.5,1.5) 
Soft Tissue Sarcoma 42,062 16/6.9 2.3 (1.3,3.8) 2.2 (0.3,4.0) 11/2.1 5.4 (2.7,9.6) 2.1 (0.6,3.7) 9/10.9 0.8 (0.4,1.6) -0.5 (-1.9,0.9) 
Other 55,891 27/8.2 3.3 (2.2,4.8) 3.4 (1.5,5.2) 9/2.7 3.3 (1.5,6.3) 1.1 (0.1,2.2) 10/12.7 0.8 (0.4,1.4) -0.5 (-1.6,0.6) 
Pheterogeneity   <0.0001a <0.0001a  <0.0001a <0.0001a  0.0032a 0.0001a 
Age at Diagnosis 
0-4 years 291,564 90/22.4 4.0 (3.2,4.9) 2.3 (1.7,3.0) 64/7.8 8.2 (6.3,10.4) 1.9 (1.4,2.5) 69/58.6 1.2 (0.9,1.5) 0.4 (-0.2,0.9) 
5-9 years 163,195 84/19.2 4.4 (3.5,5.4) 4.0 (2.9,5.1) 43/6.0 7.2 (5.2,9.7) 2.3 (1.5,3.1) 46/43.1 1.1 (0.8,1.4) 0.2 (-0.6,1.0) 
10-14 years 165,999 128/36.4 3.5 (2.9,4.2) 5.5 (4.2,6.9) 57/10.4 5.5 (4.1,7.1) 2.8 (1.9,3.7) 73/50.0 1.5 (1.1,1.8) 1.4 (0.4,2.4) 
Pheterogeneity   0.1296a 0.5264a  0.2464a 0.5622a  0.1579a 0.3301a 
Ptrend   0.0432a 0.2835a  0.2618a 0.7383a  0.2578a 0.1478a 
Table 5.3 (continued):  Standardized mortality ratios and absolute excess risks for deaths due to all, neoplastic, non-neoplastic, circulatory, respiratory, and external causes, by potential explanatory 
factors  
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk 
aPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
bPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and follow-up 
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  Circulatory Causes Respiratory Causes External Causes 
 Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Treatment Era 
<1970 135,884 146/50.0 2.9 (2.5,3.4) 7.1 (5.3,8.8) 61/14.3 4.3 (3.3,5.5) 3.4 (2.3,4.6) 65/40.9 1.6 (1.2,2.0) 1.8 (0.6,2.9) 
1970-1979 152,278 75/16.7 4.5 (3.5,5.6) 3.8 (2.7,4.9) 48/5.2 9.3 (6.8,12.3) 2.8 (1.9,3.7) 55/45.2 1.2 (0.9,1.6) 0.6 (-0.3,1.6) 
1980-1989 155,375 63/7.8 8.1 (6.2,10.3) 3.6 (2.5,4.6) 36/2.9 12.4 (8.7,17.2) 2.1 (1.4,2.9) 41/38.9 1.1 (0.8,1.4) 0.1 (-0.7,0.9) 
1990-2006 177,221 18/3.5 5.2 (3.1,8.2) 0.8 (0.4,1.3) 19/1.8 10.4 (6.2,16.2) 1.0 (0.5,1.5) 27/26.7 1.0 (0.7,1.5) 0.0 (-0.6,0.6) 
Pheterogeneity   0.0069a 0.0040a  0.1376a 0.0070a  0.3116a 0.0129a 
Ptrend   0.2729a 0.1572a  0.2536a 0.0127a  0.0655a 0.0054a 
Years Follow-Up 
5-19 years 390,711 70/9.7 7.2 (5.6,9.1) 1.5 (1.1,2.0) 69/6.4 10.8 (8.4,13.7) 1.6 (1.2,2.0) 99/82.4 1.2 (1.0,1.5) 0.4 (-0.1,0.9) 
20-29 years 132,085 71/13.0 5.4 (4.3,6.9) 4.4 (3.1,5.6) 33/3.8 8.7 (6.0,12.2) 2.2 (1.4,3.1) 44/40.0 1.1 (0.8,1.5) 0.3 (-0.7,1.3) 
30-39 years 66,379 68/20.9 3.3 (2.5,4.1) 7.1 (4.7,9.5) 32/4.4 7.2 (5.0,10.2) 4.2 (2.5,5.8) 29/20.2 1.4 (1.0,2.1) 1.3 (-0.3,2.9) 
40-49 years 24,972 63/21.3 3.0 (2.3,3.8) 16.7 (10.5,22.9) 21/5.1 4.1 (2.5,6.3) 6.4 (2.8,10.0) 14/7.3 1.9 (1.0,3.2) 2.7 (-0.3,5.6) 
50-59 years 6,102 27/11.2 2.4 (1.6,3.5) 25.9 (9.3,42.6) 8/3.7 2.1 (0.9,4.2) 7.0 (-2.1,16.1) 2/1.7 1.2 (0.1,4.3) 0.5 (-4.0,5.0) 
60+ years 508 3/1.9 1.6 (0.3,4.6) 21.5 (-45.4,88.4) 1/0.8 1.2 (0.0,6.9) 3.9 (-34.7,42.5) 0/0.1 0.0 (0.0,0.0) -3.0 (-3.0,-3.0) 
Pheterogeneity   0.0319b <0.0001b  0.0509b 0.0062b  0.8808b 0.6821b 
Ptrend   0.0011b <0.0001b  0.0001b 0.0006b  0.8769b 0.1668b 
Attained Age 
5-19 years 243,035 30/3.5 8.7 (5.8,12.4) 1.1 (0.7,1.5) 44/3.4 13.0 (9.4,17.4) 1.7 (1.1,2.2) 42/35.5 1.2 (0.9,1.6) 0.3 (-0.3,0.8) 
20-29 years 195,584 56/7.6 7.3 (5.5,9.5) 2.5 (1.7,3.2) 35/3.7 9.3 (6.5,13.0) 1.6 (1.0,2.2) 69/61.4 1.1 (0.9,1.4) 0.4 (-0.4,1.2) 
30-39 years 108,573 64/13.6 4.7 (3.6,6.0) 4.6 (3.2,6.1) 34/3.7 9.2 (6.4,12.8) 2.8 (1.7,3.8) 42/32.8 1.3 (0.9,1.7) 0.8 (-0.3,2.0) 
40-49 years 51,869 69/21.8 3.2 (2.5,4.0) 9.1 (6.0,12.2) 27/4.3 6.3 (4.2,9.2) 4.4 (2.4,6.3) 23/15.9 1.4 (0.9,2.2) 1.4 (-0.4,3.2) 
50-59 years 17,552 55/20.0 2.7 (2.1,3.6) 19.9 (11.7,28.2) 20/4.8 4.2 (2.5,6.4) 8.7 (3.7,13.7) 9/5.0 1.8 (0.8,3.4) 2.3 (-1.1,5.6) 
60+ years 4,144 28/11.5 2.4 (1.6,3.5) 39.8 (14.8,64.8) 4/4.3 0.9 (0.3,2.4) -0.8 (-10.3,8.6) 3/1.1 2.7 (0.6,8.0) 4.6 (-3.6,12.8) 
Pheterogeneity   0.0040a <0.0001a  0.0002a 0.0139a  0.9779a 0.5122a 
Ptrend   0.0002a <0.0001a  0.0049a 0.0386a  0.7864a 0.0791a 
Table 5.3 (continued):  Standardized mortality ratios and absolute excess risks for deaths due to all, neoplastic, non-neoplastic, circulatory, respiratory, and external causes, by potential explanatory 
factors  
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk 
aPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
bPheterogeneity or Ptrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and follow-up 
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<1970 1333/228.1 1 (ref) 1 (ref) 936/79.7 1 (ref) 1 (ref) 397/148.5 1 (ref) 1 (ref) 
1970-1979 1251/125.0 0.9 (0.8,1.0) 0.8 (0.7,0.8) 951/26.9 1.0 (0.9,1.1) 0.7 (0.7,0.8) 300/98.1 0.7 (0.6,0.9) 1.0 (0.8,1.3) 
1980-1989 941/85.0 0.7 (0.6,0.7) 0.5 (0.4,0.6) 728/13.1 0.7 (0.7,0.8) 0.5 (0.4,0.5) 213/71.9 0.5 (0.4,0.6) 0.9 (0.6,1.1) 
1990-2006 958/52.9 0.6 (0.6,0.7) 0.3 (0.3,0.4) 812/7.3 0.7 (0.6,0.8) 0.3 (0.3,0.4) 146/45.5 0.3 (0.2,0.4) 0.6 (0.4,0.8) 
Ptrend  <0.0001 <0.0001  <0.0001 <0.0001  <0.0001 0.0016 
Table 5.4:  Excess mortality ratios from univariate and multivariate Poisson models assessing the risk of all causes, neoplastic causes, non-neoplastic causes, circulatory causes, respiratory, and external 
causes-of-death by treatment era 
Multivariate Poisson model adjusted for sex, first primary neoplasm type, age at diagnosis, and attained age.  Ptrend was calculated using likelihood ratio tests to assess the effect of treatment era 
























<1970 146/50.0 1 (ref) 1 (ref) 61/14.3 1 (ref) 1 (ref) 65/40.9 1 (ref) 1 (ref) 
1970-1979 75/16.7 0.5 (0.4,0.8) 0.9 (0.6,1.4) 48/5.2 0.8 (0.5,1.3) 1.0 (0.7,1.7) 55/45.2 0.4 (0.1,1.8) 0.7 (0.3,1.7) 
1980-1989 63/7.8 0.5 (0.3,0.7) 1.2 (0.8,2.0) 36/2.9 0.6 (0.4,1.0) 0.9 (0.5,1.6) 41/38.9 0.1 (0.0,33.7) 0.5 (0.2,1.5) 
1990-2006 18/3.5 0.1 (0.1,0.2) 0.4 (0.2,0.8) 19/1.8 0.3 (0.2,0.5) 0.4 (0.2,0.8) 27/26.7 0 0 
Ptrend  <0.0001 0.1572  <0.0001 0.0127  0.0034 0.0054 
Table 5.4 (continued):  Excess mortality ratios from univariate and multivariate Poisson models assessing the risk of all causes, neoplastic causes, non-neoplastic causes, circulatory causes, respiratory, 
and external causes-of-death by treatment era  
Multivariate Poisson model adjusted for sex, first primary neoplasm type, age at diagnosis, and attained age.  Ptrend was calculated using likelihood ratio tests to assess the effect of treatment era 
Abbreviations: O: observed, E: expected, EMR: excess mortality ratio, CI: confidence intervals 
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Ptrend    0.0372 <0.0001a <0.0001  0.0614b <0.0001a <0.0001b  0.8823b <0.0001a 0.0229b 
CNS PNET 
 
































































































































































Ptrend    <0.0001b <0.0001a <0.0001b  <0.0001b <0.0001a <0.0001b  0.9337b 0.3789a 0.0962b 
AML 
 










































































Ptrend    0.8310b 0.1324a 0.0279b  0.1171b 0.0914a 0.0035b  0.0225b 0.9294a 0.2389b 
Hodgkin 
Lymphoma 















































































Ptrend    <0.0001b <0.0001a <0.0001b  <0.0001b <0.0001a <0.0001b  0.1327b 0.0023a 0.0237b 
 Table 5.5:  Standardized mortality ratios, absolute excess risks, and excess mortality ratios for all, neoplastic, and non-neoplastic causes-of-death, by first primary neoplastic type and treatment era 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk, EMR: excess mortality ratio, NA: not possible to reliably calculate due to very small numbers 
aPtrend determined from univariate Poisson model 
bPtrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
 
  157 










































































































Ptrend    0.9035b 0.2571a 0.0257b  0.9692b 0.4696a 0.0411b  0.9388b 0.3995a 0.3268b 
Neuroblastoma 
 








































































































































































































































Ptrend    0.6699b 0.0011a 0.0399b  0.6289b 0.0019a 0.0594b  0.6380b 0.2283a 1.0000b 
Wilms 














































































Ptrend    0.8409b <0.0001a 0.0509b  0.5596b 0.0020a 0.0070b  0.2889b 0.0117a 0.6925b 
 Table 5.5 (continued):  Standardized mortality ratios, absolute excess risks, and excess mortality ratios for all, neoplastic, and non-neoplastic causes-of-death, by first primary neoplastic type and 
treatment era 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk, EMR: excess mortality ratio, NA: not possible to reliably calculate due to very small numbers 
aPtrend determined from univariate Poisson model 
bPtrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
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   All Causes Neoplastic Non-Neoplastic 
  Person 
Years 
O/E SMR (95%CI) AER (95%CI) EMR (95%CI) O/E SMR (95%CI) AER (95%CI) EMR (95%CI) O/E SMR (95%CI) AER (95%CI) EMR (95%CI) 
Bone Sarcoma 
 

































































































































































Ptrend    0.0032b 0.0140a 0.4951b  0.0021b 0.0023a 0.5906b  0.6827b 0.9485a 0.6588b 
Other 
 















































































Ptrend    0.2055b 0.0095a 0.0001b  0.3501b 0.0520a 0.0001b  0.7290b 0.0947a 0.4198b 
Table 5.5 (continued):  Standardized mortality ratios, absolute excess risks, and excess mortality ratios for all, neoplastic, and non-neoplastic causes-of-death, by first primary neoplastic type and 
treatment era 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, CI: confidence 
interval, AER: absolute excess risk, EMR: excess mortality ratio, NA: not possible to reliably calculate due to very small numbers 
aPtrend determined from univariate Poisson model 
bPtrend determined from multivariate Poisson model adjusting for sex, first primary neoplasm type, age at diagnosis, treatment era, and attained age 
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 Attained Age 
 5-19 years 20-29 years 30-39 years 40-49 years 50-59 years 60+ years 























































































































































Table 5.6:  Absolute excess risks (AER) for neoplastic, non-neoplastic, circulatory, respiratory, external and other non-neoplastica causes-of-death by attained age as a proportion of total excess risk 
aIncludes the following causes-of-death: nervous, infection, digestive, perinatal, endocrine, genitourinary, musculoskeletal, mental, blood, other 
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Figure 5.1:  Observed (among survivors) and expected cumulative mortalities for all, neoplastic, non-neoplastic, circulatory, respiratory, and external causes-of-death, by follow-up (years since 
diagnosis), stratified by treatment era 
P determined using a log-rank test
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Population-based long-term cardiac-specific mortality 
among 34,489 five-year survivors of childhood cancer 








Purpose:  Increased risks of cardiac morbidity and mortality among childhood cancer survivors 
have been described previously.  However, little is known about the long-term risks of cardiac 
mortality and whether the risk has decreased among those more recently diagnosed.  We 
investigated the risk of long-term cardiac mortality among survivors within the recently extended 
British Childhood Cancer Survivor Study (BCCSS). 
 
Material and Methods:  The BCCSS is a population-based cohort of 34,489 five-year survivors of 
childhood cancer diagnosed from 1940-2006, and is the largest cohort to date to assess late 
mortality. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were used to 
quantify cardiac mortality excess risk.   
 
Results:  Overall, 182 cardiac deaths were observed, which was 3.4-times the number expected.  
By cardiac subgroups, survivors were 2.5-times and 5.9-times more at risk of ischemic heart 
disease (IHD) and cardiomyopathy/heart failure (CM/HF) death than expected, respectively.  
Although the SMR declined with age, 13 excess cardiac deaths per 10,000 person-years were 
observed beyond age 50.  When treatment era was assessed, a quadratic relationship was 
identified for overall cardiac and CM/HF deaths, where the excess risk was greatest among those 
diagnosed from 1980-1989.  Specifically for CM/HF deaths, survivors diagnosed from 1980-
1989 had 28.9-times more excess deaths than survivors diagnosed either before 1970 or after 







Conclusions:  Excess cardiac mortality among five-year survivors of childhood cancer remains 
increased beyond 50 years age.  However, the fact that the risk was greatest in those diagnosed 
from 1980-1989 suggests that initiatives to reduce cardiac toxicity among those treated more 







Survival from childhood cancer has improved substantially over recent decades, with 
approximately 80% of those diagnosed now surviving at least five years1.  Consequently, as 
survival prospects continue to increase, the number of survivors will also rise.  Currently, there 
are an estimated 33,000 survivors of childhood cancer in the U.K.2, and approximately 300,000-
500,000 survivors in Europe3.  With the population of survivors of childhood cancer growing, it 
becomes ever more important to assess outcomes post five-year survival as curative treatments 
are associated with long-term adverse effects, ultimately increasing the risk of premature 
mortality.   
 
Radiation and chemotherapy increase the risk of cardiovascular disease in survivors of childhood 
cancer4,5.  Previous reports have shown that cardiovascular death accounts for a large proportion 
of the excess mortality and for some types of childhood cancer is the leading cause of non-
neoplastic mortality6,7.  However, most previous studies have been restricted due to limited 
follow-up and small numbers of cardiac deaths, and thus have not been able to satisfactorily 
address the risk of cardiac mortality beyond 50 years age nor determine whether long-term excess 
mortality has declined for survivors treated in more recent treatment eras.  Thus, we investigated 
the long-term risk of cardiac mortality among nearly 35,000 survivors of childhood cancer 
diagnosed from 0-14 years within the British Childhood Cancer Survivor Study (BCCSS).  The 
BCCSS is the largest study to date to assess long-term mortality in survivors of childhood cancer.  
Furthermore, key advantages of the BCCSS compared to other studies are that it is a large, 
population-based cohort that spans from the 1940s to 2000s, making it possible to assess short- 






Material and Methods 
British Childhood Cancer Survivor Study  
The BCCSS comprises 34,489 five-year survivors of childhood cancer diagnosed from 1940-
2006 under the age of 15 years in Britain.  The cohort was identified using the National Registry 
of Childhood Tumors, which has a high estimated level of ascertainment (~99%)8.  Ethical 
approval for the study was obtained from the National Research Ethics Service and legal 
approval to process identifiable data without consent was approved by the Confidentiality 
Advisory Group.   
 
We developed a proxy for chest irradiation and anthracycline exposure based upon first primary 
neoplasm (FPN) type and year of diagnosis using the following categories: (i) unlikely exposed 
to either chest irradiation or anthracyclines, (ii) likely exposed to chest irradiation, but unlikely 
exposed to anthracyclines – henceforth called ‘likely exposed to chest irradiation,’ (iii) likely 
exposed to anthracyclines, but unlikely exposed to chest irradiation – henceforth called ‘likely 
exposed to anthracyclines,’ and (iv) likely exposed to both chest irradiation and anthracyclines 
(Table 6.1).  Survivors diagnosed before 1975 with Hodgkin lymphoma (HL), non-Hodgkin 
lymphoma (NHL), neuroblastoma, Wilms, and bone sarcoma were categorized as being likely 
exposed to chest irradiation.  Survivors diagnosed between 1975-2006 with leukemia, Hodgkin 
lymphoma (HL), non-Hodgkin lymphoma (NHL), neuroblastoma, Wilms, bone sarcoma, or soft-
tissue sarcoma were categorized as being likely exposed to anthracyclines.  Survivors of HL, 
NHL, neuroblastoma, and Wilms were also likely to be exposed to chest irradiation if diagnosed 
from 1975 onwards.  All survivors of primitive neuroectodermal tumors (PNET) of the central 







By linking with the Health and Social Care Information Centre, the BCCSS cohort was able to 
ascertain each survivor’s vital and embarkation status.  For each death, an attempt was made to 
obtain the death certificate and underlying cause-of-death as coded by the Office of National 
Statistics (England and Wales) and General Registrar Office (Scotland) using the relevant 
International Classification of Diseases (ICD).   ICD codes corresponding to a cardiac death 
were identified and sub-categorized into clinically relevant groups for analysis, specifically: 
ischemic heart disease (IHD), cardiomyopathy/heart failure (CM/HF), arrhythmias, pericardial 
disease, and valvular disease (Table 6.2).  Follow-up for cardiac mortality commenced at five-
year survival and continued until the first instance of emigration, death, or February 28, 2014. 
 
Statistical Analyses 
Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were calculated using 
standard cohort techniques9.  The SMR was defined as the ratio of the observed over expected 
number of deaths.  The AER was defined as the observed minus the expected number of deaths 
divided by person-years at risk multiplied by 10,000.  Expected numbers were calculated by 
multiplying the person-years for each sex-specific, age-specific (quinquennial), and calendar 
year-specific (single year) stratum by the corresponding mortality rate for the population of 
England and Wales and then summing across the strata10.  Multivariable Poisson regression 
models for the SMRs and AERs were used to evaluate the simultaneous effect of the following 
demographic- and cancer-related factors: sex, FPN type, age at cancer diagnosis, treatment era, 
and attained age.  If the results from the univariate and multivariate models were similar 






AERs.  If the results from the models differed (implying confounding), then the multivariate 
results were reported in terms of relative risks for the SMRs and excess mortality ratios for the 
AERs.  To test for heterogeneity, trend, or nonlinear relationships, likelihood-ratio tests within 
Poisson regression models were used.     
 
Cumulative mortality, as a function of follow-up (years since five-year survival), was estimated 
by using the stcompet command in Stata11.  Causes-of-death other than the one under study were 
treated as competing risks12.   
 
All analyses were completed using Stata statistical software11, where the criterion for statistical 









From five-year survival, the cohort was followed up for a total of 620,758 person-years, with a 
mean follow-up of 18.0 (range:0.0-68.7) years and to a mean attained age of 29.6 (range:5.5-
85.6) years at end of follow-up.  By the study exit date, 4,483 (13%) individuals in the cohort had 
died, of which 182 (4.1%) were attributed to cardiac causes (Table 6.3).  From five-year survival, 
the mean follow-up time and attained age to cardiac death was 26.4 and 39.2 years, respectively, 
which was higher than that observed for individuals who died from a non-cardiac cause.  Males 
accounted for approximately two-thirds (63.7%) of the cardiac deaths, and survivors of CNS 
tumors (excluding PNET), HL, and Wilms accounted for nearly 50% of the cardiac deaths 
observed when combined.   
 
Overall Cardiac Mortality 
Survivors of childhood cancer experienced 3.4-times (95%CI:2.9-4.0) the number of cardiac 
deaths expected from the general population, which equated to 2.1 (95%CI:1.6-2.5) excess 
cardiac deaths per 10,000 person-years (Table 6.4).  All FPN types with at least five observed 
cardiac deaths were at a statistically significant increased risk of cardiac death.  The SMR was 
substantially raised (SMR>5.0) for survivors of acute myeloid leukemia (AML), Wilms, and HL 
at 23.5 (95%CI:11.2-43.1), 6.5 (95%CI:4.0-10.0), and 5.6 (95%CI:3.9-7.8), respectively.  
Individuals likely exposed to both chest irradiation and anthracyclines were at greatest risk of 
cardiac death, with an SMR of 9.7 (95%CI:6.6-13.8).  Survivors who were likely exposed to 
anthracyclines were 7.9-fold (95%CI:5.5-11.0) more at risk of cardiac death than expected, 






than expected.  Survivors unlikely to have been exposed to either were still 2.1-times 
(95%CI:1.6-2.7) more at risk of cardiac death than that expected.  The SMR significantly 
declined (Ptrend<0.0001) and AER significantly increased (Ptrend<0.0001) with attained age 
(Table 6.5); from 0-19 to beyond 50 years age the SMR declined from 9.7-fold (95%CI:5.9-15.0) 
to 2.2-fold (95%CI:1.6-3.9) that expected, respectively, whilst for the same age groupings the 
AER rose from 0.7 (95%CI:0.4-1.1) to 12.5 (95%CI:6.1-18.9) excess cardiac deaths per 10,000 
person-years, respectively (Table 6.4).  When assessed by treatment era, evidence of a quadratic 
relationship was identified (Pquadratic=0.0238) where the SMR was higher among those treated 
in the 1980’s than those treated in decades before or since.  Compared to those diagnosed before 
1970, the relative risk SMR for cardiac death was 1.6-times (95%CI:1.1.-2.5), 2.3-times 
(95%CI:1.4-3.8), and 1.0-times (95%CI:0.4-2.1) higher among those diagnosed in 1970-1979, 
1980-1989, and 1990-2006, respectively, after adjusting for age at diagnosis, attained age, FPN 
type, and sex (Table 6).  
 
Overall, the cumulative mortality for cardiac death was 5.0% at 60 years follow-up compared to 
3.5% expected (Figure 6.1).  Among the FPN types, the cumulative mortality was greatest for 
survivors of Wilms and HL; the two cumulative mortality curves ran parallel to one another, with 
the cumulative mortality beginning to increase at 20 years follow-up for HL survivors and at 25 
years follow-up for Wilms survivors (Figure 6.2).   When assessed by likely treatment the 
cumulative mortalities were significantly different (P<0.0001); compared to the expected 
cumulative mortality of 0.2% at 35 years follow-up, the cumulative mortality for those likely to 
have been exposed to both chest irradiation and anthracyclines was 2.0% (Figure 6.3).  Survivors 






of 0.7% and 0.6% at 35 years follow-up, respectively, which was higher than the 0.1% and 0.2% 
expected, respectively.  The cumulative mortality for those unlikely to have been treated with 
chest irradiation or anthracyclines was more gradual, reaching 0.5% at 35 years follow-up.   
 
Specific Types of Cardiac Mortality 
Of the 182 cardiac deaths observed, there were 97 IHD, 52 CM/HF, 8 valvular disease, 5 
arrhythmias, 2 pericardial disease, and 18 other cardiac deaths (Table 6.7).  The SMRs for IHD, 
CM/HF, valvular, arrhythmia, pericardial, and other cardiac deaths were as follows, respectively: 
2.5 (95%CI:2.1-3.1), 5.9 (95%CI:4.4-7.7), 3.6 (95%CI:1.6-7.2), 3.4 (95%CI:1.1-8.0), 8.0 
(95%CI:1.0-29.0), and 8.3 (95%CI:4.9-13.1).  When assessed by attained age, cardiomyopathy 
accounted for 60% of the excess cardiac mortality among those aged 5-19 years at death (Table 
6.8).  Among those aged 20-29 years and 30-39 years at death, 86.7% and 80.4% of the excess 
cardiac deaths, respectively, were due to IHD and CM/HF combined.  From 40 years onwards, 
IHD deaths accounted for the majority of the excess cardiac deaths.   Due to the fact that IHD and 
CM/HF accounted for over 80% of all cardiac deaths, we consider only these two specific cardiac 
outcomes separately. 
 
 Ischemic Heart Disease Mortality 
The cumulative mortality of IHD deaths increased steadily until approximately 45 years follow-
up, at which point there was a steep increase, ultimately reaching 3.8% at 65 years follow-up 
which was 1.0% higher than that expected (Figure 6.1).  The SMR for IHD death was highest for 
survivors of Wilms (SMR:5.3,95%CI:2.7-9.5) and HL (SMR:4.6,95%CI:2.8-7.0) (Table 6.4).  






to one of the twelve FPN types analyzed also had a statistically significant elevated risk of IHD 
death.  For individuals likely exposed to both chest irradiation and anthracyclines, the risk of IHD 
death was 7.6-fold (95%CI:3.1-8.2) that expected.  Survivors likely exposed to anthracyclines or 
likely exposed to chest irradiation had similar risks for IHD death, with SMRs of 3.1 (95%CI:2.1-
4.1) and 3.0 (95%CI:2.1-4.1), respectively.  Nonetheless, survivors who were unlikely to have 
been treated with either still remained at an increased risk of IHD death (SMR:1.9,95%CI:1.4-
2.6) compared to that expected.  As attained age increased, the SMR declined significantly 
(Ptrend=0.0011) and AER increased significantly (Ptrend<0.0001) (Table 6.5); beyond 50 years 
age survivors remained over two-times (SMR:2.1,95%CI:1.3-3.8) more at risk than expected, 
which equated to 10.0 (95%CI:4.2-15.8) excess IHD deaths per 10,000 person-years (Table 6.4).  
There was no evidence of an effect in relation to treatment era for IHD deaths (Table 6.5).   
 
 Cardiomyopathy and Heart Failure Mortality  
At 65 years follow-up, the cumulative mortality for CM/HF deaths was 0.5% compared to 0.3% 
expected (Figure 6.1).  All FPN types with at least five observed CM/HF deaths were found to be 
at a substantially higher risk of CM/HF death (SMR>5.0) than that expected (Table 6.4); 
survivors of AML, NHL, and Wilms were greatest at risk, with 66.0-times (95%CI:28.5-130.0), 
10.2-times (95%CI:3.7-22.2), and 8.0-times (95%CI:2.6-18.8) the number of expected CM/HF 
deaths, respectively.  When assessed by likely treatment, survivors likely exposed to 
anthracyclines were at greatest risk of CM/HF death compared to that expected with a SMR of 
13.9 (95%CI:8.7-21.1).  Similarly, survivors likely exposed to both chest irradiation and 
anthracyclines were 13.6-times (95%CI:7.4-22.8) more at risk of CM/HF death.  Individuals 






with either (SMR:2.3,95%CI:1.1-4.2) were also at a statistically significant higher risk of CM/HF 
death than that expected.  A decrease in multiplicative risk of CM/HF death with attained age, 
compared to that expected, was not observed (Ptrend=0.8121) (Table 6.6). With regards to 
treatment era, evidence of a quadratic relationship was found for both SMRs (Pquadratic<0.0001) 
and AERs (Pquadratic=0.0016).  When the AERs were plotted for each year of diagnosis, the 
number of excess CM/HF deaths was found to be stable among those treated up to approximately 
1970, at which point the number of excess deaths began to sharply increase, ultimately peaking in 
the mid-1980s (Figure 6.4).  After further adjusting the AERs by age at diagnosis, attained age, 
FPN type, and sex, survivors diagnosed from 1970-1979, 1980-1989, and 1990-2006 had 13.9- 
(95%CI:1.1-168.5), 28.9-times (95%CI:2.4-354.6), 4.5-times (95%CI:0.3-69.4) the excess 









With the most reported cardiac deaths in one study and 73,565 person-years among those aged 
over 40 years, this study provides more reliable and unbiased findings on cardiac mortality than 
has been available previously.  Given our numbers, length of follow-up, wide calendar period of 
diagnosis, and population-based design, we have been able to determine cardiac mortality overall 
and for specific cardiac subgroups beyond 50 years age, and also investigate the impact of 
treatment era.  In doing so, this study adds 207,077 person-years and 53 additional cardiac deaths 
to our previous largest study assessing cardiac mortality13.  Furthermore, this study expands upon 
and addresses many of the limitations of previous work from the United States and Nordic 
countries, adding an additional 283,424 person-years and at least 25 cardiac deaths (definition of 
cardiac death differs between studies - our study is more restrictive) to the latest study from the 
United States14,15 and a further 289,410 person-years and at least 61 cardiac deaths (definition of 
cardiac death differs between studies - our study is more restrictive) to the latest findings from 
the Nordic countries16.  
 
Cardiac mortality estimates in this cohort were elevated at three-times that expected, which is 
lower than results previously reported by a large cohort that used a similar definition for cardiac 
mortality14.  However, this variation is likely due to the fact that the BCCSS has more follow-up 
time and the SMR declines substantially with attained age.  The risk of cardiac death remained 
elevated beyond 50 years age and the number of excess cardiac deaths was also observed to 
increase significantly with age, with 13 excess deaths occurring beyond 50 years age per 10,000 
person-years.  This finding corresponds with our previous work, which found that the principal 






and circulatory diseases as our cohort of childhood cancer survivors ages7.  When the cumulative 
mortality for cardiac deaths was assessed, the curve did not plateau up to 70 years age; in fact, the 
difference in cumulative mortality between childhood cancer survivors and the general 
population appeared to increase with age.  The fact that excess cardiac mortality is observed 
decades after treatment stresses the very long-term effects of childhood cancer and its treatment 
and the need for primary and secondary cardiac prevention17. 
 
Although previous studies have suggested that overall mortality in five-year survivors has 
decreased for survivors treated in more recent decades16,18–21, only one study has been able to 
demonstrate a reduction in deaths from non-cancer causes16.  To our knowledge, the present 
study is the first study to not only satisfactorily assess whether cardiac-specific mortality has 
changed over time, but also show a quadratic relationship where excess cardiac deaths were 
greatest for those diagnosed in the 1980s.  A quadratic relationship was also found for CM/HF 
deaths, where the number of excess deaths began to increase in the 1970s, peaked in the mid-
1980s, and then subsequently declined among those most recently diagnosed.  This quadratic 
relationship corresponds closely with the introduction of anthracycline chemotherapy, which has 
been shown to increase the risk of dilated cardiomyopathy22–24 and congestive heart failure17.  
The fact that the excess risk of cardiac death was greatest among those diagnosed in the 1980s 
suggests that measures to reduce cardiotoxicity through modified treatment and improved 
monitoring may be having a beneficial effect.  Nonetheless, reassessment is necessary in order to 
determine whether this reduction in excess mortality persists for those more recently diagnosed 







Finally, this study confirms the increased cardiovascular risks associated with thoracic 
radiotherapy and anthracycline exposure, individually and in combination, which has been 
previously observed22,23,25–30.  
      
Limitations 
A potential limitation of our study is the lack of detailed radiotherapy and chemotherapy 
information, which precluded any examination of dose-response patterns of treatment exposures 
in relation to cardiac mortality risk.  In order to assess some aspects of treatment, a proxy was 
used which was based upon type of cancer and year of diagnosis.  Although this study has 
established relationships between likely treatment exposure and the risk of cardiac outcomes, the 
proxy variable proposed is likely too crude to aid in risk stratification.  Additionally, clinical 
opinion on this treatment likelihood variable is likely to vary depending on institution, 
experience, and other factors, and thus the assumptions made when developing this proxy may 
not be tenable.   Another possible limitation of this study is that our classification of cardiac 
deaths relied on the underlying cause-of-death as listed on the death certificate, which has been 
previously shown to have imperfect accuracy31–34.  Despite the fact that there is possible 
misclassification, it is more likely that we have under-ascertained cardiac deaths and thus 
underestimated the risk of cardiac death among childhood cancer survivors, as these individuals 








Among five-year survivors of childhood cancer treated in Britain, the excess mortality from 
cardiac disease is significantly increased beyond age 50. The greatest excess risk overall, and for 
CM/HF in particular, was observed in those diagnosed from 1980-1989 and suggests that 
initiatives to reduce cardiotoxicity among those treated more recently may be having a 









Table 6.1: Treatment likelihood as defined by first primary neoplasm diagnostic group and year of diagnosis 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia
 Diagnosed <1975 Diagnosed >1975 
Unlikely Exposed to Either Chest 
Irradiation or Anthracyclines 
Leukemia (including 
AML) 




Soft tissue sarcoma 
Other 




Likely Exposed to Chest Irradiation & 








Likely Exposed to Anthracyclines & 
Unlikely Exposed to Chest Irradiation 
 Leukemia (including AML) 
Bone sarcoma 
Soft tissue sarcoma 
Likely Exposed to Both Chest Irradiation 
& Anthracyclines 






























































































































































































































































































































































































































































































































































































































































































































































































































































   










   
































































































Patient Characteristic Cardiac Death % Other Death % Total % 
       
Overall 182 4.1 4,301 95.9 4,483 100.0 
Sex            
Male 116 4.4 2,519 95.6 2,635 100.0 
Female 66 3.6 1,782 96.4 1,848 100.0 
First Primary Neoplasm Type            
CNS (excluding PNET) 32 2.4 1,304 97.6 1,336 100.0 
CNS PNET 5 1.5 336 98.5 341 100.0 
Leukemia (excluding AML) 17 1.5 1,086 98.5 1,103 100.0 
AML 10 12.2 72 87.8 82 100.0 
Hodgkin Lymphoma 34 10.1 301 89.9 335 100.0 
Non-Hodgkin Lymphoma 17 13.0 114 87.0 131 100.0 
Neuroblastoma 4 2.8 140 97.2 144 100.0 
Non-Heritable Retinoblastoma 2 6.5 29 93.5 31 100.0 
Heritable Retinoblastoma 4 2.9 135 97.1 139 100.0 
Wilms 20 10.9 164 89.1 184 100.0 
Bone Sarcoma 9 4.5 189 95.5 198 100.0 
Soft Tissue Sarcoma 12 4.7 241 95.3 253 100.0 
Other 16 7.8 190 92.2 206 100.0 
Age at Diagnosis            
Mean (Standard Deviation) 7.8 4.6 7.3 4.4 7.3 4.4 
0-4 years 63 3.8 1,599 96.2 1,662 100.0 
5-9 years 46 3.4 1,309 96.6 1,355 100.0 
10-14 years 73 5.0 1,393 95.0 1,466 100.0 
Treatment Era            
1940-1969 79 5.9 1,254 94.1 1,333 100.0 
1970-1979 49 3.9 1,202 96.1 1,251 100.0 
1980-1989 43 4.6 898 95.4 941 100.0 
1990-2006 11 1.1 947 98.9 958 100.0 
Likely Treatment            
Unlikely Exposed to Either Chest Irradiation or Anthracyclines 54 6.3 806 93.7 860 100.0 
Likely Exposed to Chest Irradiation & Unlikely Exposed to Anthracyclines  35 3.0 1,135 97.0 1,170 100.0 
Likely Exposed to Anthracyclines & Unlikely Exposed to Chest Irradiation 31 8.9 317 91.1 348 100.0 
Likely Exposed to Both Chest Irradiation & Anthracyclines 62 2.9 2,047 97.1 2,109 100.0 
Years Follow-Up            
Mean (Standard Deviation) 31.4 14.0 16.4 12.9 17.0 13.3 
5-9 years 10 0.5 2,048 99.5 2,058 100.0 
10-19 years 31 2.9 1,030 97.1 1,061 100.0 
20-29 years 43 7.8 505 92.2 548 100.0 
30-39 years 45 10.7 377 89.3 422 100.0 
40-49 years 34 12.3 243 87.7 277 100.0 
50-59 years 17 16.3 87 83.7 104 100.0 
60+ years 2 11.8 15 88.2 17 100.0 
Attained Age             
Mean (Standard Deviation) 39.2 14.7 23.7 13.4 24.3 13.8 
5-9 years 1 0.2 415 99.8 416 100.0 
10-19 years 19 1.0 1,815 99.0 1,834 100.0 
20-29 years 33 3.3 972 96.7 1,005 100.0 
30-39 years 43 8.0 493 92.0 536 100.0 
40-49 years 36 9.8 330 90.2 366 100.0 
50-59 years 32 13.4 206 86.6 238 100.0 
60+ years 18 20.5 70 79.5 88 100.0 
Table 6.3: Study characteristics of the British Childhood Cancer Survivor Study 






  Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 
Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Overall 620,758 182/53.1 3.4 (2.9,4.0) 2.1 (1.6,2.5) 97/38.2 2.5 (2.1,3.1) 0.9 (0.6,1.3) 52/8.9 5.9 (4.4,7.7) 0.7 (0.5,0.9) 
Sex 
  Male 336,802 116/42.2 2.7 (2.3,3.3) 2.2 (1.6,2.8) 71/31.6 2.2 (1.8,2.8) 1.2 (0.7,1.7) 27/6.6 4.1 (2.7,6.0) 0.6 (0.3,0.9) 
Female 283,955 66/10.9 6.0 (4.7,7.7) 1.9 (1.4,2.5) 26/6.6 4.0 (2.6,5.8) 0.7 (0.3,1.0) 25/2.3 10.9 (7.0,16.0) 0.8 (0.5,1.1) 
Pheterogeneity   <0.0001 0.5574  0.0180 0.1132  0.0006 0.4067 
First Primary Neoplasm Type 
 CNS (excluding PNET) 124,750 32/13.9 2.3 (1.6,3.3) 1.5 (0.6,2.3) 20/10.4 1.9 (1.2,3.0) 0.8 (0.1,1.5) 4/2.0 2.0 (0.5,5.0) 0.2 (-0.2,0.5) 
CNS PNET 18,699 5/1.5 3.3 (1.1,7.6) 1.9 (-0.5,4.2) 4/1.1 3.7 (1.0,9.5) 1.6 (-0.5,3.7) 1/0.3 3.7 (0.1,20.5) 0.4 (-0.7,1.4) 
Leukemia (excluding AML) 145,237 17/4.4 3.9 (2.3,6.2) 0.9 (0.3,1.4) 3/2.2 1.4 (0.3,4.0) 0.1 (-0.2,0.3) 10/1.4 7.2 (3.5,13.3) 0.6 (0.2,1.0) 
AML 13,029 10/0.4 23.5 (11.2,43.1) 7.3 (2.6,12.1) 1/0.2 4.3 (0.1,24.0) 0.6 (-0.9,2.1) 8/0.1 66.0 (28.5,130.0) 6.0 (1.8,10.3) 
Hodgkin Lymphoma 42,600 34/6.1 5.6 (3.9,7.8) 6.6 (3.9,9.2) 21/4.6 4.6 (2.8,7.0) 3.9 (1.7,6.0) 6/0.9 6.7 (2.5,14.6) 1.2 (0.1,2.3) 
NHL 30,343 17/4.1 4.2 (2.4,6.6) 4.3 (1.6,6.9) 8/3.1 2.6 (1.1,5.1) 1.6 (-0.2,3.4) 6/0.6 10.2 (3.7,22.2) 1.8 (0.2,3.4) 
Neuroblastoma 28,500 4/1.7 2.4 (0.7,6.2) 0.8 (-0.6,2.2) 1/1.2 0.9 (0.0,4.8) -0.1 (-0.7,0.6) 1/0.3 3.3 (0.1,18.1) 0.2 (-0.4,0.9) 
Non-Heritable Retinoblastoma 26,167 2/2.8 0.7 (0.1,2.6) -0.3 (-1.4,0.8) 2/2.1 0.9 (0.1,3.4) -0.0 (-1.1,1.0) 0/0.4 0 -0.2 (-0.2,-0.2) 
Heritable Retinoblastoma 20,162 4/1.9 2.1 (0.6,5.4) 1.0 (-0.9,3.0) 4/1.4 2.9 (0.8,7.4) 1.3 (-0.6,3.2) 0/0.3 0 -0.1 (-0.1,-0.1) 
Wilms 51,519 20/3.1 6.5 (4.0,10.0) 3.3 (1.6,5.0) 11/2.1 5.3 (2.7,9.5) 1.7 (0.5,3.0) 5/0.6 8.0 (2.6,18.8) 0.8 (-0.0,1.7) 
Bone Sarcoma 21,798 9/3.1 2.9 (1.3,5.4) 2.7 (-0.0,5.4) 5/2.4 2.1 (0.7,4.9) 1.2 (-0.8,3.2) 2/0.4 4.7 (0.6,16.9) 0.7 (-0.6,2.0) 
Soft Tissue Sarcoma 42,062 12/4.8 2.5 (1.3,4.3) 1.7 (0.1,3.3) 7/3.6 1.9 (0.8,4.0) 0.8 (-0.4,2.0) 5/0.7 7.1 (2.3,16.7) 1.0 (-0.0,2.1) 
Other 55,891 16/5.3 3.0 (1.7,4.9) 1.9 (0.5,3.3) 10/3.9 2.6 (1.2,4.8) 1.1 (-0.0,2.2) 4/0.8 4.7 (1.3,12.1) 0.6 (-0.1,1.3) 
Pheterogeneity   <0.0001 <0.0001  0.0286 0.0522  <0.0001 0.0002 
Age at Diagnosis 
  0-4 years 291,564 63/14.9 4.2 (3.2,5.4) 1.6 (1.1,2.2) 26/9.9 2.6 (1.7,3.9) 0.6 (0.2,0.9) 22/3.1 7.1 (4.4,10.7) 0.6 (0.3,1.0) 
5-9 years 163,195 46/13.0 3.5 (2.6,4.7) 2.0 (1.2,2.8) 24/9.1 2.6 (1.7,3.9) 0.9 (0.3,1.5) 14/2.4 5.9 (3.2,9.9) 0.7 (0.3,1.2) 
10-14 years 165,999 73/25.2 2.9 (2.3,3.6) 2.9 (1.9,3.9) 47/19.2 2.4 (1.8,3.2) 1.7 (0.9,2.5) 16/3.4 4.7 (2.7,7.6) 0.8 (0.3,1.2) 
Ptrend   0.0292 0.0286  0.7305 0.9789  0.2074 0.6909 
Treatment Era 
  <1970 135,884 79/35.6 2.2 (1.8,2.8) 3.2 (1.9,4.5) 62/28.8 2.2 (1.7,2.8) 2.4 (1.3,3.6) 4/3.7 1.1 (0.3,2.7) 0.0 (-0.3,0.3) 
1970-1979 152,278 49/10.7 4.6 (3.4,6.0) 2.5 (1.6,3.4) 26/6.9 3.8 (2.5,5.6) 1.3 (0.6,1.9) 16/2.4 6.5 (3.7,10.6) 0.9 (0.4,1.4) 
1980-1989 155,375 43/4.7 9.1 (6.6,12.3) 2.5 (1.6,3.3) 6/2.1 2.9 (1.1,6.2) 0.3 (-0.1,0.6) 28/1.7 16.7 (11.1,24.1) 1.7 (1.0,2.4) 
1990-2006 177,221 11/2.1 5.2 (2.6,9.4) 0.5 (0.1,0.9) 3/0.4 7.1 (1.5,20.6) 0.1 (-0.0,0.3) 4/1.0 3.9 (1.1,10.0) 0.2 (-0.1,0.4) 
Ptrend   0.1363 0.8254  0.9152 0.0994  0.1231 0.7405 
Table 6.4:  Standardized mortality ratios and absolute excess risks per 10,000 person-years for overall cardiac mortality, ischemic heart disease mortality, and cardiomyopathy/heart failure mortality, by 
potential explanatory factors 









  Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Likely Treatment   
Unlikely Exposed to Either Chest Irradiation 
or Anthracyclines 
264,651 62/29.7 2.1 (1.6,2.7) 1.2 (0.6,1.8) 42/22.2 1.9 (1.4,2.6) 0.7 (0.3,1.2) 10/4.4 2.3 (1.1,4.2) 0.2 (-0.0,0.4) 
Likely Exposed to Chest Irradiation & 
Unlikely Exposed to Anthracyclines 
83,072 54/15.8 3.4 (2.6,4.5) 4.6 (2.9,6.3) 37/12.5 3.0 (2.1,4.1) 2.9 (1.5,4.4) 6/1.9 3.1 (1.2,6.8) 0.5 (-0.1,1.1) 
Likely Exposed to Anthracyclines & 
Unlikely Exposed to Chest Irradiation 
176,477 35/4.4 7.9 (5.5,11.0) 1.7 (1.1,2.4) 6/1.9 3.1 (1.2,6.8) 0.2 (-0.0,0.5) 22/1.6 13.9 (8.7,21.1) 1.2 (0.6,1.7) 
Likely Exposed to Both Chest Irradiation & 
Anthracyclines 
96,558 31/3.2 9.7 (6.6,13.8) 2.9 (1.8,4.0) 12/1.6 7.6 (4.0,13.4) 1.1 (0.4,1.8) 14/1.0 13.6 (7.4,22.8) 1.3 (0.6,2.1) 
Pheterogeneity   <0.0001 0.0001  0.0014 0.0001  <0.0001 0.0005 
Attained Age 
 
5-19 years 243,035 20/2.1 9.7 (5.9,15.0) 0.7 (0.4,1.1) 1/0.1 8.0 (0.2,44.6) 0.0 (-0.0,0.1) 12/1.2 9.7 (5.0,16.9) 0.4 (0.2,0.7) 
20-29 years 195,584 33/4.2 7.8 (5.4,11.0) 1.5 (0.9,2.0) 12/1.2 10.0 (5.2,17.5) 0.6 (0.2,0.9) 16/1.9 8.6 (4.9,14.0) 0.7 (0.3,1.1) 
30-39 years 108,573 43/8.5 5.1 (3.7,6.8) 3.2 (2.0,4.4) 19/5.4 3.5 (2.1,5.5) 1.3 (0.5,2.0) 16/1.9 8.5 (4.9,13.8) 1.3 (0.6,2.0) 
40-49 years 51,869 36/15.4 2.3 (1.6,3.2) 4.0 (1.7,6.2) 24/12.3 2.0 (1.3,2.9) 2.3 (0.4,4.1) 3/1.9 1.6 (0.3,4.6) 0.2 (-0.4,0.9) 
50-59 years 17,552 32/14.8 2.2 (1.5,3.1) 9.8 (3.5,16.1) 25/12.4 2.0 (1.3,3.0) 7.2 (1.6,12.7) 4/1.3 3.0 (0.8,7.7) 1.5 (-0.7,3.8) 
60+ years 4,144 18/8.2 2.2 (1.3,3.5) 23.7 (3.6,43.8) 16/6.8 2.3 (1.3,3.8) 22.2 (3.2,41.1) 1/0.7 1.5 (0.0,8.3) 0.8 (-3.9,5.5) 
Ptrend   <0.0001 <0.0001  0.0011 <0.0001  0.8121 0.0871 
Table 6.4 (continued):  Standardized mortality ratios and absolute excess risks per 10,000 person-years for overall cardiac mortality, ischemic heart disease mortality, and cardiomyopathy/heart failure 
mortality, by potential explanatory factors 







 Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) 
Sex 
      Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 2.2 (1.6,3.0) 0.9 (0.6,1.3) 1.8 (1.1,2.8) 0.6 (0.3,1.1) 2.7 (1.5,4.6) 1.3 0.7,2.6) 
Pheterogeneity <0.0001 0.5574 0.0180 0.1132 0.0006 0.4067 
First Primary Neoplasm Type 
CNS (excluding PNET) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
CNS PNET 1.4 (0.6,3.6) 1.3 (0.3,5.2) 1.9 (0.7,5.6) 2.0 (0.4,10.2) 1.9 (0.2,16.7) 2.5 (0.1,70.2) 
Leukemia (excluding AML) 1.7 (0.9,3.0) 0.6 (0.2,1.4) 0.7 (0.2,2.4) 0.1 (0.0,5.5) 3.7 (1.2,11.7) 3.8 (0.5,31.2) 
AML 10.2 (5.0,20.7) 5.1 (2.1,12.3) 2.2 (0.3,16.6) 0.8 (0.1,11.5) 33.5 (10.1,111.2) 38.3 (4.6,316.7) 
Hodgkin Lymphoma 2.4 (1.5,3.9) 4.5 (2.2,9.4) 2.4 (1.3,4.4) 5.0 (1.7,14.4) 3.4 (1.0,12.1) 7.6 (0.8,68.7) 
NHL 1.8 (1.0,3.2) 2.9 (1.2,7.0) 1.3 (0.6,3.0) 2.1 (0.5,8.9) 5.2 (1.5,18.4) 11.3 (1.3,100.0) 
Neuroblastoma 1.0 (0.4,2.9) 0.6 (0.1,3.4) 0.4 (0.1,3.3) NA 1.7 (0.2,14.8) 1.5 (0.0,49.0) 
NH-Retinoblastoma 0.3 (0.1,1.3) NA 0.5 (0.1,2.1) NA NA NA 
H-Retinoblastoma 0.9 (0.3,2.6) 0.7 (0.1,5.1) 1.5 (0.5,4.4) 1.7 (0.3,9.7) NA NA 
Wilms 2.8 (1.6,4.9) 2.3 (1.0,5.0) 2.8 (1.3,5.8) 2.2 (0.7,7.2) 4.1 (1.1,15.2) 5.4 (0.6,50.0) 
Bone Sarcoma 1.2 (0.6,2.6) 1.8 (0.6,6.0) 1.1 (0.4,2.9) 1.5 (0.2,10.5) 2.4 (0.4,13.0) 4.6 (0.3,65.3) 
Soft Tissue Sarcoma 1.1 (0.6,2.1) 1.2 (0.4,3.6) 1.0 (0.4,2.4) 1.0 (0.2,6.2) 3.6 (1.0,13.5) 6.5 (0.7,60.7) 
Other 1.3 (0.7,2.4) 1.3 (0.5,3.4) 1.3 (0.6,2.9) 1.4 (0.4,5.5) 2.4 (0.6,9.6) 3.6 (0.3,37.4) 
Pheterogeneity <0.0001 <0.0001 0.0655 0.0003 <0.0001 0.0002 
Age at Diagnosis  
0-4 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
5-9 years 0.8 (0.6,1.2) 1.2 (0.7,2.1) 1.0 (0.6,1.7) 1.6 (0.7,4.0) 0.8 (0.4,1.6) 1.1 (0.5,2.4) 
10-14 years 0.7 (0.5,1.0) 1.7 (1.1,2.8) 0.9 (0.6,1.5) 3.0 (1.4,6.6) 0.7 (0.3,1.3) 1.2 (0.5,2.6) 
Ptrend 0.0292 0.0286 0.7305 0.0068 0.2074 0.6909 
Table 6.5: Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a univariate model, by potential explanatory factors 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, RR: relative risks, SMR: standardized mortality ratio, EMR: excess mortality ratio, 








Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) 
Treatment Era 
<1970 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1970-1979 2.1 (1.4,2.9) 0.8 (0.5,1.3) 1.7 (1.1,2.8) 0.5 (0.3,1.0) 6.1 (2.0,18.3) NA 
1980-1989 4.1 (2.8,6.0) 0.8 (0.5,1.3) 1.3 (0.6,3.1) 0.1 (0.0,0.4) 15.6 (5.5,44.4) NA 
1990-2006 2.4 (1.3,4.4) 0.2 (0.1,0.4) 3.3 (1.0,10.4) 0.1 (0.0,0.2) 3.6 (0.9,14.6) NA 
Ptrend <0.0001 <0.0001 0.0184 <0.0001 <0.0001 0.7405 
Attained Age 
5-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
20-29 years 0.8 (0.5,1.4) 2.0 (1.1,3.7) 1.2 (0.2,9.6) 15.3 (1.5,157.0) 0.9 (0.4,1.9) 1.6 (0.7,3.8) 
30-39 years 0.5 (0.3,0.9) 4.3 (2.3,8.0) 0.4 (0.1,3.3) 34.9 (3.4,357.1) 0.9 (0.4,1.9) 2.9 (1.3,6.8) 
40-49 years 0.2 (0.1,0.4) 5.4 (2.5,11.4) 0.2 (0.0,1.8) 62.9 (5.8,682.3) 0.2 (0.0,0.6) 0.5 (0.0,11.5) 
50-59 years 0.2 (0.1,0.4) 13.3 (5.9,29.8) 0.3 (0.0,1.9) 199.0 (18.6,2131.5) 0.3 (0.1,1.0) 3.4 (0.7,17.0) 
60+ years 0.2 (0.1,0.4) 32.1 (12.1,85.3) 0.3 (0.0,2.2) 615.5 (56.0,6762.8) 0.2 (0.0,1.2) 1.8 (0.0,678.7) 
Ptrend <0.0001 <0.0001 0.0011 <0.0001 0.0005 0.0871 
Table 6.5 (continued): Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a univariate model, by potential explanatory factors 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, RR: relative risks, SMR: standardized mortality ratio, EMR: excess mortality ratio, 








 Overall Cardiac Mortality Ischemic Heart Disease Mortality Cardiomyopathy/Heart Failure Mortality 
 RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) RR: SMR (95%CI) EMR (95%CI) 
Sex  Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 2.2 (1.6,3.0) 1.0 (0.7,1.6) 1.9 (1.2,3.0) 0.7 (0.3,1.3) 3.0 (1.7,5.2) 1.5 (0.8,2.9) 
Pheterogeneity <0.0001 0.8306 0.0099 0.2246 0.0002 0.2179 
First Primary Neoplasm Type  
CNS (excluding PNET) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
PNET 1.2 (0.5,3.2) 0.9 (0.2,5.4) 1.9 (0.6,5.5) 1.7 (0.2,12.8) 1.7 (0.2,15.0) 3.8 (0.2,61.0) 
Leukemia (excluding AML) 0.7 (0.4,1.4) 0.8 (0.3,1.8) 0.4 (0.1,1.5) 0.2 (0.0,5.1) 1.7 (0.5,5.4) 3.2 (0.4,23.6) 
AML 5.8 (2.8,12.1) 7.6 (3.2,18.1) 1.6 (0.2,12.4) 2.3 (0.2,23.2) 19.2 (5.7,64.8) 39.8 (5.5,289.6) 
Hodgkin Lymphoma 2.7 (1.7,4.5) 4.1 (2.0,8.3) 2.5 (1.4,4.7) 3.8 (1.4,10.1) 3.8 (1.0,13.6) 4.9 (0.5,45.8) 
NHL 2.0 (1.1,3.6) 3.0 (1.3,6.6) 1.4 (0.6,3.3) 2.1 (0.6,7.0) 5.4 (1.5,19.2) 13.8 (1.8,106.1) 
Neuroblastoma 0.7 (0.2,2.1) 0.8 (0.2,3.0) 0.4 (0.1,3.2) 0.5 (0.0,9.1) 1.2 (0.1,10.7) 2.2 (0.1,38.4) 
NH-Retinoblastoma 0.2 (0.1,1.0) 0.1 (0.0,3.1) 0.5 (0.1,2.1) 0.5 (0.0,5.0) NA NA 
H-Retinoblastoma 0.7 (0.2,2.0) 0.4 (0.0,4.7) 1.4 (0.4,4.5) 1.6 (0.2,10.1) NA NA 
Wilms 1.7 (0.9,3.1) 1.9 (0.8,4.3) 2.2 (1.0,5.1) 2.8 (0.8,9.6) 2.5 (0.7,9.9) 5.0 (0.6,41.7) 
Bone Sarcoma 1.4 (0.6,2.9) 1.6 (0.5,4.9) 1.1 (0.4,2.9) 0.9 (0.1,8.4) 2.6 (0.5,14.2) 6.2 (0.5,71.1) 
Soft Tissue Sarcoma 1.1 (0.5,2.1) 1.0 (0.3,2.9) 1.0 (0.4,2.5) 0.9 (0.2,4.5) 3.5 (0.9,13.2) 8.0 (1.0,65.0) 
Other 1.1 (0.6,2.1) 1.0 (0.4,2.8) 1.2 (0.6,2.6) 1.2 (0.3,4.6) 2.1 (0.5,8.3) 3.6 (0.4,36.0) 
Pheterogeneity <0.0001 <0.0001 0.0286 0.0522 0.0003 0.0002 
Age at Diagnosis  
0-4 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
5-9 years 0.7 (0.4,1.1) 0.7 (0.4,1.2) 0.9 (0.5,1.8) 1.0 (0.4,2.8) 0.7 (0.3,1.4) 0.7 (0.3,1.6) 
10-14 years 0.6 (0.4,0.9) 0.5 (0.3,0.9) 0.8 (0.4,1.6) 1.0 (0.4,2.8) 0.5 (0.2,1.1) 0.5 (0.2,1.2) 
Ptrend 0.0090 0.0251 0.5539 0.9789 0.0666 0.0986 
Treatment Era  
<1970 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1970-1979 1.6 (1.1,2.5) 1.3 (0.7,2.4) 1.5 (0.9,2.6) 1.0 (0.5,2.2) 8.9 (2.1,37.8) 13.9 (1.1,168.5) 
1980-1989 2.3 (1.4,3.8) 1.8 (0.9,3.4) 0.8 (0.3,2.0) 0.3 (0.1,1.3) 18.2 (3.9,84.2) 28.9 (2.4,354.6) 
1990-2006 1.0 (0.4,2.1) 0.6 (0.2,1.4) 1.0 (0.3,3.8) 0.4 (0.1,1.9) 3.7 (0.6,23.3) 4.5 (0.3,69.4) 
Ptrend 0.1363 0.8254 0.9152 0.0994 0.1231 0.3453 
Attained Age  
5-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
20-29 years 0.8 (0.5,1.5) 1.9 (1.0,3.6) 1.3 (0.2,9.9) 11.1 (1.3,98.3) 0.9 (0.4,2.0) 1.6 (0.7,3.6) 
30-39 years 0.6 (0.3,1.0) 3.7 (1.8,7.3) 0.4 (0.1,3.2) 20.8 (2.3,186.9) 1.0 (0.4,2.3) 2.9 (1.2,7.2) 
40-49 years 0.3 (0.2,0.6) 5.6 (2.5,12.7) 0.2 (0.0,1.7) 29.0 (3.0,284.1) 0.4 (0.1,1.4) NA 
50-59 years 0.4 (0.2,0.8) 16.7 (6.5,43.5) 0.2 (0.0,2.0) 89.6 (8.9,901.6) 2.2 (0.5,10.4) 21.3 (3.1,147.8) 
60+ years 0.4 (0.2,1.0) 44.8 (14.3,140.6) 0.3 (0.0,2.6) 258.0 (23.4,2849.1) 2.0 (0.1,26.7) NA 
Ptrend 0.0055 <0.0001 0.0267 <0.0001 0.8121 0.0591 
Table 6.6:  Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a multivariate model, adjusting for sex, first primary neoplasm type, age 
at diagnosis, treatment era, and attained age 
Abbreviations: CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, RR: relative risks, SMR: standardized mortality ratio, EMR: excess mortality ratio, 








 O/E SMR (95%CI) AER (95%CI) 
Overall 182/53.1 3.4 (2.9,4.0) 2.1 (1.6,2.5) 
Ischemia Heart Disease 97/38.2 2.5 (2.1,3.1) 0.9 (0.6,1.3) 
Cardiomyopathy/Heart Failure 52/8.9 5.9 (4.4,7.7) 0.7 (0.5,0.9) 
Valvular 8/2.2 3.6 (1.6,7.2) 0.1 (0.0,0.2) 
Arrhythmia 5/1.5 3.4 (1.1,8.0) 0.1 (0.0,0.1) 
Pericardial 2/0.2 8.0 (1.0,29.0) 0.0 (0.0,0.1) 
Other Cardiac 18/2.2 8.3 (4.9,13.1) 0.3 (0.1,0.4) 
Table 6.7:  Standardized mortality ratios and absolute excess risks per 10,000 person-years for deaths due to all cardiac causes and cardiac-
specific causes 







 Attained Age (% cardiac) 
 
5-19 years 20-29 years 30-39 years 40-49 years 50-59 years 60+ years 
Ischemic Heart Disease 4.9% 37.5% 39.5% 57.1% 73.0% 93.6% 
Cardiomyopathy/Heart Failure 60.0% 49.2% 40.9% 5.3% 15.5% 3.4% 
Valvular Heart Disease -1.0% 2.1% 4.5% 17.3% 3.3% -3.3% 
Arrhythmias 9.4% 5.4% 2.0% -0.9% -0.6% -1.1% 
Pericardial Disease 5.5% -0.2% 2.8% -0.3% -0.3% -0.3% 
Other Cardiac 21.3% 5.9% 10.3% 21.6% 9.0% 7.7% 
All Cardiac 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 







Figure 6.1:  Cumulative mortality of all cardiac causes, ischemic heart disease causes, and cardiomyopathy/heart failure causes among childhood cancer survivors compared to that expected in the 
general population, by follow-up (years since diagnosis) 








Figure 6.2:  Cumulative mortality for cardiac death by first primary neoplasm diagnostic groups, by follow-up (years since diagnosis), compared to that expected overall  







Figure 6.3:  Cumulative mortality for cardiac death by likely treatment, by follow-up (years since diagnosis), compared to that expected overall  
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Figure 6.4:  The graph depicts the point estimates of cardiomyopaty/heart failure absolute excess risks per 10,000 person-years for each year of diagnosis.   
The curve was produced by calculating cross medians and then using the cross medians to fit a spline11.  The table depicts the excess mortality ratio for cardiomyopathy/heart failure deaths, which was 
calculated in a multivariate Poisson model adjusting for sex, age at diagnosis, first primary neoplasm type, and attained age. 
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Population-based long-term respiratory mortality 
among 235,434 five-year survivors of cancer diagnosed 







Purpose:  Exposure to radiation and/or chemotherapy can compromise respiratory function in 
survivors of childhood, teenage, and young adult cancers, and thus it is important to monitor late 
respiratory outcomes.  We investigated the risk of long-term respiratory mortality among cancer 
survivors diagnosed before age 40 using two of the largest population-based cohorts of survivors: 
the British Childhood Cancer Survivor Study (BCCSS) and Teenage and Young Adult Cancer 
Survivor Study (TYACSS). 
 
Material and Methods:  The BCCSS comprises 34,489 five-year survivors of childhood cancer 
diagnosed in Great Britain between 1940-2006 before the age of 15.  The TYACSS includes 
200,945 five-year survivors of cancers diagnosed from age 15 to 39 between 1971-2006 in 
England and Wales.  Standardized mortality ratios (SMRs) and absolute excess risks (AERs) 
were used.   
 
Results:  Overall, 164 and 1,067 respiratory deaths were observed for the BCCSS and TYACSS 
cohorts, respectively, which was 6.8- and 1.7-times that expected.  By respiratory subgroups, the 
SMR was greatest for deaths related to pneumonitis (SMR:16.9) and fibrosis (SMR:13.8) in the 
BCCSS, and pneumonitis (SMR:2.1) and pneumonia (SMR:2.0) for TYACSS.  Those diagnosed 
with leukemia, lung, or CNS tumors in the TYACSS cohort had the greatest risks, whereas CNS, 
leukemia, and germ cell tumor survivors were at greatest risk in the BCCSS.  For all respiratory 
deaths, the SMRs declined and AERs increased with attained age.  When assessed by era, the 







Conclusions:  Among five-year survivors of cancer diagnosed before age 40, the excess 
respiratory mortality was significantly increased beyond 50 years attained age.  However, it is 







Although survival from childhood, teenage, and young adult cancer has improved substantially 
over recent decades, with approximately 80% of those diagnosed now surviving at least five 
years1,2, increased survival comes at a cost as curative treatments are often associated with 
adverse late effects.  Previous research has found that specific types of both radiotherapy and 
chemotherapy have a significant impact on respiratory function and thoracic development3.  
Direct irradiation to the chest and lungs can cause developmental abnormalities of the thoracic 
cage, as well as short-term treatment-induced lung disease, presenting as pneumonitis, and 
interstitial lung injury and long-term damage, manifesting as fibrosis3.  Only specific 
chemotherapy drugs are currently known to cause late respiratory effects, with conditions usually 
presenting acutely, there is the potential for significant morbidity and mortality in the long-term3.   
 
Due to the fact that this population of survivors is growing and that these individuals likely have 
a large proportion of their expected lives ahead, it is crucial to investigate respiratory late effects 
in order to better understand risk factors and identify vulnerable subgroups of survivors.  
Although previous literature has assessed respiratory morbidity among childhood cancer 
survivors4, to our knowledge, this is the first study to focus specifically on respiratory mortality.  
Previous studies have been prevented from satisfactorily undertaking detailed analyses relating to 
this outcome because of limited follow-up time and small numbers of respiratory deaths.  In 
addition, previous studies have not been able to satisfactorily address the risk of respiratory 
mortality beyond 50 years age nor determine whether long-term respiratory mortality has 







In this study we assessed the long-term risks of respiratory mortality among 235,434 five-year 
survivors of cancer diagnosed before the age of 40 years using the British Childhood Cancer 
Survivor Study (BCCSS) and Teenage and Young Adult Cancer Survivor Study (TYACSS).  The 
BCCSS and TYACSS are the largest studies to date to assess long-term mortality in survivors of 
childhood, teenage, and young adult cancers, and thus provide a valuable evidence base for 






Material and Methods 
Study Population 
This study investigates two of the largest population-based cohorts of survivors: the British 
Childhood Cancer Survivor Study (BCCSS)5 and Teenage and Young Adult Cancer Survivor 
Study (TYACSS)6.  The BCCSS comprises 34,489 five-year survivors of childhood cancer 
diagnosed under the age of 15 years in Great Britain from 1940-2006.  The cohort was identified 
using the National Registry of Childhood Tumors, which has a high estimated level of 
ascertainment (~99%)7.  All first primary neoplasms (FPN) were classified using the International 
Classification of Childhood Cancer8.  Similarly, TYACSS includes 200,945 five-year survivors 
of teenage and young adult cancers diagnosed from 1971-2006 between the ages of 15-39.  The 
cohort was established in cooperation with the Office for National Statistics (ONS).  As cancer 
incidence rates take up to five years after the end of a given calendar year to reach 100%9, it is 
expected that ascertainment for this cohort is essentially complete as the upper limit for diagnosis 
inclusion was 2006 and this cohort was established in 2012.  Teenage and young adult FPNs were 
classified using the categories proposed by Birch et al., which was been slightly modified to 
evaluate finer groupings10.  Also, for analyses that combined the BCCSS and TYACSS cohort, 
FPNs were classified using the proposed categories by Birch et al10.  The National Research 
Ethics Committee and Confidentiality Advisory Group gave ethical and legal approval for the 









The BCCSS and TYACSS cohorts were linked with the Health and Social Care Information 
Centre in order to ascertain each survivor’s vital and embarkation status.  An attempt was then 
made for each death to obtain the death certificate and underlying cause-of-death as coded by the 
ONS (England and Wales) and General Registrar Office (Scotland) using the relevant 
International Classification of Diseases (ICD).   A respiratory death was defined by using the 
‘diseases of the respiratory system’ chapter of the relevant ICD version; ICD codes were further 
sub-categorized into clinically relevant groups for analysis, specifically: pneumonia, chronic 
lower respiratory disease, fibrosis, pneumonitis, and other respiratory (Table 7.1).  Follow-up for 
respiratory mortality commenced at five-year survival and continued until the first occurrence of 
emigration, death, or February 28, 2014. 
 
Statistical Analyses 
To investigate the risk of premature mortality among survivors compared to that expected from 
the general population, standardized mortality ratios (SMRs) and absolute excess risks (AERs) 
were calculated using standard cohort techniques11.  The SMR was defined as the ratio of the 
observed over expected number of respiratory deaths.  The AER was defined as the observed 
minus the expected number of respiratory deaths divided by person-years at risk multiplied by 
10,000.  Expected numbers were calculated by multiplying the person-years for each sex-specific, 
age-specific (five-year bands), and calendar year-specific (one-year bands) stratum by the 
corresponding respiratory mortality rate for the population of England and Wales and then 
summing across the strata12.  In order to evaluate the simultaneous effect of demographic and 






used, adjusting for sex, FPN type, age at cancer diagnosis, treatment era, and attained age.  If the 
results from the univariate and multivariate models were similar, suggesting little confounding, 
then the univariate findings were reported in terms of SMRs.  If the results from the univariate 
and multivariate models differed (changing from statistical significant to statistically insignificant 
or statistically insignificant to statistically significant), then the multivariate results were reported 
in terms of relative risks (RR) for the SMRs and excess mortality ratios for the AERs.  
Likelihood-ratio tests within Poisson regression models were used to test for heterogeneity or 
trend.     
 
Cumulative mortality, as a function of follow-up or attained age, was estimated by using the 
stcompet command in Stata13.  Causes-of-death other than the one under study were treated as 
competing risks14.  Log rank tests were used to test for heterogeneity in the cumulative mortality 
between different groups. 
 
All analyses were completed using Stata 12.113, where the criterion for statistical significance 








British Childhood Cancer Survivor Study 
 Overall Respiratory Mortality 
The BCCSS cohort was followed up for a total of 620,758 person-years from five-year survival.  
The mean follow-up was 18.0 years (range:0.0-68.7) and mean attained age was 29.6 years 
(range:5.5-85.6) at the study exit date.  Of the 4,483 deaths observed, 164 (3.7%) were due to 
respiratory causes (Table 7.2).  Over half of the respiratory deaths were observed in survivors of 
central nervous system (CNS) tumors, including CNS primitive neuroectodermal tumors (PNET).  
The mean follow-up and attained age at time of respiratory death was 24.7 years and 32.0 years, 
respectively; this was higher than the mean follow-up and attained age for non-respiratory 
causes-of-death. 
 
Survivors of childhood cancer were 6.8-times (95%CI:5.8-7.9) more at risk of respiratory death 
than expected in the general population; this equated to 2.3 (95%CI:1.8-2.7) excess respiratory 
deaths per 10,000 person-years (Table 7.3).  All FPN types with at least five observed events 
were found to be significantly more at risk of respiratory death than that expected; however, the 
risk was substantially raised (SMR>5.0) for survivors of CNS PNET (SMR:22.6,95%CI:12.7-
37.4), acute myeloid leukemia (AML) (SMR:12.6,95%:2.6-36.7), CNS (excluding PNET) 
(SMR:11.4,95%CI:8.8-14.4), and germ cell tumors (SMR:10.5,95%CI:4.5-20.8).  As attained age 
increased, the SMR significantly declined (Ptrend<0.0001) and the AER significantly increased 
(Ptrend<0.0001) (Table 7.4); at 5-19 years age, the SMR was 14.5 (95%CI:5.8-29.9) and the 
AER was 1.7 (0.3-3.1), whilst beyond 50 years age the SMR and AER were 2.6 (95%CI:1.7-3.9) 






respiratory deaths declined significantly (Ptrend<0.0001) (Table 7.4); after adjusting for sex, age 
at diagnosis, FPN type, and attained age, survivors diagnosed from 1990-2006 experienced 40% 
(SMR RR:0.4,95%CI:0.2-0.8) of the excess respiratory deaths observed among those diagnosed 
before 1970 (Table 7.5, Figure 7.1).   
 
 Specific Types of Respiratory Mortality 
Of the 164 respiratory deaths observed, there were 77 pneumonia, 18 pneumonitis, 15 fibrosis, 11 
chronic lower respiratory disease (excluding asthma), and 43 other respiratory deaths (Table 
7.3); the corresponding SMRs were 8.2 (95%CI:6.5-10.2), 16.9 (95%CI:10.0-26.8), 13.8 
(95%CI:7.7-22.8), 1.8 (95%CI:0.9-3.2), and 6.5 (95%CI:4.7-8.8), respectively.  As nearly half of 
the respiratory deaths observed were due to pneumonia, further analyses will only be discussed 
for this respiratory-specific subgroup.  However, it is worth noting that 13/18 (72.2%) of the 
pneumonitis deaths occurred CNS (excluding PNET) survivors, which equated to a 53.8-fold 
(95%CI28.6-92.0) increased risk compared to that expected (Table 7.3).   
 
Survivors of CNS PNET, germ cell tumors, and CNS tumors (excluding PNET) were at greatest 
risk of death due to pneumonia, with SMRs of 36.1 (95%CI:17.3-66.4), 16.9 (95%CI:5.5-39.4), 
and 15.8 (95%CI:11.1-21.9), respectively (Table 7.3).  The SMRs significantly declined as 
attained age increased (Ptrend=0.0006) (Table 7.4), although 4.4 (95%CI:1.3-7.5) excess 
pneumonia deaths were observed beyond 50 years age.  With regards to treatment era, a 
significant decline (Ptrend<0.0001) in excess pneumonia deaths was observed among those more 






in 1990-2006 experienced 10% (EMR:0.1,95%CI:0.0-0.3) of the excess pneumonia deaths, after 
adjusting for sex, FPN type, age at diagnosis, and attained age (Table 7.5).        
 
Teenage and Young Adult Cancer Survivor Study 
 Overall Respiratory Mortality 
From five-year survival, the TYACSS cohort was followed up for a total of 2,867,878 person-
years.  The mean follow-up was 14.3 years (range:0.0-38.2) and attained age was 51.0 years 
(range:20.0-82.7) at the study exit date.  By the study exit date, 34,188 (17.0%) teenage and 
young adult (TYA) survivors had died; of these, 1,067 (3.1%) were due to respiratory causes 
(Table 7.6).  Over half of the respiratory deaths were observed among survivors diagnosed 
between the ages of 35-39.  The mean follow-up and attained was 21.9 years and 55.2, 
respectively, at time of respiratory death; this was again higher than the corresponding means for 
non-respiratory deaths. 
 
Overall, TYA survivors were 70% (SMR:1.7,95%CI:1.6-1.8) more likely to die from a 
respiratory cause than expected from the general population, which equated to 1.5 (95%CI:1.3-
1.7) excess respiratory deaths per 10,000 person-years (Table 7.7).  Survivors of CNS PNET, 
AML, leukemia (excluding AML), and lung cancer were at greatest risk of respiratory death, with 
SMRs of 6.8 (95%CI:1.4-19.9), 5.7 (95%CI:2.9-9.9), 4.8 (95%CI:3.1-7.1), and 4.2 (95%CI:2.8-
6.0), respectively.  As attained age increased, the SMRs significantly declined (Ptrend<0.0001) 
and AER significantly increased (Ptrend=0.0002) (Table 7.8).  When assessed by treatment era, 
a significant decline (Ptrend=0.0258) in AER was observed where those diagnosed during 2000-






diagnosed during 1971-1979, after adjusting for sex, FPN type, age at diagnosis, and attained age 
(Table 7.8).      
 
 Specific Types of Respiratory Mortality 
When the 1,067 respiratory deaths were assessed by the respiratory-specific subgroups, there 
were 390 pneumonia, 388 chronic lower respiratory (excluding asthma), 74 fibrosis, 48 
pneumonitis, and 167 other respiratory deaths (Table 7.7).  The SMR was greatest for 
pneumonitis and pneumonia deaths at 2.1 (95%CI:1.6-2.8) and 2.0 (1.8-2.3), respectively.  TYA 
survivors, however, were at a significantly increased risk of death from pulmonary fibrosis 
(SMR:1.7,95%CI:1.4-2.2), chronic lower respiratory (SMR:1.3,95%CI:1.2-1.5), and other 
respiratory deaths (SMR:1.8,95%CI:1.6-2.1) as well.        
 
When risk of pneumonia death was assessed by FPN type, survivors of CNS PNET 
(SMR:18.7,95%CI:3.9-54.7), bone tumors (SMR:5.2,95%CI:2.2-10.2), and leukemia (excluding 
AML) (SMR:5.1,95%CI:2.3-9.6), had a substantially high increased risk (SMR>5.0) of 
pneumonia death compared to that expected (Table 7.7).  As attained age increased, the SMR 
significantly declined (Ptrend<0.0001) (Table 7.8); from 20-29 years age to beyond 70 years age 
the SMR declined from 6.7 (95%CI:2.9-13.2) to 1.0 (95%CI:0.7-1.5).  With regards to treatment 
era, the number of excess pneumonia deaths significantly declined among those treated more 
recently (Ptrend=0.0020) (Table 7.9).  After adjusting for sex, FPN type, age at diagnosis, and 
attained age, survivors diagnosed from 2000-2006 experienced 50% (EMR:0.5,95%CI:0.2-1.0) of 







For chronic lower respiratory disease deaths, survivors of lung cancer were at greatest risk with 
an SMR of 4.8 (95%CI:2.7-7.8), followed by survivors of leukemia (excluding AML) 
(SMR:3.0,95%CI:1.1-6.6), and Hodgkin lymphoma (SMR:2.3,95%CI:1.6-3.1) (Table 7.7).  The 
SMR significantly decreased (Ptrend=0.0001) and AER significantly increased (Ptrend=0.0024) 
with attained age (Table 7.9).  Furthermore, when treatment era was assessed, survivors 
diagnosed more recently were significantly less likely to die from chronic lower respiratory 
disease (Ptrend=0.0003).  Individuals diagnosed from 2000-2006 experienced 10% of the excess 
chronic lower respiratory deaths observed among those diagnosed from 1971-1979, after 
adjusting for sex, FPN type, age at diagnosis, and attained age (Table 7.8).      
 
Females were 2.7-times (95%CI:1.5-4.9) more likely to die from a fibrosis-related death than 
males, after adjusting for FPN type, age at diagnosis, treatment era, and attained age (Table 7.8).  
Hodgkin lymphoma survivors were the only FPN type with a statistically significant increased 
risk of fibrosis death, which was 6.7-fold (95%CI:4.0-10.4) that expected from the general 
population (Table 7.7).  As attained age increased, the SMR significantly declined 
(Ptrend<0.0001) (Table 7.9).  The SMR was 39.2 (95%CI:4.7-141.5) among individuals aged 
20-29 years and declined to 0.6 (95%CI:0.2-1.4) among individuals aged over 60 years (Table 
7.7).  There was no evidence that the excess numbers of lung fibrosis deaths varied across era of 
treatment (Ptrend=0.9868) (Table 7.8). 
 
Finally, for pneumonitis deaths, CNS (excluding PNET), leukemia (excluding AML), and head 
and neck cancer survivors had the greatest risk of death, with SMRs of 12.3 (95%CI:7.4-19.2), 






significantly decreased as attained age increased (Ptrend=0.0078) (Table 7.9).  With regards to 
treatment era, a significant decrease in excess pneumonitis deaths among individuals more 
recently treated was not observed (Ptrend=0.6839) (Table 7.8).    
   
Comparing the BCCSS and TYACSS 
In order to assess the effect of age at diagnosis on the risk of respiratory mortality, the BCCSS 
and TYACSS cohorts were combined.  When cumulative mortality was stratified by each age at 
diagnosis group, a significant difference was found (P<0.0001), where those diagnosed at an 
older age were found to have the highest cumulative mortality (Figure 7.3).  However, when the 
effect of age at diagnosis was assessed in multivariate Poisson models adjusting for sex, FPN 
type, treatment era, and attained age, in fact the SMR (Ptrend<0.0001) and AER (Ptrend=0.0001) 
were found to significantly decline as age at diagnosis increased.  Survivors diagnosed under the 
age of 15 years appeared to have comparable risks of respiratory death, whilst individuals aged 







This is the first study to assess respiratory-specific mortality among five-year survivors of cancer 
who were diagnosed before the age of 40 years.  Furthermore, when childhood and separately 
teenage and young adult cancers were assessed individually, this is the largest study to date to 
report on respiratory mortality in relation to each group.  Previous studies from Scotland15, 
Finland16, the United States17, and the Nordic countries18 have assessed respiratory mortality in a 
portion of the age at diagnosis period utilized in this study; however, these studies had 
substantially less survivors, follow-up, and events, reporting only six, 15, 67, and 82 respiratory 
deaths, respectively.  Although we have previously reported on overall respiratory mortality 
among childhood cancer survivors in the BCCSS19, this updated analysis includes a further 
16,509 survivors of childhood cancer and adds an additional 58 respiratory deaths, which 
ultimately leads to more precise risk estimates.  Additionally, over 200,000 survivors of teenage 
and young adult cancer were included in this study.  Due to our study’s population-based design, 
large number of observed events, and long period of follow-up, this study provides the most 
comprehensive results for respiratory mortality among childhood, teenage, and young adult 
cancer survivors to date. 
 
In relation to childhood cancer, substantial excesses in risk were observed, with survivors 
experiencing approximately seven-times more respiratory deaths than that expected from the 
general population.  This finding corresponds with previous findings reported from the United 
States17,20, but is substantially lower than the 34.9-fold increased risk reported from the Nordic 
countries18.  A 70% increased risk of respiratory death was also observed in the TYACSS cohort.  






survivors, particularly individuals diagnosed between the ages of 22 and 39 years, with the 
majority of the understanding of long-term effects coming from childhood cohorts17,21,22.  
Nonetheless, our finding comparable with studies from Finland16 and Scotland15, which reported 
SMRs of 2.7 (95%CI:1.3-3.8) and 3.4 (95%CI:1.2-7.4), respectively.  Excesses in respiratory 
death were observed to increase with attained age in both the BCCSS and TYACSS, with 
substantial deaths occurring even beyond 50 years age.   
 
To date, no previous study has assessed specific types of respiratory mortality among childhood, 
teenage, and young adult cancer survivors, which is likely due to the limited follow-up and 
observed events available in previous studies.  However, our study identifies appreciable 
excesses in risk for pneumonia, chronic lower respiratory disease, fibrosis, and pneumonitis 
deaths, with particular FPN types being at a particularly high risk.  By investigating specific types 
of respiratory mortality, recommendations can be made for survivors and clinicians, which relate 
to disease specific outcome groups.  Thus, the novel findings presented in this study will provide 
useful evidence for the development of more precise clinical follow-up guidelines.     
 
In this study, survivors of CNS tumors (including PNET), germ cell tumors, and AML were 
found to have the greatest risk of respiratory death among childhood cancer survivors.  Similarly, 
survivors of CNS (including PNET), leukemia (including AML), lung cancer, bone tumors, head 
and neck cancers, and Hodgkin lymphoma were found to be at an increased risk for at least one 
of the specific types of respiratory death analyzed among teenage and young adult cancer 
survivors.  The increased risks observed in these FPN types likely relate to adverse effects of 






cyclophosphamide, methotrexate, busulfan, and cytosine araboside have all been linked to late 
respiratory effects23.  In particular, previous studies have found increased risks of adverse 
respiratory outcomes for survivors of Hodgkin lymphoma, germ cell tumors, rhabdomyosarcoma, 
neuroblastoma, bone tumors, and CNS, and acute lymphoblastic leukemia23–30.  Among CNS 
survivors, adverse respiratory outcomes are likely due to craniospinal irradiation, which can 
induce pneumonitis and late restrictive lung disease30.  Adverse respiratory outcomes are also 
well described in leukemia survivors, where both restrictive and obstructive lung disease have 
been reported23,26.   Hodgkin lymphoma survivors have also been found to be at an increased risk 
of adverse respiratory outcomes, with more than 30% of survivors were reported to have 
asymptomatic radiographic findings or restrictive changes on respiratory function24,25,31.   
Increased risks in germ cell and bone tumor survivors also likely relates to treatment as both are 
treated with respiratory-toxic agents28,29.   
 
Due to our study’s wide period of diagnosis, we also illustrated a significant decline in excess 
mortality due to all respiratory and pneumonia deaths among individuals more recently diagnosed 
for both the BCCSS and TYACSS.  Additionally, teenage and young adult cancer survivors were 
also found to experience significantly less excess deaths due to chronic lower respiratory disease 
among those more recently diagnosed.  Although previous reports have illustrated a decline with 
treatment era for non-cancer deaths32 and non-recurrence/non-external deaths20, this is the first 
study to illustrate a decline specifically for respiratory causes.  This decrease in excess mortality 
likely relates to the dramatic decrease in the radiation-induced late respiratory toxicity due to 
refined techniques of radiotherapy and increased monitoring of chemotherapy-induced 






Finally, this study reported a significant decline in the SMRs for respiratory death as age at 
diagnosis increased.  Compared to individuals diagnosed at the age of 0-4 years, survivors 
diagnosed from 5-9 and 10-14 years were each 1.2-times more likely to die from respiratory 
death.  Conversely, survivors diagnosed between the ages of 15-39 years had 30%-50% of the 
excess numbers of respiratory deaths compared to those diagnosed between the ages of 0-4 years 
at diagnosis.  This finding highlights the importance of evidence-based guidelines by age at 
diagnosis, as individuals diagnosed before 15 years age appear to exhibit similar increased risks 
to one another, which are substantially higher than those diagnosed after 15 years age.  Thus, in 
relation to respiratory death, clinical guidelines and recommendations that encompass the entire 
age at diagnosis period assessed in this study are likely unacceptable as the risk is not uniform for 
all survivors.     
 
Limitations 
As our study determined respiratory deaths based upon the underlying cause-of-death, as coded 
on the death certificate, there is possible misclassification in our study as the underlying cause-of-
death has been previously shown to have imperfect accuracy36–39.  Another limitation of this 
study is the lack of detailed radiotherapy and chemotherapy, which prevented any examination of 







In conclusion, this large-scale, population-based study provides evidence that survivors of 
childhood, teenage, and young adult cancer are at an increased risk of respiratory death, 
compared to that expected, both overall and for specific types of respiratory death.  The number 
of excess respiratory deaths was observed to increase significantly with attained age, with 
significant excesses occurring beyond 50 years age for childhood cancer survivors and beyond 60 
years age for teenage and young adult cancer survivors. Nonetheless, there is evidence that there 
is a reduction in the excess number of respiratory deaths among individuals more recently 
diagnosed, which is likely due to more modern treatments, improvements in supportive care, and 
increased screening and detection of late effects.  These findings provide unbiased and reliable 
estimates of respiratory mortality among childhood, teenage, and young adult cancer survivors, 
which provides an evidence-base on which to update clinical follow-up guidelines for childhood 
cancer survivors and to develop clinical follow-up guidelines in relation to teenage and young 










All Respiratory Pneumonia 
Chronic Lower 
Respiratory Disease 
Fibrosis Pneumonitis Other Respiratory 
ICD 7 470-527 480, 490-493 500-502, 526, 527.1 524 525 
470-479,481-483, 510-523, 527.0, 
527.2 
ICD 8 460-519 471, 480-486 518, 490-492 NA 517 460-470, 472-474, 493-516, 519 









460-478, 487, 493, 495.2-495.6, 506.1-
506.3, 506.9, 508.8-508.9,510-514, 
516.0-516.2, 516.9, 517, 518.0-518.2, 
518.4-519.9 








J69, J84.8, J95.4 
J00-J11, J20-J39, J45-46, J60.0-J63.5, 
J63.8-J66.0, J66.1-J66.8, J67.2-J67.6, 
J68.1-J68.4, J68.8-68.9, J70.1-J84.1, 
J84.9-J95.3, J95.5-J99.8 
Table 7.1 – International Classification of Diseases categorizations and sub-categorizations for respiratory causes-of-death as used in the analysis 








Patient Characteristic Respiratory Death % Other Death % Total % 
       
Overall 164 3.7 4319 96.3 4,483 100.0 
Sex       
Male 98 3.7 2537 96.3 2,635 100.0 
Female 66 3.6 1782 96.4 1,848 100.0 
First Primary Neoplasm Type       
CNS (excluding PNET) 68 5.3 1225 94.7 1,293 100.0 
PNET 15 4.4 326 95.6 341 100.0 
Leukemia (excluding AML) 23 2.1 1080 97.9 1,103 100.0 
AML 3 3.7 79 96.3 82 100.0 
Hodgkin Lymphoma 7 2.1 328 97.9 335 100.0 
Non-Hodgkin Lymphoma 5 3.8 126 96.2 131 100.0 
Neuroblastoma 6 4.2 138 95.8 144 100.0 
Non-Heritable Retinoblastoma 1 3.2 30 96.8 31 100.0 
Heritable Retinoblastoma 4 2.9 135 97.1 139 100.0 
Wilms 7 3.8 177 96.2 184 100.0 
Bone Sarcoma 1 0.5 197 99.5 198 100.0 
Soft Tissue Sarcoma 11 4.3 242 95.7 253 100.0 
Germ Cell Tumors 8 10.7 67 89.3 75 100.0 
Other 5 2.9 169 97.1 174 100.0 
Age at Diagnosis       
Mean (SD) 7.3 4.6 7.3 4.4 7.3 4.4 
0-4 64 3.9 1598 96.1 1,662 100.0 
5-9 43 3.2 1312 96.8 1,355 100.0 
10-14 57 3.9 1409 96.1 1,466 100.0 
Treatment Era       
1940-1969 61 4.6 1272 95.4 1,333 100.0 
1970-1979 48 3.8 1203 96.2 1,251 100.0 
1980-1989 36 3.8 905 96.2 941 100.0 
1990-2006 19 2.0 939 98.0 958 100.0 
Years Follow-Up       
Mean (SD) 24.7 1.1 16.7 0.2 17 13.3 
5-9 years 36 1.7 2022 98.3 2,058 100.0 
10-19 years  33 3.1 1028 96.9 1,061 100.0 
20-29 years 33 6.0 515 94.0 548 100.0 
30-39 years 32 7.6 388 91.9 422 100.0 
40-49 years 21 7.6 256 92.4 277 100.0 
50-59 years 8 7.7 95 91.3 104 100.0 
60+ years 1 5.9 15 88.2 17 100.0 
Attained Age       
Mean (SD) 32 1.2 24 0.2 24.3 13.8 
5-9 years 7 1.7 409 98.3 416 100.0 
10-19 years 37 2.0 1797 98.0 1,834 100.0 
20-29 years 35 3.5 970 96.5 1,005 100.0 
30-39 years 34 6.3 502 93.7 536 100.0 
40-49 years 27 7.4 339 92.6 366 100.0 
50-59 years 20 8.4 218 91.6 238 100.0 
60+ years 4 4.5 84 95.5 88 100.0 
Table 7.2: Study characteristics of the British Childhood Cancer Survivor Study (BCCSS) 
























Overall 620,758 164/24.2 6.8 (5.8,7.9) 2.3 (1.8,2.7) 77/9.4 8.2 (6.5,10.2) 1.1 (0.8,1.4) 11/6.1 1.8 (0.9,3.2) 0.1 (-0.0,0.2) 
Sex           
Male 336,802 98/14.9 6.6 (5.3,8.0) 2.5 (1.9,3.0) 48/6.1 7.9 (5.8,10.5) 1.2 (0.8,1.6) 4/3.6 1.1 (0.3,2.9) 0.0 (-0.1,0.1) 
Female 283,955 66/9.3 7.1 (5.5,9.0) 2.0 (1.4,2.6) 29/3.4 8.6 (5.8,12.4) 0.9 (0.5,1.3) 7/2.5 2.8 (1.1,5.8) 0.2 (-0.0,0.3) 
First Primary Neoplasm Type           
CNS (excluding PNET) 120,973 68/6.0 11.4 (8.8,14.4) 5.1 (3.8,6.5) 36/2.3 15.8 (11.1,21.9) 2.8 (1.8,3.8) 2/1.7 1.2 (0.1,4.3) 0.0 (-0.2,0.3) 
PNET 18,699 15/0.7 22.6 (12.7,37.4) 7.7 (3.6,11.7) 10/0.3 36.1 (17.3,66.4) 5.2 (1.9,8.5) 0/0.1 0 -0.1 (-0.1,-0.1) 
Leukemia (excluding AML) 145,237 23/2.7 8.5 (5.4,12.7) 1.4 (0.7,2.0) 10/1.1 8.9 (4.3,16.4) 0.6 (0.2,1.0) 0/0.2 0 -0.0 (-0.0,-0.0) 
AML 13,029 3/0.2 12.6 (2.6,36.7) 2.1 (-0.5,4.7) 0/0.1 0 -0.1 (-0.1,-0.1) 1/0.0 41.2 (1.0,229.7) 0.7 (-0.8,2.3) 
Hodgkin Lymphoma 42,600 7/2.3 3.1 (1.2,6.4) 1.1 (-0.1,2.3) 3/0.9 3.3 (0.7,9.6) 0.5 (-0.3,1.3) 0/0.6 0 -0.1 (-0.1,-0.1) 
Non-Hodgkin Lymphoma 30,343 5/1.6 3.1 (1.0,7.4) 1.1 (-0.3,2.6) 2/0.6 3.3 (0.4,12.0) 0.5 (-0.5,1.4) 1/0.5 2.2 (0.1,12.2) 0.2 (-0.5,0.8) 
Neuroblastoma 28,500 6/0.8 7.2 (2.6,15.7) 1.8 (0.1,3.5) 1/0.3 3.0 (0.1,16.5) 0.2 (-0.5,0.9) 1/0.2 6.0 (0.2,33.5) 0.3 (-0.4,1.0) 
Non-Heritable Retinoblastoma 26,167 1/1.3 0.8 (0.0,4.3) -0.1 (-0.9,0.6) 0/0.5 0 -0.2 (-0.2,-0.2) 0/0.4 0 -0.1 (-0.1,-0.1) 
Heritable Retinoblastoma 20,162 4/0.9 4.5 (1.2,11.4) 1.5 (-0.4,3.5) 3/0.4 8.2 (1.7,23.9) 1.3 (-0.4,3.0) 0/0.2 0 -0.1 (-0.1,-0.1) 
Wilms 51,519 7/1.6 4.4 (1.8,9.1) 1.1 (0.0,2.1) 1/0.7 1.5 (0.0,8.5) 0.1 (-0.3,0.4) 1/0.3 3.3 (0.1,18.4) 0.1 (-0.2,0.5) 
Bone Sarcoma 21,798 1/1.4 0.7 (0.0,4.1) -0.2 (-1.1,0.7) 0/0.5 0 -0.2 (-0.2,-0.2) 1/0.5 2.2 (0.1,12.4) 0.3 (-0.6,1.2) 
Soft Tissue Sarcoma 42,062 11/2.1 5.4 (2.7,9.6) 2.1 (0.6,3.7) 5/0.8 6.5 (2.1,15.1) 1.0 (-0.0,2.0) 2/0.6 3.4 (0.4,12.2) 0.3 (-0.3,1.0) 
Germ Cell Tumors 22,298 8/0.8 10.5 (4.5,20.8) 3.2 (0.8,5.7) 5/0.3 16.9 (5.5,39.4) 2.1 (0.1,4.1) 1/0.2 5.7 (0.1,31.8) 0.4 (-0.5,1.2) 
Other 37,370 5/2.0 2.5 (0.8,5.8) 0.8 (-0.4,2.0) 1/0.7 1.4 (0.0,7.6) 0.1 (-0.5,0.6) 1/0.6 1.5 (0.0,8.6) 0.1 (-0.4,0.6) 
Age at Diagnosis           
0-4 years 291,564 64/7.8 8.2 (6.3,10.4) 1.9 (1.4,2.5) 27/3.2 8.5 (5.6,12.3) 0.8 (0.5,1.2) 3/1.4 2.1 (0.4,6.2) 0.1 (-0.1,0.2) 
5-9 years 163,195 43/6.0 7.2 (5.2,9.7) 2.3 (1.5,3.1) 21/2.4 8.8 (5.4,13.4) 1.1 (0.6,1.7) 3/1.4 2.2 (0.5,6.5) 0.1 (-0.1,0.3) 
10-14 years 165,999 57/10.4 5.5 (4.1,7.1) 2.8 (1.9,3.7) 29/3.8 7.5 (5.0,10.8) 1.5 (0.9,2.2) 5/3.3 1.5 (0.5,3.5) 0.1 (-0.2,0.4) 
Treatment Era           
<1970 135,884 61/14.3 4.3 (3.3,5.5) 3.4 (2.3,4.6) 35/5.2 6.7 (4.7,9.3) 2.2 (1.3,3.0) 7/5.1 1.4 (0.5,2.8) 0.1 (-0.2,0.5) 
1970-1979 152,278 48/5.2 9.3 (6.8,12.3) 2.8 (1.9,3.7) 23/2.3 9.9 (6.2,14.8) 1.4 (0.7,2.0) 1/0.6 1.5 (0.0,8.6) 0.0 (-0.1,0.2) 
1980-1989 155,375 36/2.9 12.4 (8.7,17.2) 2.1 (1.4,2.9) 17/1.3 13.6 (7.9,21.8) 1.0 (0.5,1.5) 1/0.2 5.0 (0.1,27.6) 0.1 (-0.1,0.2) 
1990-2006 177,221 19/1.8 10.4 (6.2,16.2) 1.0 (0.5,1.5) 2/0.6 3.2 (0.4,11.6) 0.1 (-0.1,0.2) 2/0.1 28.9 (3.5,104.5) 0.1 (-0.0,0.3) 
Years Follow-Up           
5-9 years 161,046 36/2.3 15.4 (10.8,21.4) 2.1 (1.4,2.8) 18/1.0 18.8 (11.1,29.6) 1.1 (0.5,1.6) 2/0.1 15.1 (1.8,54.5) 0.1 (-0.1,0.3) 
10-19 years 229,665 33/4.0 8.2 (5.6,11.5) 1.3 (0.8,1.8) 13/1.8 7.4 (3.9,12.7) 0.5 (0.2,0.8) 2/0.2 9.2 (1.1,33.2) 0.1 (-0.0,0.2) 
20-29 years 132,085 33/3.8 8.7 (6.0,12.2) 2.2 (1.4,3.1) 16/1.9 8.4 (4.8,13.7) 1.1 (0.5,1.7) 1/0.3 3.4 (0.1,18.7) 0.1 (-0.1,0.2) 
30-39 years 66,379 32/4.4 7.2 (5.0,10.2) 4.2 (2.5,5.8) 16/2.0 7.8 (4.5,12.7) 2.1 (0.9,3.3) 0/0.9 0 -0.1 (-0.1,-0.1) 
40-49 years 24,972 21/5.1 4.1 (2.5,6.3) 6.4 (2.8,10.0) 9/1.7 5.3 (2.4,10.1) 2.9 (0.6,5.3) 5/2.1 2.4 (0.8,5.6) 1.2 (-0.6,2.9) 
50+ years 6,610 9/4.6 2.0 (0.9,3.8) 6.7 (-2.2,15.6) 5/1.1 4.7 (1.5,10.9) 6.0 (-0.7,12.6) 1/2.5 0.4 (0.0,2.2) -2.2 (-5.2,0.7) 
Attained Age           
5-9 years 38,220 7/0.5 14.5 (5.8,29.9) 1.7 (0.3,3.1) 3/0.2 13.7 (2.8,40.2) 0.7 (-0.2,1.6) 1/0.0 34.7 (0.9,193.2) 0.3 (-0.3,0.8) 
10-19 years 204,815 37/2.9 12.7 (9.0,17.5) 1.7 (1.1,2.2) 18/1.1 15.8 (9.4,25.0) 0.8 (0.4,1.2) 0/0.1 0 -0.0 (-0.0,-0.0) 
20-29 years 195,584 35/3.7 9.3 (6.5,13.0) 1.6 (1.0,2.2) 14/1.7 8.3 (4.5,13.9) 0.6 (0.3,1.0) 3/0.2 14.7 (3.0,42.9) 0.1 (-0.0,0.3) 
30-39 years 108,573 34/3.7 9.2 (6.4,12.8) 2.8 (1.7,3.8) 20/2.0 10.3 (6.3,15.8) 1.7 (0.9,2.5) 1/0.3 3.6 (0.1,20.2) 0.1 (-0.1,0.2) 
40-49 years 51,869 27/4.3 6.3 (4.2,9.2) 4.4 (2.4,6.3) 10/2.0 5.1 (2.4,9.4) 1.5 (0.4,2.7) 2/0.8 2.4 (0.3,8.5) 0.2 (-0.3,0.8) 
50+ years 21,697 24/9.1 2.6 (1.7,3.9) 6.8 (2.4,11.3) 12/2.5 4.9 (2.5,8.5) 4.4 (1.3,7.5) 4/4.6 0.9 (0.2,2.2) -0.3 (-2.1,1.5) 
Table 7.3:  Standardized mortality ratios and absolute excess risks per 10,000 person-years for overall respiratory, pneumonia, and chronic lower respiratory disease mortality, by potential explanatory 
factors, for the British Childhood Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, AER: absolute 

























Overall 620,758 15/1.1 13.8 (7.7,22.8) 0.2 (0.1,0.3) 18/1.1 16.9 (10.0,26.8) 0.3 (0.1,0.4) 43/6.6 6.5 (4.7,8.8) 0.6 (0.4,0.8) 
Sex 
 
         
Male 336,802 6/0.7 8.5 (3.1,18.6) 0.2 (0.0,0.3) 11/0.7 16.3 (8.1,29.1) 0.3 (0.1,0.5) 29/3.9 7.4 (5.0,10.7) 0.7 (0.4,1.1) 
Female 283,955 9/0.4 23.6 (10.8,44.7) 0.3 (0.1,0.5) 7/0.4 18.1 (7.3,37.3) 0.2 (0.1,0.4) 14/2.7 5.1 (2.8,8.6) 0.4 (0.1,0.7) 
First Primary Neoplasm Type 
 
         
CNS (excluding PNET) 120,973 3/0.3 10.4 (2.2,30.5) 0.2 (-0.1,0.5) 13/0.2 53.8 (28.6,92.0) 1.1 (0.5,1.6) 14/1.5 9.5 (5.2,16.0) 1.0 (0.4,1.6) 
PNET 18,699 2/0.0 78.9 (9.6,285.1) 1.1 (-0.4,2.5) 0/0.0 0 -0.0 (-0.0,-0.0) 3/0.2 15.2 (3.1,44.4) 1.5 (-0.3,3.3) 
Leukemia (excluding AML) 145,237 3/0.1 39.0 (8.0,113.9) 0.2 (-0.0,0.4) 1/0.2 6.3 (0.2,34.9) 0.1 (-0.1,0.2) 9/1.1 8.1 (3.7,15.4) 0.5 (0.1,0.9) 
AML 13,029 2/0.0 281.0 (34.0,1015.0) 1.5 (-0.6,3.7) 0/0.0 0 -0.0 (-0.0,-0.0) 0/0.1 0 -0.1 (-0.1,-0.1) 
Hodgkin Lymphoma 42,600 1/0.1 9.5 (0.2,52.7) 0.2 (-0.3,0.7) 0/0.1 0 -0.0 (-0.0,-0.0) 3/0.6 5.4 (1.1,15.7) 0.6 (-0.2,1.4) 
Non-Hodgkin Lymphoma 30,343 1/0.1 12.4 (0.3,69.2) 0.3 (-0.3,0.9) 0/0.1 0 -0.0 (-0.0,-0.0) 1/0.4 2.6 (0.1,14.7) 0.2 (-0.4,0.9) 
Neuroblastoma 28,500 1/0.0 29.8 (0.8,166.2) 0.3 (-0.3,1.0) 1/0.0 27.2 (0.7,151.6) 0.3 (-0.3,1.0) 2/0.3 7.7 (0.9,27.9) 0.6 (-0.4,1.6) 
Non-Heritable Retinoblastoma 26,167 0/0.1 0 -0.0 (-0.0,-0.0) 0/0.1 0 -0.0 (-0.0,-0.0) 1/0.3 3.1 (0.1,17.5) 0.3 (-0.5,1.0) 
Heritable Retinoblastoma 20,162 0/0.0 0 -0.0 (-0.0,-0.0) 0/0.0 0 -0.0 (-0.0,-0.0) 1/0.2 4.2 (0.1,23.2) 0.4 (-0.6,1.3) 
Wilms 51,519 2/0.1 34.0 (4.1,122.8) 0.4 (-0.2,0.9) 0/0.1 0 -0.0 (-0.0,-0.0) 3/0.5 6.0 (1.2,17.5) 0.5 (-0.2,1.1) 
Bone Sarcoma 21,798 0/0.1 0 -0.0 (-0.0,-0.0) 0/0.1 0 -0.0 (-0.0,-0.0) 0/0.3 0 -0.1 (-0.1,-0.1) 
Soft Tissue Sarcoma 42,062 0/0.1 0 -0.0 (-0.0,-0.0) 1/0.1 11.6 (0.3,64.8) 0.2 (-0.2,0.7) 3/0.5 6.0 (1.2,17.6) 0.6 (-0.2,1.4) 
Germ Cell Tumors 22,298 0/0.0 0 -0.0 (-0.0,-0.0) 1/0.0 28.1 (0.7,156.4) 0.4 (-0.4,1.3) 1/0.2 4.5 (0.1,25.1) 0.3 (-0.5,1.2) 
Other 37,370 0/0.1 0 -0.0 (-0.0,-0.0) 1/0.1 12.2 (0.3,67.8) 0.2 (-0.3,0.8) 2/0.5 4.3 (0.5,15.4) 0.4 (-0.3,1.2) 
Age at Diagnosis 
 
         
0-4 years 291,564 8/0.3 28.0 (12.1,55.3) 0.3 (0.1,0.5) 8/0.4 22.2 (9.6,43.8) 0.3 (0.1,0.5) 18/2.6 7.0 (4.1,11.0) 0.5 (0.2,0.8) 
5-9 years 163,195 2/0.3 8.0 (1.0,28.7) 0.1 (-0.1,0.3) 4/0.3 14.6 (4.0,37.5) 0.2 (-0.0,0.5) 13/1.7 7.5 (4.0,12.9) 0.7 (0.3,1.1) 
10-14 years 165,999 5/0.5 9.1 (3.0,21.3) 0.3 (0.0,0.5) 6/0.4 14.0 (5.1,30.4) 0.3 (0.0,0.6) 12/2.3 5.2 (2.7,9.1) 0.6 (0.2,1.0) 
Treatment Era 
 
         
<1970 135,884 0/0.8 0 -0.1 (-0.1,-0.1) 5/0.5 10.5 (3.4,24.4) 0.3 (0.0,0.7) 14/2.7 5.2 (2.8,8.7) 0.8 (0.3,1.4) 
1970-1979 152,278 8/0.2 45.9 (19.8,90.4) 0.5 (0.1,0.9) 8/0.3 30.8 (13.3,60.7) 0.5 (0.1,0.9) 8/1.8 4.5 (2.0,8.9) 0.4 (0.0,0.8) 
1980-1989 155,375 5/0.1 64.0 (20.8,149.3) 0.3 (0.0,0.6) 4/0.2 21.5 (5.9,55.1) 0.2 (-0.0,0.5) 9/1.2 7.6 (3.5,14.4) 0.5 (0.1,0.9) 
1990-2006 177,221 2/0.0 54.1 (6.5,195.3) 0.1 (-0.0,0.3) 1/0.1 7.1 (0.2,39.7) 0.0 (-0.1,0.2) 12/1.0 12.5 (6.4,21.8) 0.6 (0.2,1.0) 
Years Follow-Up 
 
         
5-9 years 161,046 4/0.0 164.9 (44.9,422.2) 0.2 (0.0,0.5) 1/0.1 14.0 (0.4,78.2) 0.1 (-0.1,0.2) 11/1.1 9.6 (4.8,17.2) 0.6 (0.2,1.0) 
10-19 years 229,665 6/0.1 100.4 (36.8,218.5) 0.3 (0.0,0.5) 3/0.2 17.3 (3.6,50.4) 0.1 (-0.0,0.3) 9/1.8 4.9 (2.2,9.3) 0.3 (0.1,0.6) 
20-29 years 132,085 4/0.1 38.7 (10.6,99.2) 0.3 (-0.0,0.6) 4/0.2 20.0 (5.5,51.3) 0.3 (-0.0,0.6) 8/1.3 6.2 (2.7,12.2) 0.5 (0.1,0.9) 
30-39 years 66,379 1/0.2 5.4 (0.1,29.9) 0.1 (-0.2,0.4) 7/0.2 30.1 (12.1,62.1) 1.0 (0.2,1.8) 8/1.1 7.3 (3.1,14.3) 1.0 (0.2,1.9) 
40-49 years 24,972 0/0.3 0 -0.1 (-0.1,-0.1) 2/0.2 9.0 (1.1,32.4) 0.7 (-0.4,1.8) 5/0.8 6.3 (2.0,14.6) 1.7 (-0.1,3.4) 
50+ years 6,610 0/0.4 0 -0.6 (-0.6,-0.6) 1/0.2 6.1 (0.2,34.1) 1.3 (-1.7,4.2) 2/0.5 4.4 (0.5,16.0) 2.3 (-1.8,6.5) 
Attained Age 
 
         
5-9 years 38,220 1/0.0 174.1 (4.4,970.2) 0.3 (-0.3,0.8) 0/0.0 0 -0.0 (-0.0,-0.0) 2/0.2 9.2 (1.1,33.4) 0.5 (-0.3,1.2) 
10-19 years 204,815 4/0.0 144.6 (39.4,370.3) 0.2 (0.0,0.4) 1/0.1 12.3 (0.3,68.6) 0.0 (-0.1,0.1) 14/1.5 9.3 (5.1,15.5) 0.6 (0.3,1.0) 
20-29 years 195,584 7/0.1 108.4 (43.6,223.4) 0.4 (0.1,0.6) 5/0.2 25.1 (8.1,58.5) 0.2 (0.0,0.5) 6/1.6 3.8 (1.4,8.2) 0.2 (-0.0,0.5) 
30-39 years 108,573 2/0.1 18.6 (2.3,67.2) 0.2 (-0.1,0.4) 3/0.2 15.8 (3.2,46.0) 0.3 (-0.1,0.6) 8/1.2 6.8 (2.9,13.3) 0.6 (0.1,1.1) 
40-49 years 51,869 1/0.2 5.4 (0.1,30.1) 0.2 (-0.2,0.5) 6/0.2 26.0 (9.5,56.5) 1.1 (0.2,2.0) 8/1.0 7.7 (3.3,15.3) 1.3 (0.3,2.4) 
50+ years 21,697 0/0.7 0 -0.3 (-0.3,-0.3) 3/0.3 8.6 (1.8,25.2) 1.2 (-0.3,2.8) 5/1.1 4.6 (1.5,10.8) 1.8 (-0.2,3.8) 
Table 7.3 (continued):  Standardized mortality ratios and absolute excess risks per 10,000 person-years for fibrosis, pneumonitis, and other respiratory mortality, by potential explanatory factors, for the 
British Childhood Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, AER: absolute 



































      
      
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 1.1 (0.8,1.5) 0.8 (0.6,1.2) 1.1 (0.7,1.7) 0.7 (0.4,1.2) 2.5 (0.7,8.6) 12.6 (0.0,136520.6) 2.8 (1.0,7.7) 1.9 (0.6,6.0) 1.1 (0.4,2.9) 0.8 (0.3,2.1) 70.7 (0.4,1.3) 0.5 (0.2,1.2) 
Pheterogeneity 0.6509 0.2519 0.7192 0.2233 0.1316 0.1728 0.0514 0.02437 0.8272 0.5891 0.2483 0.0955 
First Primary Neoplasm Type             
CNS (excluding PNET) 2.1 (1.1,4.0) 2.4 (1.1,5.2) 2.4 (1.0,6.2) 2.8 (0.9,8.3) 0.3 (0.0,2.5) 0.1 (0.0,885.5) NA NA 4.6 (0.6,35.3) 4.9 
(0.5,44.4) 
1.6 (0.5,5.5) 1.7 (0.4,7.6) 
PNET 4.2 (1.9,9.2) 3.6 (1.5,8.9) 5.6 (1.9,16.3) 5.2 (1.5,17.5) NA NA NA NA NA NA 2.5 (0.5,12.5) 2.5 (0.4,15.5) 
Leukemia (excluding AML) 1.6 (0.8,3.2) 0.7 (0.3,1.6) 1.4 (0.5,4.0) 0.6 (0.2,2.1) NA NA NA NA 0.5 (0.0,8.6) 0.3 (0.0,6.3) 1.3 (0.4,5.0) 0.9 (0.2,4.3) 
AML 2.3 (0.7,8.4) 1.0 (0.2,4.2) NA NA 12.2 (1.1,134.8) 2.2 (0.1,37.3) NA NA NA NA NA NA 
Hodgkin Lymphoma 0.6 (0.2,1.5) 0.5 (0.1,1.9) 0.5 (0.1,2.1) 0.5 (0.1,3.4) NA NA NA NA NA NA 0.9 (0.2,4.4) 1.0 (0.1,6.7) 
Non-Hodgkin Lymphoma 0.6 (0.2,1.7) 0.5 (0.1,2.3) 0.5 (0.1,2.6) 0.5 (0.0,4.3) 0.6 (0.1,7.1) 0.5 (0.0,32.8) NA NA NA NA 0.4 (0.0,4.2) 0.3 (0.0,10.7) 
Neuroblastoma 1.3 (0.5,3.6) 0.9 (0.3,2.8) 0.5 (0.1,3.9) 0.2 (0.0,5.3) 1.8 (0.2,19.7) 0.9 (0.0,18.8) NA NA 2.3 (0.1,37.4) 1.6 
(0.1,29.9) 
1.3 (0.2,7.7) 1.0 (0.1,8.3) 
Non-Heritable Retinoblastoma 0.1 (0.0,1.1) NA NA NA NA NA NA NA NA NA 0.5 (0.1,5.0) 0.4 (0.0,10.5) 
Heritable Retinoblastoma 0.8 (0.3,2.6) 0.7 (0.2,3.1) 1.3 (0.3,5.3) 1.3 (0.2,6.8) NA NA NA NA NA NA 0.7 (0.1,6.7) 0.6 (0.0,11.7) 
Wilms 0.8 (0.3,2.1) 0.5 (0.1,1.6) 0.2 (0.0,2.0) 0.1 (0.0,20.5) 1.0 (0.1,10.8) 0.4 (0.0,12.5) NA NA NA NA 1.0 (0.2,4.9) 0.8 (0.1,5.6) 
Bone Sarcoma 0.1 (0.0,1.1) NA NA NA 0.7 (0.1,7.3) 0.8 (0.0,44.3) NA NA NA NA NA NA 
Soft Tissue Sarcoma 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Germ Cell Tumors 2.0 (0.8,4.9) 1.5 (0.5,4.4) 2.6 (0.8,9.0) 2.1 (0.5,8.5) 1.7 (0.2,18.6) 1.1 (0.1,24.2) NA NA 2.4 (0.2,38.6) 2.0 
(0.1,38.2) 
0.7 (0.1,7.2) 0.6 (0.0,10.3) 
Other 0.5 (0.2,1.3) 0.4 (0.1,1.9) 0.2 (0.0,1.8) 0.1 (0.0,106.1) 0.5 (0.0,5.0) 0.3 (0.0,104.2) NA NA 1.0 (0.1,16.7) 1.1 
(0.1,23.3) 
0.7 (0.1,4.3) 0.7 (0.1,6.6) 
Pheterogeneity <0.0001 <0.0001 <0.0001 <0.0001 0.4222 0.7460 0.0100 0.2211 0.0074 0.0036 0.5436 0.6517 
Age at Diagnosis             
0-4 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
5-9 years 0.9 (0.6,1.3) 1.2 (0.8,1.8) 1.0 (0.6,1.8) 1.4 (0.7,2.7) 1.1 (0.2,5.2) 1.9 (0.1,36.7) 0.3 (0.1,1.3) 0.4 (0.1,2.3) 
 
0.7 (0.2,2.2) 0.9 (0.2,3.1) 1.1 (0.5,2.2) 1.3 (0.6,3.0) 
10-14 years 0.7 (0.5,1.0) 1.5 (1.0,2.2) 0.9 (0.5,1.5) 1.9 (1.0,3.4) 0.7 (0.2,3.0) 1.9 (0.1,54.0) 0.3 (0.1,1.0) 1.0 (0.3,3.4) 0.6 (0.2,1.8) 1.3 (0.4,4.0) 0.7 (0.4,1.6) 1.1 (0.5,2.7) 
Ptrend 0.0271 0.0871 0.6448 0.0443 0.6183 0.6766 0.0470 0.8651 0.3833 0.7079 0.4603 0.7589 
Treatment Era             
<1970 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1970-1979 2.2 (1.5,3.2) 0.8 (0.5,1.3) 1.5 (0.9,2.5) 0.6 (0.3,1.1) 1.1 (0.1,9.2) 0.2 (0.0,85.5) NA NA 2.9 (1.0,9.0) 1.5 (0.5,5.1) 0.9 (0.4,2.1) 0.5 (0.2,1.5) 
1980-1989 2.9 (1.9,4.4) 0.6 (0.4,1.0) 2.0 (1.1,3.6) 0.5 (0.2,0.9) 3.6 (0.4,29.6) 0.4 (0.0,15.5) NA NA 2.1 (0.6,7.7) 0.7 (0.2,3.0) 1.5 (0.6,3.4) 0.6 (0.2,1.6) 
1990-2006 2.4 (1.5,4.1) 0.3 (0.2,0.5) 0.5 (0.1,2.0) 0.0 (0.0,0.3) 21.3 (4.4,102.4) 
3 
0.8 (0.0,18.5) NA NA 0.7 (0.1,5.8) 0.1 (0.0,1.7) 2.4 (1.1,5.1) 0.7 (0.3,1.8) 
Ptrend <0.0001 <0.0001 0.3187 <0.0001 0.0060 0.5342 <0.0001 0.9769 0.7960 0.0490 0.0257 0.7080 
Attained Age             
5-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
10-19 years 0.9 (0.4,2.0) 1.0 (0.4,2.3) 1.2 (0.3,3.9) 1.1 (0.3,4.2) NA NA 0.8 (0.1,7.4) 0.7 (0.1,6.8) NA NA 1.0 (0.2,4.4) 1.3 (0.2,6.9) 
20-29 years 0.6 (0.3,1.4) 0.9 (0.4,2.3) 0.6 (0.2,2.1) 0.9 (0.2,3.4) 0.4 (0.0,4.1) 0.6 (0.1,5.9) 0.6 (0.1,5.1) 1.4 (0.2,11.2) NA NA 0.4 (0.1,2.0) 0.5 (0.1,3.2) 
30-39 years 0.6 (0.3,1.4) 1.6 (0.7,3.9) 0.7 (0.2,2.5) 2.3 (0.6,8.5) 0.1 (0.0,1.7) 0.3 (0.0,7.7) 0.1 (0.0,1.2) 0.7 (0.1,7.8) NA NA 0.7 (0.2,3.5) 1.3 (0.2,7.8) 
40-49 years 0.4 (0.2,1.0) 2.6 (1.0,6.4) 0.4 (0.1,1.3) 2.1 (0.5,9.0) 0.1 (0.0,0.8) 0.9 (0.0,20.2) 0.0 (0.0,0.5) 0.6 (0.0,13.5) NA NA 0.8 (0.2,4.0) 2.9 (0.5,16.5) 
50+ years 0.2 (0.1,0.4) 4.0 (1.4,11.2) 0.4 (0.1,1.3) 6.0 (1.5,24.8) 0.0 (0.0,0.2) NA NA NA NA NA 0.5 (0.1,2.6) 3.9 (0.6,26.3) 
Ptrend <0.0001 0.0001 0.0006 0.0010 0.0020 0.6828 <0.0001 0.6138 0.5042 0.0001 0.3771 0.0666 
Table 7.4 Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a univariate model, by potential explanatory factors, for the British 
Childhood Cancer Survivor Study  
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, RR: relative risks, SMR: standardized mortality ratio, 

































      
      
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 1.1 (0.8,1.5) 0.8 (0.5,1.1) 1.1 (0.7,1.8) 0.7 (0.4,1.2) 2.6 (0.8,9.2) 4.7 (0.5,44.2) 2.1 (0.7,5.9) 1.9 (0.6,5.4) 1.0 (0.4,2.7) 0.7 (0.3,1.8) 0.7 (0.4,1.3) 0.6 (0.3,1.3) 
Pheterogeneity 0.6243 0.1861 0.6489 0.2185 0.1196 0.1201 0.1693 0.2474 0.9454 0.4345 0.2149 0.1596 
First Primary Neoplasm Type             
CNS (excluding PNET) 2.2 (1.1,4.1) 2.3 (1.1,4.8) 2.5 (1.0,6.4) 2.6 (0.9,7.5) 0.3 (0.0,2.3) NA NA NA 5.0 (0.7,38.7) 4.9 (0.6,39.3) 1.7 (0.5,5.8) 2.0 (0.4,10.1) 
PNET 3.5 (1.6,7.7) 3.8 (1.6,9.0) 5.2 (1.8,15.2) 5.4 (1.7,17.5) NA NA NA NA NA NA 2.4 (0.5,11.8) 2.9 (0.4,19.8) 
Leukemia (excluding AML) 0.9 (0.4,1.8) 0.8 (0.3,1.9) 1.0 (0.3,3.0) 0.9 (0.3,3.1) NA NA NA NA 0.3 (0.0,4.9) 0.3 (0.0,5.7) 1.1 (0.3,4.3) 1.2 (0.2,6.9) 
AML 1.4 (0.4,5.0) 1.4 (0.3,5.7) NA NA 3.7 (0.3,49.0) 1.4 (0.1,17.5) NA NA NA NA NA NA 
Hodgkin Lymphoma 0.6 (0.2,1.5) 0.5 (0.1,1.7) 0.5 (0.1,2.2) 0.3 (0.0,3.2) NA NA NA NA NA NA 0.9 (0.2,4.7) 0.9 (0.1,8.0) 
Non-Hodgkin Lymphoma 0.6 (0.2,1.8) 0.5 (0.1,2.1) 0.5 (0.1,2.8) 0.4 (0.0,3.8) 0.7 (0.1,8.0) NA NA NA NA NA 0.4 (0.0,4.2) 0.2 (0.0,58.4) 
Neuroblastoma 1.0 (0.3,2.6) 0.9 (0.3,2.8) 0.4 (0.0,3.2) 0.1 (0.0,665145.6) 1.2 (0.1,15.6) 2.0 (0.1,43.0) NA NA 1.5 (0.1,23.9) 1.5 (0.1,26.2) 1.2 (0.2,7.2) 1.3 (0.1,11.2) 
Non-Heritable Retinoblastoma 0.1 (0.0,1.0) 0.0 (0.0,163.7) NA NA NA NA NA NA NA NA 0.6 (0.1,5.5) 0.6 (0.0,10.1) 
Heritable Retinoblastoma 0.7 (0.2,2.2) 0.6 (0.1,2.6) 1.0 (0.2,4.5) 1.1 (0.2,5.7) NA NA NA NA NA NA 0.7 (0.1,7.5) 0.8 (0.1,12.7) 
Wilms 0.6 (0.2,1.5) 0.5 (0.1,1.6) 0.2 (0.0,1.6) 0.1 (0.0,4.8) 0.7 (0.1,8.4) NA NA NA NA NA 1.0 (0.2,5.0) 0.8 (0.1,8.0) 
Bone Sarcoma 0.2 (0.0,1.2) NA NA NA 0.7 (0.1,7.6) 0.5 (0.0,6.0) NA NA NA NA NA NA 
Soft Tissue Sarcoma 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Germ Cell Tumors 1.6 (0.6,3.9) 1.5 (0.5,4.3) 2.3 (0.7,8.0) 2.3 (0.6,8.8) 1.1 (0.1,12.9) NA NA NA 1.9 (0.1,31.1) 1.9 (0.1,32.9) 0.7 (0.1,7.2) 0.8 (0.1,12.6) 
Other 0.5 (0.2,1.5) 0.3 (0.1,1.8) 0.2 (0.0,1.9) NA 0.4 (0.0,4.7) NA NA NA 1.3 (0.1,21.1) 1.2 (0.1,22.8) 0.8 (0.1,4.7) 1.0 (0.1,8.5) 
Pheterogeneity <0.0001 <0.0001 <0.0001 <0.0001 0.5536 0.1888 0.2201 0.2249 0.0016 0.0026 0.5939 0.6510 
Age at Diagnosis             
0-4 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
5-9 years 0.7 (0.5,1.1) 0.8 (0.5,1.4) 0.8 (0.4,1.5) 1.0 (0.5,2.1) 1.4 (0.2,10.2) NA 0.4 (0.1,1.9) 0.3 (0.1,2.0) 0.4 (0.1,1.3) 0.3 (0.1,1.2) 1.0 (0.4,2.2) 1.1 (0.4,2.6) 
10-14 years 0.8 (0.5,1.2) 1.0 (0.6,1.7) 1.0 (0.5,1.8) 1.5 (0.7,3.1) 1.0 (0.1,6.8) NA 1.1 (0.3,4.5) 1.1 (0.3,4.6) 0.4 (0.1,1.3) 0.3 (0.1,1.0) 0.8 (0.3,1.9) 0.8 (0.2,2.4) 
Ptrend 0.2738 0.9293 0.9444 0.2539 0.8895 0.4420 0.9640 0.9541 0.1281 0.0628 0.5977 0.6727 
Treatment Era             
<1970 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1970-1979 1.5 (1.0,2.3) 1.1 (0.7,1.7) 1.3 (0.7,2.3) 0.8 (0.4,1.5) 0.6 (0.1,5.5) 0.9 (0.1,15.0) NA NA 2.9 (0.7,11.6) 3.8 (1.0,14.5) 0.9 (0.3,2.4) 0.6 (0.2,2.1) 
1980-1989 1.7 (1.1,2.9) 0.9 (0.6,1.6) 1.5 (0.8,2.9) 0.6 (0.3,1.3) 1.0 (0.1,10.6) 0.5 (0.0,8.9) NA NA 2.0 (0.3,11.6) 3.8 (0.7,21.1) 1.9 (0.7,5.3) 1.4 (0.4,4.9) 
1990-2006 1.2 (0.6,2.2) 0.4 (0.2,0.8) 0.3 (0.1,1.2) 0.1 (0.0,0.3) 3.6 (0.4,31.0) 0.8 (0.1,10.8) NA NA 0.6 (0.0,8.4) 1.5 (0.1,21.0) 3.1 (1.0,9.4) 1.8 (0.5,7.1) 
Ptrend 0.2230 0.0153 0.5303 <0.0001 0.3824 0.8376 0.4018 0.4424 0.9683 0.2870 0.0210 0.2873 
Attained Age             
5-9 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
10-19 years 0.8 (0.4,1.9) 0.9 (0.4,2.2) 1.0 (0.3,3.4) 0.8 (0.2,3.1) NA NA 0.7 (0.1,6.6) 0.8 (0.1,7.5) NA NA 1.1 (0.2,5.0) 1.3 (0.2,7.1) 
20-29 years 0.6 (0.3,1.5) 0.7 (0.3,1.8) 0.5 (0.1,1.7) 0.4 (0.1,1.7) 0.5 (0.0,6.6) NA 0.5 (0.1,5.1) 1.2 (0.1,11.1) NA NA 0.6 (0.1,3.2) 0.5 (0.1,3.9) 
30-39 years 0.6 (0.3,1.5) 1.1 (0.4,2.8) 0.5 (0.1,1.9) 0.8 (0.2,3.2) 0.2 (0.0,3.9) NA 0.1 (0.0,1.1) 0.5 (0.0,6.7) NA NA 1.4 (0.2,7.7) 2.1 (0.3,15.8) 
40-49 years 0.5 (0.2,1.2) 1.6 (0.6,4.3) 0.3 (0.1,1.0) 0.6 (0.1,2.9) 0.1 (0.0,2.2) NA 0.0 (0.0,0.7) 0.5 (0.0,15.6) NA NA 1.9 (0.3,11.6) 5.3 (0.6,43.9) 
50+ years 0.2 (0.1,0.6) 2.5 (0.8,7.9) 0.3 (0.1,1.2) 1.2 (0.3,6.2) 0.0 (0.0,0.7) NA NA NA NA NA 1.2 (0.2,8.9) 6.4 (0.6,67.1) 
Ptrend 0.0003 0.0127 0.0018 0.5757 0.0742 1.0000 0.0003 0.5474 0.9015 0.0001 0.4031 0.0359 
Table 7.5:  Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a multivariate model, adjusting for sex, first primary neoplasm type, age 
at diagnosis, treatment era, and attained age, for the British Childhood Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, RR: relative risks, SMR: standardized mortality ratio, 






Patient Characteristic Respiratory Death % Other Death % Total % 
       
Overall 1067 3.1 33121 96.9 34188 100.0 
Sex       
Male 472 3.9 11614 96.1 12086 100.0 
Female 595 2.7 21507 97.3 22102 100.0 
First Primary Neoplasm Type       
Breast 135 1.3 10477 98.7 10612 100.0 
Testicular 98 4.9 1910 95.1 2008 100.0 
Cervix 152 5.7 2492 94.3 2644 100.0 
Melanoma 25 1.1 2295 98.9 2320 100.0 
Hodgkin Lymphoma 134 4.4 2937 95.6 3071 100.0 
CNS (excluding PNET) 129 3.2 3865 96.8 3994 100.0 
Non-Hodgkin Lymphoma 72 4.2 1647 95.8 1719 100.0 
Thyroid 13 3.1 402 96.9 415 100.0 
Gastrointestinal 47 3.4 1346 96.6 1393 100.0 
Soft Tissue Sarcoma 30 3.4 863 96.6 893 100.0 
Ovary 22 3.1 695 96.9 717 100.0 
Bladder 27 4.6 555 95.4 582 100.0 
Other Genitourinary 35 4.1 819 95.9 854 100.0 
Head & Neck 42 6.1 648 93.9 690 100.0 
Leukemia (excluding AML) 25 3.3 743 96.7 768 100.0 
Other 26 4.9 501 95.1 527 100.0 
Bone Tumor 11 3.0 361 97.0 372 100.0 
Acute Myeloid Leukemia 12 5.5 205 94.5 217 100.0 
Lung 29 10.1 258 89.9 287 100.0 
CNS PNET 3 2.9 102 97.1 105 100.0 
Age at Diagnosis       
Mean (SD) 33.2 6 22.1 5.8 33.1 5.8 
15-19 53 3.8 1360 96.2 1413 100.0 
20-24 80 3.3 2329 96.7 2409 100.0 
25-29 136 2.9 4592 97.1 4728 100.0 
30-34 256 2.8 8927 97.2 9183 100.0 
35-39 542 3.3 15913 96.7 16455 100.0 
Treatment Era       
1971-1979 447 4.7 8984 95.3 9431 100.0 
1980-1989 412 3.3 11913 96.7 12325 100.0 
1990-1990 169 1.9 8812 98.1 8981 100.0 
2000-2006 39 1.1 3412 98.9 3451 100.0 
Years Follow-Up       
Mean (SD) 21.9 0.0 14.6 0.0 14.8 0.0 
5-9 years 159 1.1 14237 98.9 14396 100.0 
10-19 years 277 2.6 10509 97.4 10786 100.0 
20-29 years 381 6.6 5730 93.8 6111 100.0 
30-39 years 240 9.6 2505 91.3 2745 100.0 
40+ years 10 7.1 140 93.3 150 100.0 
Attained Age       
Mean (SD) 55.2 0.4 47.7 0.1 47.9 0.1 
20-29 years 20 1.6 1252 98.4 1272 100.0 
30-39 years 103 1.8 5735 98.2 5838 100.0 
40-49 years 227 1.5 14424 98.5 14651 100.0 
50-59 years 314 4.2 7183 95.8 7497 100.0 
60+ years 403 8.2 4527 91.8 4930 100.0 
Table 7.6: Study characteristics of the Teenage and Young Adult Cancer Survivor Study (TYACSS) 






  All Respiratory Pneumonia Chronic Lower Respiratory Disease 
 
Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Overall 2,867,878 1067/643.2 1.7 (1.6,1.8) 1.5 (1.3,1.7) 390/191.1 2.0 (1.8,2.3) 0.7 (0.6,0.8) 388/295.0 1.3 (1.2,1.5) 0.3 (0.2,0.5) 
Sex 
 
         
Male 1,096,504 472/265.3 1.8 (1.6,1.9) 1.9 (1.5,2.3) 186/86.2 2.2 (1.9,2.5) 0.9 (0.7,1.2) 144/112.1 1.3 (1.1,1.5) 0.3 (0.1,0.5) 
Female 1,771,374 595/378.0 1.6 (1.5,1.7) 1.2 (1.0,1.5) 204/104.9 1.9 (1.7,2.2) 0.6 (0.4,0.7) 244/183.0 1.3 (1.2,1.5) 0.3 (0.2,0.5) 
First Primary Neoplasm Type 
 
         
Breast 444,041 135/117.8 1.1 (1.0,1.4) 0.4 (-0.1,0.9) 44/32.2 1.4 (1.0,1.8) 0.3 (-0.0,0.6) 56/58.4 1.0 (0.7,1.2) -0.1 (-0.4,0.3) 
Testicular 358,212 98/79.7 1.2 (1.0,1.5) 0.5 (-0.0,1.1) 34/26.5 1.3 (0.9,1.8) 0.2 (-0.1,0.5) 37/32.7 1.1 (0.8,1.6) 0.1 (-0.2,0.5) 
Cervix 384,507 152/85.4 1.8 (1.5,2.1) 1.7 (1.1,2.4) 44/23.5 1.9 (1.4,2.5) 0.5 (0.2,0.9) 87/41.6 2.1 (1.7,2.6) 1.2 (0.7,1.7) 
Melanoma 295,141 25/57.1 0.4 (0.3,0.6) -1.1 (-1.4,-0.8) 5/17.1 0.3 (0.1,0.7) -0.4 (-0.6,-0.3) 13/25.7 0.5 (0.3,0.9) -0.4 (-0.7,-0.2) 
Hodgkin Lymphoma 270,034 134/42.8 3.1 (2.6,3.7) 3.4 (2.5,4.2) 39/14.2 2.7 (2.0,3.8) 0.9 (0.5,1.4) 40/17.4 2.3 (1.6,3.1) 0.8 (0.4,1.3) 
CNS (excluding PNET) 227,447 129/41.5 3.1 (2.6,3.7) 3.8 (2.9,4.8) 63/13.0 4.8 (3.7,6.2) 2.2 (1.5,2.9) 18/17.9 1.0 (0.6,1.6) 0.0 (-0.4,0.4) 
Non-Hodgkin Lymphoma 124,611 72/26.0 2.8 (2.2,3.5) 3.7 (2.4,5.0) 30/8.2 3.7 (2.5,5.2) 1.8 (0.9,2.6) 15/11.3 1.3 (0.7,2.2) 0.3 (-0.3,0.9) 
Thyroid 111,952 13/20.9 0.6 (0.3,1.1) -0.7 (-1.3,-0.1) 4/6.1 0.7 (0.2,1.7) -0.2 (-0.5,0.2) 6/9.6 0.6 (0.2,1.4) -0.3 (-0.7,0.1) 
Gastrointestinal 102,795 47/33.4 1.4 (1.0,1.9) 1.3 (0.0,2.6) 17/9.6 1.8 (1.0,2.8) 0.7 (-0.1,1.5) 20/16.0 1.3 (0.8,1.9) 0.4 (-0.5,1.2) 
Soft Tissue Sarcoma 92,295 30/20.4 1.5 (1.0,2.1) 1.0 (-0.1,2.2) 13/6.1 2.1 (1.1,3.6) 0.7 (-0.0,1.5) 13/9.2 1.4 (0.8,2.4) 0.4 (-0.4,1.2) 
Ovary 80,825 22/18.1 1.2 (0.8,1.8) 0.5 (-0.6,1.6) 12/5.0 2.4 (1.2,4.2) 0.9 (0.0,1.7) 7/8.9 0.8 (0.3,1.6) -0.2 (-0.9,0.4) 
Bladder 83,660 27/31.6 0.9 (0.6,1.2) -0.6 (-1.8,0.7) 9/9.2 1.0 (0.4,1.9) -0.0 (-0.7,0.7) 14/15.0 0.9 (0.5,1.6) -0.1 (-1.0,0.8) 
Other Genitourinary 68,726 35/21.3 1.6 (1.1,2.3) 2.0 (0.3,3.7) 13/6.0 2.2 (1.2,3.7) 1.0 (-0.0,2.0) 14/10.4 1.3 (0.7,2.3) 0.5 (-0.5,1.6) 
Head & Neck 57,915 42/16.4 2.6 (1.9,3.5) 4.4 (2.2,6.6) 17/4.8 3.5 (2.0,5.6) 2.1 (0.7,3.5) 16/7.6 2.1 (1.2,3.4) 1.5 (0.1,2.8) 
Leukemia (excluding AML) 39,610 25/5.2 4.8 (3.1,7.1) 5.0 (2.5,7.5) 9/1.8 5.1 (2.3,9.6) 1.8 (0.3,3.3) 6/2.0 3.0 (1.1,6.6) 1.0 (-0.2,2.2) 
Other 48,857 26/11.5 2.3 (1.5,3.3) 3.0 (0.9,5.0) 14/3.4 4.1 (2.3,6.9) 2.2 (0.7,3.7) 8/5.3 1.5 (0.6,2.9) 0.5 (-0.6,1.7) 
Bone Tumor 33,461 11/4.6 2.4 (1.2,4.3) 1.9 (-0.0,3.9) 8/1.5 5.2 (2.2,10.2) 1.9 (0.3,3.6) 1/1.8 0.6 (0.0,3.1) -0.2 (-0.8,0.3) 
Acute Myeloid Leukemia 20,536 12/2.1 5.7 (2.9,9.9) 4.8 (1.5,8.1) 3/0.8 4.0 (0.8,11.6) 1.1 (-0.6,2.7) 1/0.7 1.4 (0.0,7.6) 0.1 (-0.8,1.1) 
Lung 19,281 29/7.0 4.2 (2.8,6.0) 11.4 (5.9,16.9) 9/2.0 4.5 (2.1,8.5) 3.6 (0.6,6.7) 16/3.3 4.8 (2.7,7.8) 6.6 (2.5,10.6) 
CNS PNET 3,973 3/0.4 6.8 (1.4,19.9) 6.4 (-2.1,15.0) 3/0.2 18.7 (3.9,54.7) 7.1 (-1.4,15.7) 0/0.2 0 -0.4 (-0.4,-0.4) 
Age at Diagnosis 
 
         
15-19 years 192,725 53/8.7 6.1 (4.6,8.0) 2.3 (1.6,3.0) 17/3.8 4.4 (2.6,7.1) 0.7 (0.3,1.1) 9/1.6 5.6 (2.6,10.6) 0.4 (0.1,0.7) 
20-24 years 330,513 80/24.5 3.3 (2.6,4.1) 1.7 (1.1,2.2) 31/9.8 3.1 (2.1,4.5) 0.6 (0.3,1.0) 17/6.9 2.5 (1.4,3.9) 0.3 (0.1,0.6) 
25-29 years 540,128 136/67.4 2.0 (1.7,2.4) 1.3 (0.8,1.7) 66/23.3 2.8 (2.2,3.6) 0.8 (0.5,1.1) 29/25.3 1.1 (0.8,1.6) 0.1 (-0.1,0.3) 
30-34 years 776,141 256/163.2 1.6 (1.4,1.8) 1.2 (0.8,1.6) 102/49.2 2.1 (1.7,2.5) 0.7 (0.4,0.9) 84/73.2 1.1 (0.9,1.4) 0.1 (-0.1,0.4) 
35-39 years 1,028,370 542/379.5 1.4 (1.3,1.6) 1.6 (1.1,2.0) 174/104.9 1.7 (1.4,1.9) 0.7 (0.4,0.9) 249/188.0 1.3 (1.2,1.5) 0.6 (0.3,0.9) 
Treatment Era          
1970-1979 662,969 447/313.7 1.4 (1.3,1.6) 2.0 (1.4,2.6) 146/84.1 1.7 (1.5,2.0) 0.9 (0.6,1.3) 205/160.9 1.3 (1.1,1.5) 0.7 (0.2,1.1) 
1980-1989 1,051,484 412/231.5 1.8 (1.6,2.0) 1.7 (1.3,2.1) 157/70.2 2.2 (1.9,2.6) 0.8 (0.6,1.1) 146/105.4 1.4 (1.2,1.6) 0.4 (0.2,0.6) 
1990-1999 849,407 169/81.6 2.1 (1.8,2.4) 1.0 (0.7,1.3) 68/30.1 2.3 (1.8,2.9) 0.4 (0.3,0.6) 33/25.4 1.3 (0.9,1.8) 0.1 (-0.0,0.2) 
2000-2006 304,018 39/16.4 2.4 (1.7,3.2) 0.7 (0.3,1.1) 19/6.7 2.8 (1.7,4.4) 0.4 (0.1,0.7) 4/3.3 1.2 (0.3,3.1) 0.0 (-0.1,0.2) 
Years Follow-Up 
 
         
5-9 years 927,451 159/52.6 3.0 (2.6,3.5) 1.1 (0.9,1.4) 86/24.4 3.5 (2.8,4.3) 0.7 (0.5,0.9) 18/9.0 2.0 (1.2,3.2) 0.1 (0.0,0.2) 
10-19 years 1,213,840 277/151.9 1.8 (1.6,2.1) 1.0 (0.8,1.3) 121/57.7 2.1 (1.7,2.5) 0.5 (0.3,0.7) 73/50.4 1.4 (1.1,1.8) 0.2 (0.0,0.3) 
20-29 years 566,854 381/235.4 1.6 (1.5,1.8) 2.6 (1.9,3.2) 114/63.9 1.8 (1.5,2.1) 0.9 (0.5,1.3) 162/120.6 1.3 (1.1,1.6) 0.7 (0.3,1.2) 
30-39 years 154,612 241/188.6 1.3 (1.1,1.4) 3.4 (1.4,5.4) 67/41.5 1.6 (1.3,2.0) 1.6 (0.6,2.7) 130/107.2 1.2 (1.0,1.4) 1.5 (0.0,2.9) 
40+ years 5,122 9/14.7 0.6 (0.3,1.2) -11.0 (-22.5,0.4) 2/3.6 0.6 (0.1,2.0) -3.1 (-8.5,2.3) 5/7.8 0.6 (0.2,1.5) -5.5 (-14.0,3.1) 
Attained Age 
 
         
20-29 years 125,623 20/2.5 7.9 (4.8,12.2) 1.4 (0.7,2.1) 8/1.2 6.7 (2.9,13.2) 0.5 (0.1,1.0) 2/0.1 16.2 (2.0,58.7) 0.1 (-0.1,0.4) 
30-39 years 584,866 103/21.7 4.7 (3.9,5.8) 1.4 (1.1,1.7) 54/11.5 4.7 (3.5,6.1) 0.7 (0.5,1.0) 7/1.7 4.1 (1.7,8.5) 0.1 (0.0,0.2) 
40-49 years 1,197,156 227/101.6 2.2 (2.0,2.5) 1.0 (0.8,1.3) 113/45.4 2.5 (2.1,3.0) 0.6 (0.4,0.7) 38/21.6 1.8 (1.2,2.4) 0.1 (0.0,0.2) 
50-59 years 684,634 314/186.6 1.7 (1.5,1.9) 1.9 (1.4,2.4) 112/58.2 1.9 (1.6,2.3) 0.8 (0.5,1.1) 120/82.3 1.5 (1.2,1.7) 0.5 (0.2,0.9) 
60-69 years 240,185 305/225.4 1.4 (1.2,1.5) 3.3 (1.9,4.7) 78/50.5 1.5 (1.2,1.9) 1.1 (0.4,1.9) 161/130.7 1.2 (1.0,1.4) 1.3 (0.2,2.3) 
70+ years 35,414 98/105.5 0.9 (0.8,1.1) -2.1 (-7.6,3.4) 25/24.3 1.0 (0.7,1.5) 0.2 (-2.6,3.0) 60/58.6 1.0 (0.8,1.3) 0.4 (-3.9,4.7) 
Table 7.7:  Standardized mortality ratios and absolute excess risks per 10,000 person-years for all, pneumonia, and chronic lower respiratory mortality, by potential explanatory factors, for the Teenage 
and Young Adult Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, AER: absolute 






  Fibrosis Pneumonitis Other Respiratory 
 
Person-Years O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) O/E SMR (95%CI) AER (95%CI) 
Overall 2,867,878 74/42.7 1.7 (1.4,2.2) 0.1 (0.1,0.2) 48/22.5 2.1 (1.6,2.8) 0.1 (0.0,0.1) 167/91.9 1.8 (1.6,2.1) 0.3 (0.2,0.4) 
Sex 
 
         
Male 1,096,504 29/20.7 1.4 (0.9,2.0) 0.1 (-0.0,0.2) 28/10.3 2.7 (1.8,3.9) 0.2 (0.1,0.3) 85/36.1 2.4 (1.9,2.9) 0.4 (0.3,0.6) 
Female 1,771,374 45/22.0 2.0 (1.5,2.7) 0.1 (0.1,0.2) 20/12.2 1.6 (1.0,2.5) 0.0 (-0.0,0.1) 82/55.8 1.5 (1.2,1.8) 0.1 (0.0,0.2) 
First Primary Neoplasm Type 
 
         
Breast 444,041 8/7.0 1.2 (0.5,2.3) 0.0 (-0.1,0.1) 4/3.6 1.1 (0.3,2.8) 0.0 (-0.1,0.1) 23/16.6 1.4 (0.9,2.1) 0.1 (-0.1,0.4) 
Testicular 358,212 9/6.1 1.5 (0.7,2.8) 0.1 (-0.1,0.2) 3/3.2 0.9 (0.2,2.7) -0.0 (-0.1,0.1) 15/11.2 1.3 (0.8,2.2) 0.1 (-0.1,0.3) 
Cervix 384,507 7/5.0 1.4 (0.6,2.9) 0.1 (-0.1,0.2) 2/2.8 0.7 (0.1,2.6) -0.0 (-0.1,0.1) 12/12.5 1.0 (0.5,1.7) -0.0 (-0.2,0.2) 
Melanoma 295,141 2/3.7 0.5 (0.1,2.0) -0.1 (-0.2,0.0) 2/2.1 0.9 (0.1,3.4) -0.0 (-0.1,0.1) 3/8.5 0.4 (0.1,1.0) -0.2 (-0.3,-0.1) 
Hodgkin Lymphoma 270,034 19/2.8 6.7 (4.0,10.4) 0.6 (0.3,0.9) 3/1.6 1.8 (0.4,5.4) 0.1 (-0.1,0.2) 33/6.7 4.9 (3.4,6.9) 1.0 (0.6,1.4) 
CNS (excluding PNET) 227,447 3/2.8 1.1 (0.2,3.2) 0.0 (-0.1,0.2) 19/1.5 12.3 (7.4,19.2) 0.8 (0.4,1.1) 26/6.3 4.2 (2.7,6.1) 0.9 (0.4,1.3) 
Non-Hodgkin Lymphoma 124,611 4/1.8 2.2 (0.6,5.5) 0.2 (-0.1,0.5) 3/1.0 3.1 (0.6,9.0) 0.2 (-0.1,0.4) 20/3.7 5.3 (3.3,8.2) 1.3 (0.6,2.0) 
Thyroid 111,952 0/1.3 0 -0.1 (-0.1,-0.1) 0/0.7 0 -0.1 (-0.1,-0.1) 3/3.1 1.0 (0.2,2.8) -0.0 (-0.3,0.3) 
Gastrointestinal 102,795 3/2.4 1.2 (0.3,3.6) 0.1 (-0.3,0.4) 0/1.1 0 -0.1 (-0.1,-0.1) 7/4.3 1.6 (0.7,3.4) 0.3 (-0.2,0.8) 
Soft Tissue Sarcoma 92,295 1/1.4 0.7 (0.0,4.0) -0.0 (-0.3,0.2) 1/0.7 1.4 (0.0,7.7) 0.0 (-0.2,0.2) 2/2.9 0.7 (0.1,2.5) -0.1 (-0.4,0.2) 
Ovary 80,825 0/1.1 0 -0.1 (-0.1,-0.1) 0/0.6 0 -0.1 (-0.1,-0.1) 3/2.6 1.2 (0.2,3.4) 0.0 (-0.4,0.5) 
Bladder 83,660 3/2.6 1.2 (0.2,3.4) 0.1 (-0.4,0.5) 0/1.1 0 -0.1 (-0.1,-0.1) 1/3.8 0.3 (0.0,1.5) -0.3 (-0.6,-0.1) 
Other Genitourinary 68,726 4/1.4 2.8 (0.8,7.1) 0.4 (-0.2,0.9) 1/0.7 1.5 (0.0,8.1) 0.0 (-0.2,0.3) 3/2.8 1.1 (0.2,3.1) 0.0 (-0.5,0.5) 
Head & Neck 57,915 1/1.2 0.8 (0.0,4.5) -0.0 (-0.4,0.3) 5/0.6 8.8 (2.9,20.6) 0.8 (0.0,1.5) 3/2.1 1.4 (0.3,4.1) 0.1 (-0.4,0.7) 
Leukemia (excluding AML) 39,610 4/0.3 12.1 (3.3,31.0) 0.9 (-0.1,1.9) 3/0.2 13.7 (2.8,39.9) 0.7 (-0.2,1.6) 3/0.9 3.4 (0.7,10.0) 0.5 (-0.3,1.4) 
Other 48,857 1/0.8 1.2 (0.0,6.9) 0.0 (-0.4,0.4) 1/0.4 2.5 (0.1,14.0) 0.1 (-0.3,0.5) 2/1.6 1.2 (0.2,4.5) 0.1 (-0.5,0.6) 
Bone Tumor 33,461 1/0.3 3.3 (0.1,18.3) 0.2 (-0.4,0.8) 1/0.2 5.4 (0.1,30.0) 0.2 (-0.3,0.8) 0/0.8 0 -0.2 (-0.2,-0.2) 
Acute Myeloid Leukemia 20,536 3/0.1 24.1 (5.0,70.6) 1.4 (-0.3,3.1) 0/0.1 0 -0.0 (-0.0,-0.0) 5/0.4 12.6 (4.1,29.3) 2.2 (0.1,4.4) 
Lung 19,281 1/0.5 1.8 (0.0,10.2) 0.2 (-0.8,1.3) 0/0.2 0 -0.1 (-0.1,-0.1) 3/0.9 3.5 (0.7,10.1) 1.1 (-0.7,2.9) 
CNS PNET 3,973 0/0.0 0 -0.1 (-0.1,-0.1) 0/0.0 0 -0.0 (-0.0,-0.0) 0/0.1 0 -0.2 (-0.2,-0.2) 
Age at Diagnosis 
 
         
15-19 years 192,725 8/0.4 21.5 (9.3,42.3) 0.4 (0.1,0.7) 4/0.5 8.4 (2.3,21.4) 0.2 (-0.0,0.4) 15/2.4 6.3 (3.5,10.4) 0.7 (0.3,1.0) 
20-24 years 330,513 9/1.3 7.1 (3.2,13.4) 0.2 (0.1,0.4) 7/1.2 5.9 (2.4,12.1) 0.2 (0.0,0.3) 16/5.3 3.0 (1.7,4.9) 0.3 (0.1,0.6) 
25-29 years 540,128 7/4.0 1.7 (0.7,3.6) 0.1 (-0.0,0.2) 8/2.8 2.8 (1.2,5.5) 0.1 (-0.0,0.2) 26/11.8 2.2 (1.4,3.2) 0.3 (0.1,0.4) 
30-34 years 776,141 21/10.8 1.9 (1.2,3.0) 0.1 (0.0,0.2) 10/6.0 1.7 (0.8,3.1) 0.1 (-0.0,0.1) 39/24.0 1.6 (1.2,2.2) 0.2 (0.0,0.4) 
35-39 years 1,028,370 29/26.2 1.1 (0.7,1.6) 0.0 (-0.1,0.1) 19/12.0 1.6 (1.0,2.5) 0.1 (-0.0,0.2) 71/48.3 1.5 (1.1,1.9) 0.2 (0.1,0.4) 
Treatment Era          
1970-1979 662,969 28/22.5 1.2 (0.8,1.8) 0.1 (-0.1,0.2) 22/8.6 2.6 (1.6,3.9) 0.2 (0.1,0.3) 46/37.6 1.2 (0.9,1.6) 0.1 (-0.1,0.3) 
1980-1989 1,051,484 27/14.7 1.8 (1.2,2.7) 0.1 (0.0,0.2) 14/8.2 1.7 (0.9,2.9) 0.1 (-0.0,0.1) 68/33.1 2.1 (1.6,2.6) 0.3 (0.2,0.5) 
1990-1999 849,407 17/4.7 3.6 (2.1,5.8) 0.1 (0.0,0.2) 9/4.5 2.0 (0.9,3.8) 0.1 (-0.0,0.1) 42/16.9 2.5 (1.8,3.4) 0.3 (0.1,0.4) 
2000-2006 304,018 2/0.9 2.3 (0.3,8.5) 0.0 (-0.1,0.1) 3/1.2 2.6 (0.5,7.5) 0.1 (-0.1,0.2) 11/4.3 2.5 (1.3,4.5) 0.2 (0.0,0.4) 
Years Follow-Up 
 
         
5-9 years 927,451 9/2.0 4.6 (2.1,8.6) 0.1 (0.0,0.1) 8/2.2 3.6 (1.6,7.2) 0.1 (0.0,0.1) 38/15.0 2.5 (1.8,3.5) 0.2 (0.1,0.4) 
10-19 years 1,213,840 20/7.5 2.7 (1.6,4.1) 0.1 (0.0,0.2) 8/5.9 1.4 (0.6,2.7) 0.0 (-0.0,0.1) 55/30.4 1.8 (1.4,2.4) 0.2 (0.1,0.3) 
20-29 years 566,854 32/15.5 2.1 (1.4,2.9) 0.3 (0.1,0.5) 22/7.7 2.9 (1.8,4.3) 0.3 (0.1,0.4) 51/27.7 1.8 (1.4,2.4) 0.4 (0.2,0.7) 
30-39 years 154,612 13/16.3 0.8 (0.4,1.4) -0.2 (-0.7,0.2) 10/6.2 1.6 (0.8,3.0) 0.2 (-0.2,0.6) 21/17.4 1.2 (0.7,1.8) 0.2 (-0.3,0.8) 
40+ years 5,122 0/1.4 0 -2.7 (-2.7,-2.7) 0/0.5 0 -1.0 (-1.0,-1.0) 2/1.3 1.5 (0.2,5.4) 1.3 (-4.1,6.7) 
Attained Age 
 
         
20-29 years 125,623 2/0.1 39.2 (4.7,141.5) 0.2 (-0.1,0.4) 1/0.1 8.1 (0.2,45.3) 0.1 (-0.1,0.2) 7/1.0 6.7 (2.7,13.8) 0.5 (0.1,0.9) 
30-39 years 584,866 14/0.6 22.4 (12.3,37.6) 0.2 (0.1,0.4) 7/1.0 6.8 (2.7,14.1) 0.1 (0.0,0.2) 21/6.8 3.1 (1.9,4.7) 0.2 (0.1,0.4) 
40-49 years 1,197,156 13/4.4 2.9 (1.6,5.0) 0.1 (0.0,0.1) 12/4.5 2.7 (1.4,4.7) 0.1 (0.0,0.1) 51/25.7 2.0 (1.5,2.6) 0.2 (0.1,0.3) 
50-59 years 684,634 23/10.9 2.1 (1.3,3.2) 0.2 (0.0,0.3) 9/6.9 1.3 (0.6,2.5) 0.0 (-0.1,0.1) 50/28.3 1.8 (1.3,2.3) 0.3 (0.1,0.5) 
60-69 years 240,185 16/17.0 0.9 (0.5,1.5) -0.0 (-0.4,0.3) 16/6.7 2.4 (1.4,3.9) 0.4 (0.1,0.7) 34/20.5 1.7 (1.2,2.3) 0.6 (0.1,1.0) 
70+ years 35,414 6/9.6 0.6 (0.2,1.4) -1.0 (-2.4,0.3) 3/3.4 0.9 (0.2,2.6) -0.1 (-1.1,0.9) 4/9.6 0.4 (0.1,1.1) -1.6 (-2.7,-0.5) 
Table 7.7 (continued):  Standardized mortality ratios and absolute excess risks per 10,000 person-years for fibrosis, pneumonitis, and other respiratory mortality, by potential explanatory factors, for the 
Teenage and Young Adult Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, SMR: standardized mortality ratio, AER: absolute 


































      
      
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 1.1 (1.0,1.3) 0.8 (0.6,1.0) 1.1 (0.9,1.5) 0.6 (0.4,0.9) 1.2 (0.9,1.6) 0.8 (0.4,1.5) 2.7 (1.5,4.9) 3.3 (1.4,8.2) 0.8 
(0.4,1.6) 
0.5 (0.2,1.3) 0.8 (0.5,1.2) 0.7 (0.4,1.2) 
Pheterogeneity 0.1452 0.0457 0.2903 0.0121 0.2830 0.4700 0.0006 0.0032 .5950 0.1499 0.2592 0.1455 
First Primary Neoplasm Type             
Breast 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Testicular 1.0 (0.8,1.4) 0.6 (0.2,2.7) 0.9 (0.5,1.5) 0.2 (0.0,4.3) 1.4 (0.8,2.3) NA 2.8 (0.9,8.9) NA 0.6 
(0.1,3.0) 
0.2 (0.0,91528.9) 0.7 (0.3,1.4) 0.5 (0.1,5.2) 
Cervix 1.5 (1.2,1.9) 2.3 (1.0,5.5) 1.2 (0.8,1.9) 1.3 (0.5,3.3) 2.2 (1.6,3.1) NA 1.1 (0.4,3.0) 0.9 (0.0,31.3) 0.6 
(0.1,3.4) 
1.0 (0.0,56.0) 0.7 (0.3,1.3) NA 
Melanoma 0.4 (0.2,0.6) NA 0.2 (0.1,0.5) NA 0.6 (0.3,1.0) NA 0.5 (0.1,2.4) 1.2 (0.0,44.4) 0.7 
(0.1,3.9) 
NA 0.2 (0.1,0.7) NA 
Hodgkin Lymphoma 2.3 (1.7,3.0) 6.5 (2.9,14.5) 1.7 (1.1,2.7) 2.3 (0.9,5.8) 2.4 (1.5,3.8) NA 6.2 (2.5,15.7) 20.5 (1.0,415.4) 0.9 
(0.2,4.7) 
0.7 (0.0,110.5) 2.5 (1.3,4.6) 5.9 (1.4,24.5) 
CNS (excluding PNET) 2.4 (1.9,3.2) 7.5 (3.4,16.4) 3.2 (2.1,4.8) 5.5 (2.4,12.3) 1.1 (0.6,1.9) NA 1.1 (0.3,4.1) 2.7 (0.1,72.5) 7.8 
(2.4,25.4) 
21.0 (0.7,599.8) 2.2 (1.2,4.1) 5.2 (1.3,21.1) 
Non-Hodgkin Lymphoma 2.3 (1.7,3.1) 6.7 (2.9,15.5) 2.5 (1.5,4.2) 4.4 (1.8,10.5) 1.5 (0.8,2.7) NA 2.8 (0.8,9.7) 5.4 (0.2,174.9) 2.0 
(0.4,9.7) 
3.5 (0.1,172.6) 2.9 (1.5,5.6) 6.6 (1.5,27.9) 
Thyroid 0.5 (0.3,0.9) NA 0.4 (0.2,1.2) NA 0.7 (0.3,1.6) NA NA NA NA NA 0.6 (0.2,1.9) 0.3 (0.0,225.8) 
Gastrointestinal 1.3 (0.9,1.8) 2.0 (0.6,6.2) 1.4 (0.8,2.5) 1.1 (0.3,4.8) 1.4 (0.8,2.4) NA 1.8 (0.5,7.0) NA NA NA 1.1 (0.4,2.6) 1.8 (0.3,12.4) 
Soft Tissue Sarcoma 1.2 (0.8,1.8) 2.0 (0.6,6.4) 1.5 (0.8,2.8) 2.2 (0.7,6.7) 1.5 (0.8,2.9) NA 0.8 (0.1,6.5) 3.3 (0.1,120.3) 0.9 
(0.1,8.2) 
NA 0.4 (0.1,1.7) NA 
Ovary 1.0 (0.6,1.6) 1.8 (0.5,6.4) 1.7 (0.9,3.1) 2.5 (0.8,8.2) 0.8 (0.4,1.8) NA NA NA NA NA 0.8 (0.2,2.6) 0.6 (0.0,78.2) 
Bladder 0.8 (0.5,1.3) NA 0.8 (0.4,1.7) NA 1.1 (0.6,2.1) NA 2.3 (0.6,9.4) 8.3 (0.2,280.8) NA NA 0.2 (0.0,1.3) NA 
Other Genitourinary 1.5 (1.0,2.2) 3.7 (1.4,10.0) 1.6 (0.9,3.1) 2.4 (0.8,7.6) 1.5 (0.8,2.7) NA 3.4 (1.0,11.5) 8.4 (0.3,268.3) 1.2 
(0.1,10.6) 
NA 0.7 (0.2,2.4) NA 
Head & Neck 2.3 (1.6,3.3) 7.2 (2.9,17.6) 2.6 (1.5,4.7) 4.3 (1.6,11.8) 2.5 (1.4,4.4) NA 1.2 (0.2,10.1) NA 6.1 
(1.5,24.8) 
14.8 (0.4,518.6) 0.8 (0.2,2.9) 1.0 (0.0,29.5) 
Leukemia (excluding AML) 3.3 (2.1,5.1) 10.3 (4.1,25.5) 3.1 (1.5,6.5) 5.2 (1.7,15.9) 3.0 (1.3,7.1) NA 9.6 (2.7,34.1) 32.3 (1.4,757.6) 7.5 
(1.5,37.7) 
19.7 (0.6,700.8) 1.5 (0.4,5.4) 3.2 (0.4,23.7) 
Other 1.9 (1.3,2.9) 5.2 (1.9,14.3) 2.9 (1.6,5.4) 5.0 (1.8,14.2) 1.6 (0.8,3.5) NA 1.4 (0.2,11.2) 5.0 (0.1,212.3) 1.6 
(0.2,15.2) 
2.8 (0.0,330.1) 0.8 (0.2,3.3) 0.7 (0.0,116.0) 
Bone Tumor 1.6 (0.9,3.0) 3.5 (1.0,12.2) 3.1 (1.4,6.9) 5.7 (1.9,17.7) 0.5 (0.1,3.9) NA 2.7 (0.3,22.5) NA 2.6 
(0.3,26.0) 
5.6 (0.1,372.9) NA NA 
Acute Myeloid Leukemia 3.7 (2.0,6.7) 11.0 (4.0,30.1) 2.2 (0.7,7.3) 3.5 (0.7,17.1) 1.4 (0.2,10.0) NA 14.9 (3.8,59.4) 37.0 (1.4,976.2) NA NA 5.4 (2.0,14.9) 12.8 (2.5,64.1) 
Lung 4.0 (2.6,6.0) 15.3 (6.2,37.7) 3.6 (1.7,7.5) 6.5 (2.0,21.0) 5.6 (3.1,10.2) NA 3.3 (0.4,26.9) 17.7 (0.4,733.0) NA NA 2.3 (0.7,7.9) 4.0 (0.4,41.3) 
CNS PNET 4.3 (1.4,13.6) 14.2 (3.2,62.7) 10.5 (3.2,34.8) 20.8 (5.0,86.3) NA NA NA NA NA NA NA NA 
Pheterogeneity <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Age at Diagnosis             
15-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
20-24 years 0.8 (0.5,1.1) 1.0 (0.6,1.6) 1.1 (0.6,2.0) 1.7 (0.7,3.9) 0.6 (0.3,1.3) 0.7 (0.2,2.1) 0.6 (0.2,1.7) 0.7 (0.3,2.0) 1.2 
(0.3,4.5) 
1.2 (0.3,6.0) 0.6 (0.3,1.2) 0.6 (0.2,1.5) 
25-29 years 0.6 (0.4,0.9) 0.8 (0.5,1.3) 1.3 (0.7,2.4) 2.2 (0.9,5.2) 0.3 (0.1,0.7) 0.1 (0.0,1.3) 0.3 (0.1,0.9) 0.3 (0.1,1.2) 0.8 
(0.2,3.0) 
0.8 (0.1,4.0) 0.5 (0.2,1.1) 0.5 (0.2,1.3) 
30-34 years 0.6 (0.4,0.9) 0.9 (0.5,1.5) 1.2 (0.7,2.3) 2.5 (1.0,6.1) 0.4 (0.2,0.8) 0.3 (0.1,1.1) 0.6 (0.2,1.6) 0.6 (0.2,2.2) 0.6 
(0.2,2.5) 
0.4 (0.1,2.5) 0.4 (0.2,0.9) 0.4 (0.2,1.3) 
35-39 years 0.7 (0.5,1.0) 1.2 (0.7,2.0) 1.2 (0.6,2.2) 2.9 (1.2,7.2) 0.5 (0.2,1.0) 0.9 (0.3,2.7) 0.5 (0.2,1.4) 0.3 (0.1,1.4) 0.8 
(0.2,3.2) 
0.4 (0.1,2.1) 0.4 (0.2,0.9) 0.5 (0.2,1.3) 
Ptrend 0.2554 0.3826 0.8123 0.0144 0.5776 0.2869 0.3906 0.1296 .5533 0.0984 0.0571 0.2331 
Treatment Era             
1971-1979 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1980-1989 1.0 (0.9,1.2) 1.0 (0.7,1.3) 1.0 (0.8,1.3) 1.1 (0.7,1.7) 0.9 (0.7,1.2) 0.6 (0.3,1.0) 0.9 (0.5,1.7) 1.0 (0.4,2.5) 0.5 
(0.2,1.0) 
0.5 (0.2,1.4) 1.5 (1.0,2.2) 2.1 (0.9,4.8) 
1990-1999 1.0 (0.8,1.2) 0.8 (0.6,1.1) 0.9 (0.6,1.2) 0.6 (0.4,1.0) 0.8 (0.5,1.1) 0.4 (0.2,0.9) 1.0 (0.5,2.0) 1.4 (0.5,3.8) 0.4 
(0.1,1.1) 
0.8 (0.2,2.6) 1.9 (1.1,3.0) 2.4 (0.9,6.1) 
2000-2006 0.9 (0.7,1.4) 0.6 (0.3,1.0) 1.0 (0.6,1.6) 0.5 (0.2,1.0) 0.6 (0.2,1.6) 0.1 (0.0,5.4) 0.4 (0.1,2.0) 0.4 (0.0,3.8) 0.4 
(0.1,1.7) 
0.9 (0.1,5.2) 1.9 (0.9,4.1) 2.4 (0.8,7.9) 
Ptrend 0.7131 0.0258 0.5202 00115 0.1483 0.0040 0.5136 0.9868 .076  0.6839 0.0126 0.0933 
Attained Age             
20-29 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
30-39 years 0.9 (0.5,1.5) 1.4 (0.8,2.5) 0.7 (0.3,1.6) 1.1 (0.4,2.8) 0.5 (0.1,2.4) 1.1 (0.2,7.4) 1.1 (0.2,5.2) 2.9 (0.6,14.1) 1.3 
(0.1,11.5) 
2.7 (0.3,27.6) 0.8 (0.3,2.1) 1.0 (0.4,3.0) 
40-49 years 0.5 (0.3,0.8) 1.3 (0.7,2.4) 0.4 (0.2,0.9) 0.8 (0.3,2.3) 0.2 (0.0,1.0) 2.2 (0.4,12.8) 0.2 (0.0,1.0) 1.7 (0.3,9.9) 0.6 
(0.1,5.9) 
3.3 (0.3,38.2) 0.8 (0.3,2.0) 1.6 (0.5,5.0) 
50-59 years 0.4 (0.2,0.6) 2.2 (1.1,4.2) 0.3 (0.1,0.7) 1.0 (0.4,3.0) 0.2 (0.0,0.8) 8.6 (1.5,49.5) 0.1 (0.0,0.7) 4.6 (0.7,28.9) 0.3 
(0.0,3.1) 
4.6 (0.3,61.4) 0.9 (0.3,2.3) 3.4 (1.0,12.3) 
60-69 years 0.3 (0.2,0.5) 3.8 (1.8,8.0) 0.2 (0.1,0.6) 1.5 (0.5,4.6) 0.1 (0.0,0.6) 11.9 (1.8,76.6) 0.1 (0.0,0.4) 2.4 (0.1,51.9) .5 
(0.0,5.4) 
27.6 (2.0,388.4) 1.0 (0.3,2.9) 6.2 (1.3,29.2) 
70+ years 0.2 (0.1,0.4) NA 0.2 (0.1,0.4) 0.4 (0.0,58.5) 0.1 (0.0,0.5) 8.2 (0.4,162.8) 0.0 (0.0,0.3) NA .1 
(0.0,2.2) 
19.2 (0.3,1157.9) 0.3 (0.1,1.4) NA 
Ptrend <0.0001 0.0002 <0.0001 0.4897 0.0002 <0.0001 <0.0001 0.3456 . 488 0.3021 0.7295 0.0082 
Table 7.8:  Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a multivariate model, adjusting for sex, first primary neoplasm type, age 
at diagnosis, treatment era, and attained age, for the Teenage and Young Adult Cancer Survivor Study 
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, RR: relative risks, SMR: standardized mortality ratio, 

































      
      
Male 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Female 0.9 (0.8,1.0) 0.6 (0.5,0.9) 0.9 (0.8,1.1) 0.7 (0.5,0.9) 1.0 (0.8,1.3) 1.2 (0.5,2.9) 1.5 (0.9,2.3) 1.7 (0.4,6.8) 0.6 (0.3,1.1) 0.3 (0.1,1.0) 0.6 (0.5,0.9) 0.3 (0.2,0.7) 
Pheterogeneity 0.0476 0.0055 0.3039 0.0154 0.7236 0.7054 0.1122 0.3973 0.0769 0.0208 0.0024 0.0016 
First Primary Neoplasm Type          
Breast 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Testicular 1.1 (0.8,1.4) 1.3 (0.2,7.2) 0.9 (0.6,1.5) NA 1.2 (0.8,1.8) NA 1.3 (0.5,3.3) NA 0.8 (0.2,3.8) NA 1.0 (0.5,1.9) 0.7 (0.1,8.8) 
Cervix 1.6 (1.2,2.0) 4.5 (1.1,17.7) 1.4 (0.9,2.1) NA 2.2 (1.6,3.1) NA 1.2 (0.4,3.4) NA 0.7 (0.1,3.6) NA 0.7 (0.3,1.4) NA 
Melanoma 0.4 (0.2,0.6) NA 0.2 (0.1,0.5) NA 0.5 (0.3,1.0) NA 0.5 (0.1,2.2) NA 0.9 (0.2,4.7) NA 0.3 (0.1,0.8) NA 
Hodgkin Lymphoma 2.7 (2.2,3.5) 8.7 (2.3,33.7) 2.0 (1.3,3.1) NA 2.4 (1.6,3.6) NA 5.8 (2.5,13.2) NA 1.7 (0.4,7.5) NA 3.5 (2.1,6.0) 6.8 (1.5,31.4) 
CNS (excluding PNET) 2.7 (2.1,3.5) 10.0 (2.6,38.4) 3.5 (2.4,5.2) NA 1.0 (0.6,1.8) NA 0.9 (0.2,3.5) NA 11.2 (3.8,32.9) NA 3.0 (1.7,5.3) 6.0 (1.3,28.7) 
Non-Hodgkin Lymphoma 2.4 (1.8,3.2) 9.5 (2.4,37.8) 2.7 (1.7,4.3) NA 1.4 (0.8,2.5) NA 1.9 (0.6,6.3) NA 2.8 (0.6,12.5) NA 3.9 (2.1,7.0) 9.1 (1.9,43.6) 
Thyroid 0.5 (0.3,1.0) NA 0.5 (0.2,1.3) NA 0.7 (0.3,1.5) NA NA NA NA NA 0.7 (0.2,2.3) NA 
Gastrointestinal 1.2 (0.9,1.7) 3.4 (0.7,17.9) 1.3 (0.7,2.3) NA 1.3 (0.8,2.2) NA 1.1 (0.3,4.0) NA NA NA 1.2 (0.5,2.8) 1.8 (0.2,20.5) 
Soft Tissue Sarcoma 1.3 (0.9,1.9) 2.7 (0.5,15.3) 1.5 (0.8,2.9) NA 1.5 (0.8,2.7) NA 0.6 (0.1,5.0) NA 1.3 (0.1,11.2) NA 0.5 (0.1,2.1) NA 
Ovary 1.1 (0.7,1.7) 1.3 (0.1,18.4) 1.8 (0.9,3.3) NA 0.8 (0.4,1.8) NA NA NA NA NA 0.8 (0.2,2.8) 0.3 (0.0,2167.8) 
Bladder 0.7 (0.5,1.1) NA 0.7 (0.4,1.5) NA 1.0 (0.5,1.7) NA 1.0 (0.3,3.9) NA NA NA 0.2 (0.0,1.4) NA 
Other Genitourinary 1.4 (1.0,2.1) 5.2 (1.1,24.9) 1.6 (0.9,2.9) NA 1.4 (0.8,2.5) NA 2.4 (0.7,8.0) NA 1.3 (0.1,11.9) NA 0.8 (0.2,2.6) NA 
Head & Neck 2.2 (1.6,3.2) 11.5 (2.8,47.2) 2.6 (1.5,4.5) NA 2.2 (1.3,3.8) NA 0.7 (0.1,5.7) NA 8.0 (2.2,29.9) NA 1.0 (0.3,3.4) 1.0 (0.0,71.8) 
Leukemia (excluding AML) 4.2 (2.7,6.4) 12.9 (3.1,53.3) 3.7 (1.8,7.6) NA 3.1 (1.4,7.3) NA 10.5 (3.2,34.9) NA 12.4 (2.8,55.5) NA 2.5 (0.7,8.2) 3.7 (0.4,32.8) 
Other 2.0 (1.3,3.0) 7.7 (1.7,34.2) 3.0 (1.7,5.5) NA 1.6 (0.7,3.3) NA 1.1 (0.1,8.7) NA 2.3 (0.3,20.5) NA 0.9 (0.2,3.8) 0.6 (0.0,816.8) 
Bone Tumor 2.1 (1.1,3.9) 4.9 (0.9,26.3) 3.8 (1.8,8.0) NA 0.6 (0.1,4.2) NA 2.8 (0.4,22.8) NA 4.9 (0.5,43.8) NA NA NA 
Acute Myeloid Leukemia 5.0 (2.7,8.9) 12.5 (2.8,55.5) 2.9 (0.9,9.3) NA 1.4 (0.2,10.3) NA 21.0 (5.6,79.1) NA NA NA 9.1 (3.5,23.9) 15.6 (2.7,90.2) 
Lung 3.6 (2.4,5.4) 29.5 (7.2,121.1) 3.3 (1.6,6.7) NA 5.0 (2.9,8.7) NA 1.6 (0.2,12.7) NA NA NA 2.5 (0.8,8.3) 7.7 (0.9,67.4) 
CNS PNET 6.0 (1.9,18.7) 16.7 (2.6,108.8) 13.7 
(4.2,44.0) 
NA NA NA NA NA NA NA NA NA 
Pheterogeneity <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Age at Diagnosis             
15-19 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
20-24 years 0.5 (0.4,0.8) 0.7 (0.5,1.1) 0.7 (0.4,1.3) 0.9 (0.4,2.1) 0.4 (0.2,1.0) 0.8 (0.3,2.5) 0.3 (0.1,0.9) 0.6 (0.2,1.7) 0.7 (0.2,2.4) 1.0 (0.2,4.0) 0.5 (0.2,1.0) 0.5 (0.2,1.3) 
25-29 years 0.3 (0.2,0.5) 0.6 (0.3,0.9) 0.6 (0.4,1.1) 1.2 (0.6,2.4) 0.2 (0.1,0.4) 0.2 (0.0,3.4) 0.1 (0.0,0.2) 0.1 (0.0,0.9) 0.3 (0.1,1.1) 0.5 (0.1,2.5) 0.3 (0.2,0.7) 0.4 (0.2,1.0) 
30-34 years 0.3 (0.2,0.3) 0.5 (0.3,0.8) 0.5 (0.3,0.8) 1.0 (0.5,2.0) 0.2 (0.1,0.4) 0.4 (0.1,2.3) 0.1 (0.0,0.2) 0.3 (0.1,1.0) 0.2 (0.1,0.6) 0.3 (0.0,1.9) 0.3 (0.1,0.5) 0.3 (0.1,0.8) 
35-39 years 0.2 (0.2,0.3) 0.7 (0.4,1.1) 0.4 (0.2,0.6) 1.0 (0.5,2.0) 0.2 (0.1,0.5) 1.5 (0.6,4.0) 0.1 (0.0,0.1) 0.1 (0.0,3.2) 0.2 (0.1,0.6) 0.4 (0.1,1.9) 0.2 (0.1,0.4) 0.3 (0.1,0.9) 
Ptrend <0.0001 0.0527 <0.0001 0.9467 0.0482 0.7007 <0.0001 0.0016 0.0005 0.0819 0.0001 0.0169 
Treatment Era             
1971-1979 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
1980-1989 1.2 (1.1,1.4) 0.9 (0.6,1.2) 1.3 (1.0,1.6) 0.9 (0.5,1.4) 1.1 (0.9,1.3) 0.6 (0.2,1.4) 1.5 (0.9,2.5) 1.4 (0.2,11.2) 0.7 (0.3,1.3) 0.3 (0.1,1.2) 1.0 (1.0,1.0) 1.0 (1.0,1.0) 
1990-1999 1.5 (1.2,1.7) 0.5 (0.3,0.8) 1.3 (1.0,1.7) 0.5 (0.3,0.8) 1.0 (0.7,1.5) 0.1 (0.0,0.7) 2.9 (1.6,5.3) 1.8 (0.2,13.0) 0.8 (0.4,1.7) 0.3 (0.1,1.1) 1.7 (1.2,2.4) 2.6 (0.5,13.4) 
2000-2006 1.7 (1.2,2.3) 0.4 (0.2,0.7) 1.6 (1.0,2.6) 0.4 (0.2,1.0) 0.9 (0.3,2.5) 0.0 (0.0,13.5) 1.9 (0.4,7.9) 0.5 (0.0,9.8) 1.0 (0.3,3.3) 0.3 (0.0,2.2) 2.0 (1.3,3.1) 2.3 (0.4,12.1) 
Ptrend <0.0001 <0.0001 0.0103 0.0020 0.6922 0.0003 0.0023 0.7621 0.5919 0.0619 0.0006 0.7202 
Attained Age             
20-29 years 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
30-39 years 0.6 (0.4,1.0) 1.0 (0.6,1.7) 0.7 (0.3,1.5) 1.3 (0.6,3.2) 0.3 (0.1,1.2) 0.6 (0.1,3.6) 0.6 (0.1,2.5) 1.5 (0.3,6.8) 0.8 (0.1,6.8) 1.5 (0.1,16.1) 0.5 (0.2,1.1) 0.5 (0.2,1.5) 
40-49 years 0.3 (0.2,0.4) 0.8 (0.4,1.3) 0.4 (0.2,0.8) 1.0 (0.4,2.5) 0.1 (0.0,0.4) 0.9 (0.2,4.8) 0.1 (0.0,0.3) 0.5 (0.1,2.4) 0.3 (0.0,2.5) 0.9 (0.1,10.0) 0.3 (0.1,0.7) 0.4 (0.2,1.3) 
50-59 years 0.2 (0.1,0.3) 1.3 (0.8,2.4) 0.3 (0.1,0.6) 1.4 (0.6,3.6) 0.1 (0.0,0.4) 3.7 (0.8,17.9) 0.1 (0.0,0.2) 1.1 (0.2,5.8) 0.2 (0.0,1.3) 0.4 (0.0,15.5) 0.3 (0.1,0.6) 0.7 (0.2,2.0) 
60-69 years 0.2 (0.1,0.3) 2.4 (1.2,4.6) 0.2 (0.1,0.5) 2.1 (0.8,5.9) 0.1 (0.0,0.3) 8.4 (1.6,45.7) 0.0 (0.0,0.1) NA 0.3 (0.0,2.2) 5.6 (0.5,60.6) 0.2 (0.1,0.6) 1.2 (0.4,4.0) 
70+ years 0.1 (0.1,0.2) NA 0.2 (0.1,0.3) 0.4 (0.0,254852.3) 0.1 (0.0,0.3) 2.7 (0.0,119394.2) 0.0 (0.0,0.1) NA 0.1 (0.0,1.1) NA 0.1 (0.0,0.2) NA 
Ptrend <0.0001 0.1077 <0.0001 0.3523 0.0001 0.0024 <0.0001 0.1649 0.0078 0.7659 <0.0001 0.9770 
Table 7.9:  Relative risks of the standardized mortality ratio and excess mortality ratios per 10,000 person-years estimated using a univariate model, by potential explanatory factors, for the Teenage and 
Young Adult Cancer Survivor Study  
Abbreviations:  CNS: central nervous system, PNET: primitive neuroectodermal tumor, AML: acute myeloid leukemia, O: observed, E: expected, RR: relative risks, SMR: standardized mortality ratio, 
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Figure 7.1:  Cumulative mortality for respiratory deaths, by treatment era, for the British Childhood Cancer Survivor Study  
The table depicts the excess mortality ratio for respiratory deaths, by treatment era, which was calculated in a multivariate Poisson model adjusting for sex, age at diagnosis, first primary neoplasm type, 
and attained age 


















































Figure 7.2:  Cumulative mortality for respiratory deaths, by treatment era, for the Teenage and Young Adult Cancer Survivor Study  
The table depicts the excess mortality ratio for respiratory deaths, by treatment era, which was calculated in a multivariate Poisson model adjusting for sex, age at diagnosis, first primary neoplasm type, 
and attained age  



























20 25 30 35 40 45 50 55 60 65 70
Attained Age
O: 1971-1979 O: 1980-1989 O: 1990-1999 O: 2000-2006
E: 1971-1979 E: 1980-1989 E: 1990-1999 E: 2000-2006








Figure 7.3:  Cumulative mortality for respiratory deaths, by age at diagnosis 
The table depicts the risk ratio for the SMR and excess mortality ratio for respiratory deaths, by age at diagnosis, which was calculated in a multivariate Poisson model adjusting for sex, first primary 







1.  Stiller C. National Registry of Childhood Tumours Progress Report.; 2012. 
http://www.ncin.org.uk/publications/reports/. 
2.  Cancer Research UK. Teenage and young adult cancer survival statistics. 2015. 
http://www.cancerresearchuk.org/cancer-info/cancerstats/teenage-and-young-adult-
cancer/survival/. Accessed April 23, 2015. 
3.  Schwartz CL, Hobbie WL, Constine LS, Ruccione KS. Survivors of Childhood and Adolescent 
Cancer. 2nd ed. Springer-Verlag; 2005. 
4.  Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and 
adolescent cancer: A report from the Childhood Cancer Survivor Study. Cancer. 
2002;95(11):2431-2441. doi:10.1002/cncr.10978. 
5.  Hawkins MM, Lancashire ER, Winter DL, et al. The British Childhood Cancer Survivor Study: 
Objectives, methods, population structure, response rates and initial descriptive information. 
Pediatr Blood Cancer. 2008;50(5):1018-1025. doi:10.1002/pbc.21335. 




7.  Kroll ME, Murphy MFG, Carpenter LM, Stiller CA. Childhood cancer registration in Britain: 
capture-recapture estimates of completeness of ascertainment. Br J Cancer. 2011;104(7):1227-
1233. doi:10.1038/bjc.2011.70. 
8.  Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood 
cancer, third edition. Cancer. 2005;103(7):1457-1467. doi:10.1002/cncr.20910. 
9.  Office for National Statistics. Cancer Statistics Registrations, England, 2012 - Background Notes.; 
2012. 
10.  Birch JM, Alston RD, Kelsey AM, Quinn MJ, Babb P, McNally RJQ. Classification and incidence 
of cancers in adolescents and young adults in England 1979-1997. Br J Cancer. 2002;87(11):1267-
1274. doi:10.1038/sj.bjc.6600647. 
11.  Breslow NE, Day NE. Statistical methods in cancer research. Volume II--The design and analysis 
of cohort studies. IARC Sci Publ. 1987;(82):1-406. http://www.ncbi.nlm.nih.gov/pubmed/3329634. 
Accessed May 21, 2015. 
12.  Office for National Statistics. Mortality Statistics: Deaths Registered in England and Wales (Series 







13.  StatCorp. Stata 12.1. 
14.  Coviello V, Boggess M. Cumulative incidence estimation in the presence of competing risks. Stata 
J. 2004;4(2):103-112. http://ageconsearch.umn.edu/bitstream/116230/2/sjart_st0059.pdf. 
15.  Brewster DH, Clark D, Hopkins L, et al. Subsequent mortality experience in five-year survivors of 
childhood, adolescent and young adult cancer in Scotland: a population based, retrospective cohort 
study. Eur J Cancer. 2013;49(15):3274-3283. doi:10.1016/j.ejca.2013.05.004. 
16.  Prasad PK, Signorello LB, Friedman DL, Boice JD, Pukkala E. Long-term non-cancer mortality in 
pediatric and young adult cancer survivors in Finland. Pediatr Blood Cancer. 2012;58(3):421-427. 
doi:10.1002/pbc.23296. 
17.  Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of 
childhood cancer: The childhood cancer survivor study. J Natl Cancer Inst. 2008;100(19):1368-
1379. doi:10.1093/jnci/djn310. 
18.  Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of 
cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin 
Oncol. 2001;19(13):3173-3181. http://www.ncbi.nlm.nih.gov/pubmed/11432883. Accessed June 
23, 2015. 
19.  Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of 
childhood cancer. JAMA. 2010;304(2):172-179. doi:10.1001/jama.2010.923. 
20.  Armstrong GT, Pan Z, Ness KK, Srivastava D, Robison LL. Temporal trends in cause-specific late 
mortality among 5-year survivors of childhood cancer. J Clin Oncol. 2010;28(7):1224-1231. 
doi:10.1200/JCO.2009.24.4608. 
21.  Coccia PF, Pappo AS, Altman J, et al. Adolescent and Young Adult Oncology. 2014. 
22.  Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: 
A summary from the childhood cancer survivor study. J Clin Oncol. 2009;27(14):2328-2338. 
doi:10.1200/JCO.2008.21.1425. 
23.  Bleyer WA, Barr RD. Cancer in Adolescents and Young Adults. Berlin Heidelberg: Springer-
Verlag; 2007. 
24.  Nysom K, Holm K, Hertz H, Hesse B. Risk factors for reduced pulmonary function after malignant 
lymphoma in childhood. Med Pediatr Oncol. 1998;30(4):240-248. 
http://www.ncbi.nlm.nih.gov/pubmed/9473759. Accessed July 7, 2015. 
25.  Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin’s disease: pulmonary, cardiac, and 
thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys. 






26.  Griese M, Rampf U, Hofmann D, Führer M, Reinhardt D, Bender-Götze C. Pulmonary 
complications after bone marrow transplantation in children: twenty-four years of experience in a 
single pediatric center. Pediatr Pulmonol. 2000;30(5):393-401. 
http://www.ncbi.nlm.nih.gov/pubmed/11064430. Accessed July 7, 2015. 
27.  Mosher RB, McCarthy BJ. Late effects in survivors of bone tumors. J Pediatr Oncol Nurs. 
1998;15(2):72-84; quiz 85-89. http://www.ncbi.nlm.nih.gov/pubmed/9597816. Accessed July 7, 
2015. 
28.  Kharasch VS, Lipsitz S, Santis W, Hallowell JA, Goorin A. Long-term pulmonary toxicity of 
multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors. 
Med Pediatr Oncol. 1996;27(2):85-91. doi:10.1002/(SICI)1096-911X(199608)27:2<85::AID-
MPO4>3.0.CO;2-P. 
29.  Hale GA, Marina NM, Jones-Wallace D, et al. Late effects of treatment for germ cell tumors 
during childhood and adolescence. J Pediatr Hematol Oncol. 21(2):115-122. 
http://www.ncbi.nlm.nih.gov/pubmed/10206457. Accessed July 7, 2015. 
30.  Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC. Restrictive lung disease following 
treatment for malignant brain tumors: a potential late effect of craniospinal irradiation. J Clin 
Oncol. 1995;13(6):1478-1485. http://www.ncbi.nlm.nih.gov/pubmed/7751895. Accessed July 7, 
2015. 
31.  Horning SJ, Adhikari A, Rizk N, Hoppe RT, Olshen RA. Effect of treatment for Hodgkin’s disease 
on pulmonary function: results of a prospective study. J Clin Oncol. 1994;12(2):297-305. 
http://www.ncbi.nlm.nih.gov/pubmed/7509383. Accessed May 28, 2015. 
32.  Garwicz S, Anderson H, Olsen JH, et al. Late and very late mortality in 5-year survivors of 
childhood cancer: Changing pattern over four decades-Experience from the Nordic countries. Int J 
Cancer. 2012;131(7):1659-1666. doi:10.1002/ijc.27393. 
33.  Wohl ME, Griscom NT, Traggis DG, Jaffe N. Effects of therapeutic irradiation delivered in early 
childhood upon subsequent lung function. Pediatrics. 1975;55(4):507-516. 
http://www.ncbi.nlm.nih.gov/pubmed/165450. Accessed April 20, 2015. 
34.  Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10-18 years after irradiation for 
Hodgkin’s disease. Eur J Cancer. 1993;29A(3):343-347. 
http://www.ncbi.nlm.nih.gov/pubmed/8398331. Accessed July 7, 2015. 
35.  Salloum E, Tanoue LT, Wackers FJ, Zelterman D, Hu GL, Cooper DL. Assessment of cardiac and 
pulmonary function in adult patients with Hodgkin’s disease treated with ABVD or MOPP/ABVD 
plus adjuvant low-dose mediastinal irradiation. Cancer Invest. 1999;17(3):171-180. 
http://www.ncbi.nlm.nih.gov/pubmed/10099655. Accessed July 7, 2015. 
36.  Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-
death statement. Arch Intern Med. 2001;161(2):277-284. 






37.  Messite J, Stellman SD. Accuracy of death certificate completion: the need for formalized 
physician training. JAMA. 1996;275(10):794-796. http://www.ncbi.nlm.nih.gov/pubmed/8598597. 
Accessed June 2, 2015. 
38.  Devis T, Rooney C, Office for National Statistics. Death Certification and the Epidemiologist.; 
1999. 
39.  Swerdlow AJ. Interpretation of England and Wales cancer mortality data: the effect of enquiries to 
certifiers for further information. Br J Cancer. 1989;59(5):787-791. 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2247208&tool=pmcentrez&rendertype
























Survival from childhood, teenage, and young adult cancer has improved substantially over recent 
decades due to improvements in treatment and supportive care, centralization of treatment, and 
inclusion in clinical trials, with approximately 80% of those diagnosed now surviving at least five 
years1,2.  However, improved survival comes at a cost, as certain curative treatments are 
associated with adverse late effects.  With the population of survivors of childhood, teenage, and 
young adult cancer increasing rapidly with time, it is ever more important to determine adverse 
late effects in order to improve standards of care for current and future survivors.   
 
Late effects of cancer and its treatment may occur soon after receiving treatment or may not 
present for many decades3.  In order to maximize survival whilst also minimizing the risk of 
long-term sequelae, detailed evidence of the risks faced by survivors is required in order to 
provide the most appropriate recommendations.  Using the BCCSS and TYACSS cohorts, this 
thesis aimed to add to the current body of literature on late adverse effects subsequent to 
childhood, teenage, and young adult cancer through the following five studies: 
1. Study 1:  To assess a wide range of adverse health (mortality, SPNs, 
hospitalizations/healthcare usage, quality-of-life) and social (educational attainment, 
marital status, alcohol and smoking habits) outcomes among five-year survivors of 
childhood bone sarcoma within the BCCSS cohort. 
2. Study 2:  To assess aspects of mental health dysfunction among five-year survivors of 
childhood cancer within the BCCSS cohort. 
3. Study 3:  To quantify the risk of late cause-specific mortality among five-year survivors 




4. Study 4:  To quantify the risk of cardiac mortality among five-year survivors of childhood 
cancer within the BCCSS extended cohort. 
5. Study 5:  To quantify the risk of respiratory mortality among five-year survivors of 
childhood, teenage, and young adult cancers within the BCCSS and TYACSS cohorts. 
 
The findings in this thesis in particular strengthen and expand upon premature mortality among 
these survivors, providing the most comprehensive studies to date on treatment era effects, very 
late (beyond 50 years age) mortality, and cause-specific mortality, where cardiac and respiratory 
deaths were assessed particularly in more detail.  Furthermore, this thesis assessed late effects 
among childhood bone sarcoma survivors, which highlighted the increased risks observed among 
these survivors for both health and social outcomes.  Aspects of mental health dysfunction were 
also analyzed, with substantial increased risks in dysfunction being observed among survivors of 
CNS tumors and bone sarcoma.  Collectively, these findings provide a unique contribution in the 
field of late effects of childhood, teenage, and young adult cancers, which will increase 
knowledge around late effects and have numerous implications on future research in the field.    
 
8.2 Implications of Research 
Due to the population-based design, long available follow-up time, and large size of the BCCSS 
and TYACSS cohorts, the results from the studies included in this thesis provide a reliable and 
unbiased basis to update, with regards to childhood cancers, and develop, with regards to teenage 
and young adult cancers, evidence-based clinical follow-up guidelines.  Furthermore, these 
findings will be useful as they provide evidence for risk stratification and planning intervention 




comprehensive survivorship programs, this thesis has fulfilled its final aim of contributing to the 
prevention or control of adverse health outcomes among childhood, teenage, and young adult 
cancer survivors.   
 
8.3 Limitations of Research 
The main limitations of the work presented in this thesis relate to the lack of treatment and 
genetic information, which prevented more detailed interpretation of the results, as well as 
investigations into the association of adverse health and social outcomes with these risk factors.  
Although some crude treatment information (i.e. ‘yes’ or ‘no’ for radiotherapy, chemotherapy, 
and surgery) was recorded for the BCCSS and TYACSS cohorts using a population-based 
method, such as a registry, the vast majority of survivors have missing information.  This is a 
consequence of examining historical cohorts where treatment and genetic data is not easily 
available, let alone detailed enough to complete analyses that will be useful for risk stratification.  
Although it would be ideal to retrospectively collect treatment and genetic information for all of 
the survivors within the two cohorts investigated, it is to date impossible given the high level of 
costs associated with this task, the lack of interest from funders, and the sheer implausibility for 
the TYACSS cohort due to it including over 200,000 survivors.  For these reasons, treatment and 
genetic analyses are largely infeasible when using the BCCSS and TYACSS in cohort-
approached research, and thus these limitations were unavoidable for this thesis.   
 
These limitations, however, can be overcome within future projects that instead use a case-
control approach, making it feasible to collect detailed treatment information and/or genetic 




PanCareSurFup (http://www.pancaresurfup.eu//), PROCARDIO (http://www.procardio.eu//), and 
CEREBRAD (http://www.cerebad-fp7.eu//) projects, which investigate the risk of SPNs, cardiac 
morbidity and mortality, and cerebrovascular morbidity and mortality through case-control 
studies.  These studies will be able to investigate the dose-response relationship of treatment 
exposures, whilst also collecting DNA samples – both of which will provide valuable 
contributions to risk stratification, clinical guidelines, and the current knowledge of late effects 
after childhood, teenage, and young adult cancers.    
 
8.4 Future Research 
Further research is necessary in the field of late effects among childhood, teenage, and young 
adult cancers.  With regards to childhood cancer survivors, additional analyses are needed to 
determine the very late effects of cancer and its treatment, particularly among individuals who 
have reached late adulthood and old age.  Reassessment of previous literature is also necessary, 
as treatment of childhood cancer has evolved markedly across decades; thus, findings from more 
historical cohorts may not be generalizable to individuals more recently diagnosed.  Analyses that 
assess trends in treatment and late effects would also be useful to serve as predictors of the future 
changes in late effects, which may in return assist in the prevention or control of these adverse 
outcomes.  Finally, more studies assessing dose-response relationships between specific 
treatments and adverse late effects are needed in order to provide a stronger evidence base for 
clinical follow-up guidelines. 
 
With regards to teenage and young adult cancer survivors, the Department of Health, National 




identified a need for accurate information on adverse outcomes among these individuals4.  
Although the findings from this thesis contribute to the knowledge of late effects among 
individuals diagnosed with cancer between the ages of 15 to 39, further research is needed on 
mortality, SPNs, chronic health conditions, health related quality-of-life, and many psychosocial 
outcomes in order to form a body of literature that, when combined, will provide reliable 
estimates of the risks among teenage and young adult cancer survivors.  As a result, additional 
research will provide a stronger evidence base for counseling and educating survivors, informing 
clinicians, updating clinical follow-up guidelines, and evaluating current and future treatment 
protocols.   
 
8.5 Conclusions 
The work undertaken in the present thesis aimed to further the current knowledge of late adverse 
effects of cancer and its treatment among five-year survivors of childhood, teenage, and young 
adult cancers.  The series of studies included in this thesis described a wide range of health and 
social outcomes, and generally revealed that survivors of cancer diagnosed before the age of 40 
years were at an increased risk of each adverse outcome compared to that expected from the 
general population.  Although increased risks were observed, the degree varied by demographic 
and cancer factors, stressing the importance of providing clinical follow-up that is driven by risk 
stratification.  The findings presented in this thesis add to the literature pertaining to adverse 
outcomes among childhood, teenage, and young adult cancer survivors and provide a reliable, 
unbiased, and comprehensive evidence-base for informing survivors and clinicians, updating 
clinical guidelines, improving follow-up standards, evaluating risks and benefits of future 
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Appendix 3:  Cohort characteristics of the British Childhood Cancer Survivor Study 
aAs of 28 February 2014 






 n % n % N % 
Sex       
Male 9,886 55.0% 9,053 54.8% 18,939 100.0% 
Female 8,094 45.0% 7,456 45.2% 15,550 100.0% 
First Primary Neoplasm Type       
Central Nervous System Tumor  (excluding Primitive 
Neuroectodermal Tumor) 3,576 19.9% 3,394 20.6% 6,970 100.0% 
Central Nervous System Primitive Neuroectodermal Tumor 634 3.5% 564 3.4% 1,198 100.0% 
Leukemia (excluding  Acute Myeloid Leukemia) 4,516 25.1% 4,977 30.1% 9,493 100.0% 
Acute Myeloid Leukemia 336 1.9% 645 3.9% 981 100.0% 
Hodgkin Lymphoma 1,326 7.4% 908 5.5% 2,234 100.0% 
Non-Hodgkin Lymphoma 878 4.9% 671 4.1% 1,549 100.0% 
Neuroblastoma 766 4.3% 769 4.7% 1,535 100.0% 
Non-Heritable Retinoblastoma 648 3.6% 358 2.2% 1,006 100.0% 
Heritable Retinoblastoma 552 3.1% 198 1.2% 750 100.0% 
Wilms 1,441 8.0% 947 5.7% 2,388 100.0% 
Bone Sarcoma 664 3.7% 531 3.2% 1,195 100.0% 
Soft Tissue Sarcoma 1,181 6.6% 966 5.9% 2,147 100.0% 
Other 1,462 8.1% 1,581 9.6% 3,043 100.0% 
Age at Diagnosis       
0-4 8,250 45.9% 7,447 45.1% 15,697 100.0% 
5-9 4,810 26.8% 4,454 27.0% 9,264 100.0% 
10-14 4,920 27.4% 4,608 27.9% 9,528 100.0% 
Years Since Diagnosisa       
Mean (range) 31.3 (5.0-73.7) 14.0 (5.0-22.2) 23.0 (5.0-73.7) 
5-9 years 1,524 8.5% 3,898 23.6% 5,422 100.0% 
10-19 years 950 5.3% 10,671 64.6% 11,621 100.0% 
20-29 years 5,960 33.1% 1,940 11.8% 7,900 100.0% 
30-39 years 5,443 30.3% 0 0.0% 5,443 100.0% 
40-49 years 2,806 15.6% 0 0.0% 2,806 100.0% 
50-59 years 1,155 6.4% 0 0.0% 1,155 100.0% 
60+ years 142 0.8% 0 0.0% 142 100.0% 
Attained Agea       
Mean (range) 37.8 (5.7-85.6) 20.6 (5.5-36.8) 29.6 (5.5-85.6) 
5-9 years 302 1.7% 549 3.3% 851 100.0% 
10-19 years 1,404 7.8% 7,041 42.6% 8,445 100.0% 
20-29 years 3,057 17.0% 7,676 46.5% 10,733 100.0% 
30-39 years 5,375 29.9% 1,243 7.5% 6,618 100.0% 
40-49 years 4,850 27.0% 0 0.0% 4,850 100.0% 
50-59 years 2,097 11.7% 0 0.0% 2,097 100.0% 
60-69 years 813 4.5% 0 0.0% 813 100.0% 
70+ years 82 0.5% 0 0.0% 82 100.0% 
Radiotherapy       
No 3,878 21.6% 302 1.8% 4,180 100.0% 
Yes 9,253 51.5% 97 0.6% 9,350 100.0% 
Missing 4,849 27.0% 16,110 97.6% 20,959 100.0% 
Chemotherapy       
No 6,065 33.7% 143 0.9% 6,208 100.0% 
Yes 6,680 37.2% 252 1.5% 6,932 100.0% 
Missing 5,235 29.1% 16,114 97.6% 21,349 100.0% 
Surgery       
No 7,477 41.6% 264 1.6% 7,741 100.0% 
Yes 6,026 33.5% 150 0.9% 6,176 100.0% 
Missing 4,477 24.9% 16,095 97.5% 20,572 100.0% 
Vital Statusa       
Alive 14,300 79.5% 15,706 95.1% 30,006 100.0% 


















































aAs of 28 February 2014 
 
 
Complete TYACSS (1971-2006) 
 N % 
Sex   
Male 76,666 38.2% 
Female 124,279 61.9% 
First Primary Neoplasm Type   
Breast 36,236 18.0% 
Testicular 24,309 12.1% 
Cervix 23,281 11.6% 
Melanoma 22,446 11.2% 
Hodgkin 16,971 8.5% 
CNS (excl. PNET) 16,954 8.4% 
NHL 9,467 4.7% 
Thyroid 7,809 3.9% 
Gastrointestinal 7,224 3.6% 
STS 6,130 3.1% 
Ovary 4,885 2.4% 
Bladder 4,685 2.3% 
Other GU 4,672 2.3% 
Head & Neck 3,961 2.0% 
Leukemia (excl. AML) 3,338 1.7% 
Other 3,056 1.5% 
Bone Tumor 2,241 1.1% 
AML 1,735 0.9% 
Lung 1,219 0.6% 
PNET 326 0.2% 
Age at Diagnosis   
15-19 years 12,249 6.1% 
20-24 years 21,257 10.6% 
25-29 years 35,894 17.9% 
30-34 years 54,541 27.1% 
35-39 years 77,004 38.3% 
Years Since Diagnosisa   
Mean (range)   
5-9 years 38,162 19.0% 
10-19 years 77,995 38.8% 
20-29 years 53,001 26.4% 
30-39 years 28,335 14.1% 
40+ years 3,452 1.7% 
Attained Agea   
Mean (range)   
20-29 years 4,393 2.2% 
30-39 years 24,273 12.1% 
40-49 years 71,604 35.6% 
50-59 years 58,428 29.1% 
60-69 years 32,855 16.4% 
70-79 years 9,104 4.5% 
80+ years 288 0.1% 
Vital Statusa   
Alive 166,757 83.0% 







Appendix 5:  Publication arising from Chapter 3 
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